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Cardiac fibrosis is the main pathophysiological processes contributing to heart failure, affecting 
900,000 people in the U.K. Excessive extracellular matrix (ECM) production and increased 
proliferation of cardiac fibroblasts contributes towards cardiac fibrosis, which increases 
myocardium stiffness, causing systolic/diastolic cardiac dysfunction and ultimately heart failure. 
Current treatment options are only partially effective. Hence, a better understanding of the 
underlying mechanisms is required to help develop novel therapies. In this thesis, the effects of 
cAMP-signalling on cardiac fibroblast proliferation and migration were investigated.  
cAMP signalling, via PKA and EPAC1, inhibited cardiac fibroblasts proliferation but not migration. 
This was associated with a change in cell morphology, actin remodelling and reduced RhoA-ROCK 
signalling. Cyclic-AMP also inhibited SRF and TEAD-dependent transcription. Inhibition of SRF 
resulted from reduced nuclear localisation of MKL1, which involved PKA and EPAC1 signalling. 
Pharmacological and siRNA-mediated inhibition of SRF and TEAD co-factors MKL1/2 and 
YAP/TAZ, respectfully, inhibited cardiac fibroblasts proliferation. 
cAMP signalling was associated with a reduction in EPAC1 gene expression, which was mediated 
by both PKA and EPAC1 signalling and dependent on inhibition of actin polymerisation. Promoter 
analysis identified an EPAC1 promoter TEAD binding-element that was essential for maximal 
EPAC1 promoter activity. Inhibition of TEAD activity with siRNA gene silencing, dominant 
negative mutants or pharmacological inhibitors repressed EPAC1 expression. Importantly, a 
constitutively active YAP mutant rescued EPAC1 promoter activity but not endogenous EPAC1 
mRNA levels after cAMP elevation, indicating involvement of additional mechanism. cAMP 
reduced histone3-lysine27 acetylation at the EPAC1 proximal promoter, which contributed towards 
EPAC1 repression.  
Taken together, these data demonstrate an important role of PKA and EPAC induced actin 
remodelling and inhibition of MKL-SRF and YAP/TAZ-TEAD in mediating the anti-mitogenic 
effects of cAMP in cardiac fibroblasts. The data also describes the existence of a negative feedback 
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1.1 Normal cardiac interstitium 
In the adult mammalian heart, ventricular myocytes are arranged in layers of 3 to 5 cells thick, 
where neighbouring layers are mechanically and electrically coupled together but adjacent layers 
are separated by clefts with little cell-to-cell coupling (Leonard, Smaill et al. 2012). Layers of 
myocytes are separated by interstitial collagen deposited by interconnected networks of fibroblasts. 
Myocardial tissues consist of several different cell types, such as: myocytes; cardiac fibroblasts; 
endothelial cells; and vascular smooth muscle cells, although most of the cells consist of myocytes 
and cardiac fibroblasts (Souders, Bowers et al. 2009). Cardiac myocytes and cardiac fibroblasts 
cooperate to maintain the electrical and contractile nature of a mammalian heart. In addition, cardiac 
fibroblasts not only preserve the three-dimensional structure of the heart, but they also contribute 
to the development of the heart, angiogenesis and responses to tissue injuries, which will be 
discussed in detail later (Camelliti, Borg et al. 2005, Souders, Bowers et al. 2009). 
1.2 Heart failure 
Heart failure is a condition in which the heart is not able to pump enough blood around the 
pulmonary or systemic circulation to support normal functioning of the organs. It is characterised 
as a progressive disorder, which originates from myocardium insults (e.g. infarction, infection, 
pressure overload, volume overload) or disruption to myocardial contraction (e.g. owing to 
arrythmia) that prevent the heart from pumping blood efficiently (Mann and Bristow 2005). Over 
500000 of the UK population are living with heart failure and its risks increase with aging. Major 
causes of heart failure include hypertensive heart disease and injuries caused by myocardial 
infarction (MI) as a result of ischaemic heart disease (Leonard, Smaill et al. 2012). The development 
of HF can be linked to continuous pathophysiological alterations in the geometry of the heart 
chambers (e.g. dilatation) and myocardium (e.g. wall thinning, increased stiffness) which are 
associated with progressive reorganisation of the cardiac extracellular matrix (ECM) (Mann and 
Bristow 2005). Excessive deposition of ECM produced by cardiac fibroblasts, causes stiffness, 
which reduces myocardial elasticity (i.e. compliance), leading to diastolic dysfunction, and 
contractility, leading to systolic dysfunction. 
1.3 Cardiac fibrosis 
Cardiac fibrosis can occur after any kind of myocardial insult, such as: inflammation (e.g. infection 
or autoimmunity); MI; and aging-related arterial stiffness (Ivey and Tallquist 2016). The main cell 
type implicated in the fibrotic remodelling process is the cardiac fibroblast. While defining and 




negative effects, there is still much uncertainty about their unique gene expression profile, functions 
and origins (Ivey and Tallquist 2016). 
Cardiac fibroblasts originate from mesenchymal cells. They are defined as non-vascular, non-
inflammatory and non-epithelial cells. They make an abundant population of cells in the 
myocardium, responsible for 60-70% by numbers or approximately 20% by volume (Camelliti, 
Borg et al. 2005, Baudino, Carver et al. 2006). Even though cardiac fibroblasts share similar 
structural and ECM regulating functions with the fibroblasts of other organs within the body, they 
have a different behaviour towards certain stimuli, which implies organ specificity (Brown, Ambler 
et al. 2005). 
1.4 Mechanisms underlying cardiac fibrosis 
Cardiac fibrosis can be summarised in three different phases: the initiating phase; the effective 
phase; and the amplificative phase. A study carried out in 2014 demonstrated that, following 
stimulation, the levels of pro-fibrotic growth factors are increased, which, in turn, trigger the fibrotic 
response (Kong, Christia et al. 2014). In the next phase, these circulating pro-fibrotic growth factors 
bind to their specific receptors, which activate specific pathological transcription factors and 
signalling pathways such as: Protein Kinase B (PKB); Mitogen-Activated Protein Kinases (MAPK); 
and Nuclear Factor Kappa B (NF-κB). These pathological activations induce the transformation of 
cardiac fibroblasts to myofibroblasts, which respond by synthesizing ECM components (e.g. 
collagen 1, collagen 3 and matrix metalloproteinases (MMPs)) or by proliferating, migrating and 
expressing α-smooth muscle actin (α-SMA), as well as angiotensin II receptors and angiotensin 
converting enzyme (ACE) (Souders, Bowers et al. 2009, Ma, Yuan et al. 2018). Furthermore, pro-
fibrotic transcription factors control the production and secretion of pro-fibrotic growth factors (e.g. 
transforming growth factorβ, TGF-β) by cardiac fibroblasts and other cells (including 
cardiomyocytes and inflammatory cells) in the myocardium. Finally, these pro-fibrotic growth 
factors can form and regulate positive feedback mechanisms and further amplify the extent of the 
cardiac fibrotic response (Kong, Christia et al. 2014, Frieler and Mortensen 2015, Ma, Yuan et al. 
2018). 
1.5 Cellular effectors of cardiac fibrosis 
Since adult mammalian cardiomyocytes have insignificant regenerative capacity, acute 
cardiomyocyte death (following acute MI or any cardiac insult)initiates an inflammatory reaction, 
which eventually leads to the replacement of dead myocardium with collagen scars by cardiac 




overload and myocardial inflammation, may trigger profibrotic signalling pathways even when 
cardiomyocyte death is absent. Several different cell types could also play essential roles in the 
fibrotic remodelling of the heart, either directly by stimulating the production of matrix proteins 
from fibroblasts, or indirectly via the secretion of fibrogenetic mediators e.g. by mast cells, 
lymphocytes and macrophages, cardiomyocytes or vascular cells. In all of the aforementioned 
conditions, cardiac fibroblasts are differentiated into secretory and contractile cells (known as 
myofibroblasts) by TGF-β1; and these myofibroblasts are associated in the cardiac fibrotic 
remodelling and cardiac healing (Kong, Christia et al. 2014). Myofibroblasts are activated 
fibroblasts differentiated from endogenous fibroblasts, stem cells and infiltrating pericytes. They 
are different from unstimulated fibroblasts because they express more contractile proteins (such as 
smooth muscle α-actin) and are able to secrete different factors, such as platelet-derived growth 
factor (PDGF) and stem cell factors (Powell, Mifflin et al. 1999). 
1.6 Marker proteins and the origin of cardiac fibroblasts 
No cardiac fibroblast-specific molecular marker has been reported yet. Previous results were 
obtained using co-labelling with panels of antibodies that can identify cardiac fibroblasts (Ma, Yuan 
et al. 2018). For example, vimentin, a constituent of the intermediate-filament family of proteins 
has been used to identify the purity of isolated cardiac fibroblasts in vitro. However, endothelial 
cells and smooth muscle cells can also express it (Mork, van Deurs et al. 1990, Ivey and Tallquist 
2016). 
Once differentiated and activated, myofibroblasts can express α-SMA. As a result, α-SMA can be 
used to recognise cardiac myofibroblasts, but α-SMA can also be expressed in other cell types, such 
as vascular smooth muscle cells (Weber 1997, Ivey and Tallquist 2016). In addition to α-SMA, 
fibronectin containing extra domain A (ED-A) is also highly expressed in myofibroblasts (Santiago, 
Dangerfield et al. 2010) and deposited in ECM (Dobaczewski, Bujak et al. 2006). However, it could 
also be co-localised in endothelial cells (Chang, Chen et al. 2004) and macrophages (Doddapattar, 
Gandhi et al. 2015). 
Moreover, Fibroblast Specific Protein (FSP1) is proposed as a specific marker for cardiac 
fibroblasts, but an investigation reported that cells expressing this protein were a small subset of 
cardiac fibroblasts (Moore-Morris, Guimaraes-Camboa et al. 2014, Ivey and Tallquist 2016). 
Another protein that has been reported to be a specific marker of cardiac fibroblasts is known as 
Periostin. It is a secreted protein and is linked with cell adhesion (Ivey and Tallquist 2016). A study 




cardiac fibroblasts following an injury to the heart. However, another study carried out in mice 
demonstrated that most Periostin is secreted and then deposited extracellularly and only a tiny 
portion can be spotted intracellularly (Snider, Hinton et al. 2008). This could limit the utility of this 
protein in the study of cardiac fibroblasts  (Kanisicak, Khalil et al. 2016). A study carried out in rats 
and mice reported that immunostaining of another protein known as Discoidin Domain Receptor 
(DDR) 2, which is a tyrosine kinase receptor, can only label a small proportion of the cardiac 
fibroblasts (Banerjee, Fuseler et al. 2007, Ivey and Tallquist 2016).Further investigation on specific 
markers of cardiac fibroblasts would be of interest to unveil the mechanism of cardiac fibrosis. 
Another significant debate in the study of cardiac fibroblasts is their origin (Ma, Yuan et al. 2018). 
The traditional belief is that cardiac fibrosis is the result of the proliferation and migration of 
resident cardiac fibroblasts. This phenomenon is supported by an investigation carried out in 2017 
where the authors demonstrated that TGF-β induced the proliferation and migration of isolated mice 
cardiac fibroblasts (Ma, Yuan et al. 2017). Moreover, an investigation carried out in mice showed 
that pressure overload could be an important driving factor for the activation and proliferation of 
resident cardiac fibroblasts (Moore-Morris, Guimaraes-Camboa et al. 2014). On the other hand, this 
concept has been challenged by the following discoveries: cardiac fibroblasts quickly transform into 
cardiac myofibroblasts even in the absence of stimuli in vitro; and proliferating cardiac fibroblast-
like cells predominate in the areas close to the blood vessels, suggesting that, they can migrate from 
blood circulation (Ma, Yuan et al. 2018). Moreover, another investigation carried out in mice 
cardiac fibroblasts demonstrated that endothelial cells can also contribute to the total population of 
cardiac fibroblasts (Zeisberg, Tarnavski et al. 2007). The authors used FSP1 to identify cardiac 
fibroblasts and tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE1) as the 
marker for endothelial cells, although TIE1 could identify immune lineages as well. To add to the 
complexity, other investigations that used different genetic markers, such as Fetal Liver Kinase 1 
(FLK1) and VE-Cadherin, reported limited input of endothelial cells to the total population of 
cardiac fibroblasts (Alva, Zovein et al. 2006). Further investigations focusing on the contribution 
of the endothelial-cell-derived cardiac fibroblasts would be of interest (Ma, Yuan et al. 2018). 
1.7 Physiological functions of cardiac fibroblasts 
There are lots of studies highlighting the prominent roles of cardiac fibroblasts to support and 
maintain physiological cardiac development, structure and function  (Frangogiannis 2012, Deb and 




Normally, Cardiac fibroblasts are constantly exposed to mechanical signals, and proper regulation 
of these mechanical stimulations maintain normal cardiac function (Catalucci, Latronico et al. 
2008). Furthermore, mechanical load results in a significant enhancement of ECM components, 
ECM specific receptors, growth factors and cytokines (Butt and Bishop 1997, Souders, Bowers et 
al. 2009). 
Moreover, there is evidence that cardiac fibroblasts are involved in the preservation of the three-
dimensional structure of the heart via the autocrine and paracrine action of secreted factors and the 
direct cell to cell interaction (Souders, Bowers et al. 2009). 
1.7.1 Role of cardiac fibroblasts during heart development 
In contrast to the well described roles of adult cardiac fibroblasts, there is not much known about 
the roles of these cells during heart development. An experiment conducted on mouse embryonic 
cardiac fibroblasts suggested that they could form a fibrous skeleton which would provide structural 
support for the cardiomyocytes (Leda, Tsuchihashi et al. 2009). Moreover, co-culture experiments 
suggested that embryonic cardiac fibroblasts could promote cardiomyocyte-genesis during heart 
development, an effect which required fibronectin and collagen 3 (Leda, Tsuchihashi et al. 2009).  
1.7.2 Role of cardiac fibroblasts in angiogenesis 
The involvement of fibroblasts in angiogenesis was first reported back in 1993, where it was 
demonstrated that mouse embryo fibroblasts promoted formation of capillary-like tubes by 
endothelial cells (Montesano, Pepper et al. 1993), In addition, in vitro and in vivo experiments have 
unveiled the crucial role of cardiac fibroblasts in angiogenesis during development and disease 
stages. Their role in this process has been reported to be via the synthesis and accumulation of ECM, 
growth factors and cytokines (such as Interleukins 1 and 6), all of which would allow them to control 
their environment through autocrine and paracrine signalling. Growth factors secreted by fibroblasts 
include Fibroblast Growth Factor 2 (FGF2) and Vascular Endothelial Growth Factor A (VEGFA) 
(Murakami and Simons 2008), both of which can act on endothelial cells and have got important 
roles in neovascularisation and coronary collateral formation in order to support the blood supply 
to myocardium after injuries (Souders, Bowers et al. 2009). In contrast, it has been reported that, 
Pigment Epithelium-Derived Growth Factor (PEDF), which is expressed in both cardiac myocytes 





These studies underline the pro and anti-angiogenic effects of cardiac fibroblasts in the sprouting 
of blood vessels and imply that proper regulation of these factors is vital for cardiac angiogenesis 
and vascular development (Souders, Bowers et al. 2009). 
In addition to the growth factors secreted by cardiac fibroblasts, other factors are crucial in 
angiogenesis, such as MMPs and Tissue Inhibitors of Metalloproteinases (TIMPs). The MMPs exert 
their effects in part by degrading the ECM, promoting endothelial cell migration and proliferation. 
They can also control endothelial cell adhesion and survival leading to the activation or inhibition 
of vascularisation. On the other hand, an experiment carried out in mice in 2003 by Hamano and 
co-workers demonstrated that the cleavage of MMP-9 generates tumstatin (an angiogenesis 
inhibitor fragment of collagen 4) which plays an important role in the inhibition of pathological 
angiogenesis (Hamano, Zeisberg et al. 2003). Like MMPs, TIMPs can have pro and anti-
neovascularisation effects too. In a study carried out by Yamada and colleagues in mice, it was 
shown that, TIMP-1 deficient mice showed slower angiogenesis in their retina (Yamada, Tobe et 
al. 2001).  In another study, it was observed that, exogenous TIMP-1 promoted the formation of 
new blood vessels. Moreover, a mutant version of TIMP-1 did not induce angiogenesis. It was also 
demonstrated that the activity of TIMP-1 is dependent on the activity of MMPs (Liu, Chen et al. 
2008). 
As mentioned before, TIMPs can inhibit angiogenesis at different stages which could be mediated 
by either the decline in the expression of MMPs or the reduction in their activities (Lambert, Dasse 
et al. 2004). 
Taken together, these studies demonstrate the significance of fibroblasts in the regulation of 
angiogenesis. 
1.7.3 Role of cardiac fibroblast in electrical signalling 
Cardiac fibroblasts have other intriguing roles in addition to angiogenesis. Due to their high 
membrane conductae, they can be good conductors of electrical signals A study carried out in rats 
in 1997 highlighted the importance of gap and cell junctions through connexins (Cx) in the 
maturation of electromechanical performance the mammalian heart. (Angst, Khan et al. 1997). Later 
on, it was demonstrated that cardiac fibroblasts have the ability of making network of cells that are 
connected to the ECM via integrins, to each other through specific cadherins and to cardiac 
myocytes by different types of receptors including Cx (Banerjee, Yekkala et al. 2006). A year later, 
Chilton and co-workers studied the intracellular coupling in co-cultured adult rabbit ventricular 




investigation demonstrated that once ventricular myocytes were preloaded with the dye and co-
cultured with the myofibroblasts for about a day, the fluorescent dye could be detected in about half 
of the population of myofibroblasts. To further confirm it, they also treated their co-cultured cells 
with gap junction uncoupler, which significantly decreased the flow of the dye. Furthermore, their 
immunostaining unveiled the expression of Cx43 in their co-cultured cells. Their study 
demonstrated that stimulation of adult rabbit ventricular myocytes can have effects on the 
intracellular calcium ions (Ca2+) of the co-cultured myofibroblasts most probably through Cx43 
(Chilton, Giles et al. 2007). Another study carried out in adult mouse cardiac fibroblasts identified 
the Cxs involved in gap junctions between them. Using Quantitative real time-Polymerase Chain 
Reaction (qPCR) and Western Blotting, they showed the presence of proteins and mRNAs of Cx40 
and Cx43. Moreover, their analysisshowed that cardiac fibroblasts are functionally coupled together 
to form an extensive coupled cell network that could link different regions of myocytes that would 
normally be electrically isolated by connective tissues (Louault, Benamer et al. 2008). 
Baudino and co-workers used in vitro cell-cell interaction assays to further confirm the 
communication between cardiac fibroblasts and myocytes via the formation of tight cell to cell 
junctions (Baudino, McFadden et al. 2008). 
In addition to gap junctions, the ion channels of cardiac fibroblasts play an intriguing role in 
signalling; and it has been shown that abnormalities in them may result in cardiac arrhythmia and 
dysfunction (Shibukawa, Chilton et al. 2005). An investigation carried out on adult rat cardiac 
fibroblasts and myofibroblasts highlighted the importance of one of these ionic channels (inwardly 
rectifying potassium channels), which play important roles in the regulation of resting membrane 
potential, survival, proliferation and the contractility of cardiac fibroblasts. It was concluded that 
these channels are activated by the electrical coupling (contact) between the cardiac fibroblasts and 
cardiomyocytes via gap junctions (Chilton, Ohya et al. 2005). 
1.7.4 Roles of cardiac fibroblasts in wound healing 
One of the crucial roles of cardiac fibroblasts is to heal wounds after any type of injury to the heart. 
They play central roles in various aspects of wound healing, from the deposition of ECM, to the 
formation of new blood vessels at the site of the injury and the maturation of scar (Deb and Ubil 
2014). A study carried out on mouse hearts suggested that after MI injury, cardiac fibroblasts rapidly 
differentiate into their active forms (myofibroblasts) and proliferate (Christia, Bujak et al. 2013). 
The highest number of myofibroblasts was achieved within 3 days of ischaemia-reperfusion injury. 




compared to its peak, indicating the dynamic feature of the cardiac fibroblasts at the site of the 
injury (Christia, Bujak et al. 2013). Following an injury to the myocardium, activated cardiac 
fibroblasts express proteins necessary for contraction (such as: α-SMA) and secrete collagens that 
are needed for the structural integrity of the heart (Deb and Ubil 2014). These early repair responses 
from activated cardiac fibroblasts are crucial in wound healing following a cardiac injury as it has 
been reported that interruption in this process by loss of function experiments could result in 
downregulation of cardiac performance and retarded wound healing (Duan, Gherghe et al. 2012).  
In the later stages of wound healing, the scar gradually contracts, collagen fibres at the site of the 
injury cross-link together, which increases the tensile strength of the scar and its surface area gets 
reduced. It has been suggested that, myofibroblasts (which express contractile proteins) contribute 
to this process, which is known as scar thinning (Deb and Ubil 2014). Scar thinning could lead to 
adverse changes in ventricular chamber geometry and compliance, would increase the 
haemodynamic burden on the remaining viable myocytes and over time could result in the 
development of congestive heart failure (Deb and Ubil 2014). 
1.8 Pathological functions of cardiac fibroblasts 
As mentioned earlier, cardiac fibrosis is defined by an overall accumulation of ECM in the 
myocardium and is an essential element of most cardiac pathologies. It develops when excessive 
amounts of ECM is produced by myocardial fibroblasts in order to form a scar tissue and as a result 
of this normal degradation of ECM is disrupted (Berk, Fujiwara et al. 2007). Figure 1.1 summarises 
the phases of cardiac fibrosis.  
As mentioned earlier, heart is made of muscles referred as myocardium. The laminar architecture 
of the myocardium is characterised by complex networks of ECM proteins containing mainly 
fibrillar collagen (Kong, Christia et al. 2014). The half-lives of mature fibrillar collagens are 
between 80-120 days which shows their highly stability. The homeostatic control of collagen in a 
normal heart is mainly controlled by the cardiac fibroblasts and requires constant synthesis and 
degradation of matrix proteins. The consequence of any disturbance in the metabolism of collagen 
would be catastrophic: it could induce functional and structural abnormalities in the heart (Kong, 
Christia et al. 2014). After MI, cardiac fibroblasts proliferate and migrate faster and deposit more 
ECM in order to prevent cardiac rupture. However, their protective mechanism could also have 
deleterious and negative side effects which includes permanent change in the shape of the heart 






Figure 1.1: Pathogenesis of cardiac fibrosis 
Any kind of cardiac injury would stimulate the production of specific hormones and cytokines. This 
would promote the activation of cardiac fibroblasts to cardiac myofibroblasts. Once cardiac 
fibroblasts are activated, they proliferate and migrate which would cause the excessive production 
of ECM. This would lead to cardiac fibrosis and eventually heart failure. Angio II: angiotensin II; 




1.8.1 Cardiac fibrosis enhances stiffness of the heart 
Irrespective of the initial cause, any kind of injury to the heart provokes sustained cardiac fibrotic 
responses, which results in an irregular heart architecture and impairs its normal function (Ma, Yuan 
et al. 2018). In 1988, it was reported that the stiffness in the adult rat myocardium is related to the 
fibrosis. In addition, an investigation carried out in 1989 on intact rat myocardium suggested that 
cardiac fibrosis associated with myocyte death has unique morphological features involving fibrillar 
collagen, which, because of its structure, location and alignment, could lead to an enhanced 
myocardial stiffness (Carroll, Janicki et al. 1989). Moreover, cardiac fibrosis would cause the 
slippage of cardiomyocytes resulting in a decrease of the number of cardiomyocytes layers in the 
left ventricle (Kong, Christia et al. 2014). In 1994, an experiment conducted by Beltrami et al in 
patients suggested that myocardial fibrosis resulted in the expansion of left ventricle and reduction 
in the ventricular mass-to-chamber volume ratio, implying left ventricular dilation (Beltrami, Finato 
et al. 1994). Later on, it was suggested that continued deposition of ECM and stiffness of the heart 
could impair the contractile behaviour of the heart muscles (Weber 1997). 
1.8.2 Cardiac fibrosis impairs the conduction of electrical impulses in the heart 
Cardiac fibrosis impairs the coordination of excitation-contraction coupling in the myocardium, 
which would result in the disruption of systolic and diastolic functions (Janicki and Brower 2002). 
On the other hand, the breakdown of ECM via the action of MMPs (enzymes capable of the 
degradation of ECM components) has been reported to induce left ventricular enlargement 
(Iwanaga, Aoyama et al. 2002). 
The severe outcomes resulting from the impairment of the collagen network in a fibrotic heart could 
be due to different mechanisms. It has been reported that fibrillar collagen helps to sustain normal 
myocardial systolic performance by enabling transduction of cardiomyocyte contraction into the 
myocardial force development. An impairment would induce an imbalance and uncoordinated 
contraction of cardiomyocyte bundles (Baicu, Stroud et al. 2003). 
Moreover, interactions between collagen and laminin with their receptors could have an essential 
role in the homeostasis of cardiomyocytes (Wang, Hoshijima et al. 2006). In the same investigation, 
it was also suggested that mutations in laminin alpha4 cause abnormalities in the structure of 
cardiovascular ECM, which could lead to insufficient supply of oxygen to the myocardium and 
cause ischaemia (Wang, Hoshijima et al. 2006), illustrating the connection between matrix network 




Furthermore, cardiac fibrosis is thought to impair anisotropic conduction, slowing down the 
velocities of electrical conductions and generating re-entry circuits (Khan and Sheppard 2006, 
Kong, Christia et al. 2014). More than a decade ago, it was reported that, patients who suffer from 
chronic Atrial Fibrillation exhibit higher levels of myocardial interstitial fibrosis compared to the 
control group (Tagawa, Higuchi et al. 2001, Corradi, Callegari et al. 2004). Later, a study carried 
out by Verheule et al suggested that, atrial fibrosis can be a sufficient factor to induce atrial 
fibrillation in transgenic mice overexpressing TGF-β. Hence, atrial fibrosis could be a significant 
contributor to atrial fibrillation, even in the absence of other proarrhythmic factors (Verheule, Sato 
et al. 2004). 
In addition, as fibrosis develops, myocardial bundles are separated, which could induce a disruption 
in the transverse conduction an lead to arrhythmia by atrial fibrillation (Spach, Miller et al. 1982). 
An investigation in dog hearts confirmed that fibrosis could interfere with conduction in the atria 
which induced atrial fibrillation (Li, Fareh et al. 1999). 
1.9 Potential therapeutic target for cardiac fibrosis 
Following MI, the main reasons for the development of cardiac fibrosis are the differentiation of 
cardiac fibroblasts to cardiac myofibroblasts, their proliferation and their migration (Fan and Guan 
2016). Consequently, controlling the differentiation of cardiac fibroblasts, their proliferation and 
migration rates could be crucial to inhibit cardiac fibrosis. As previously reported, different growth 
factors and cytokines (TGF-β, angiotensin II and PDGF) play important roles in the differentiation 
process. Therefore, current therapies (either systematic or localised) are mainly focused on 
decreasing the secretion of these growth factors and cytokines which in turn would retard the 
proliferation and migration rate of these activated cardiac fibroblasts (Reilly 2015, Fan and Guan 
2016). Some of these current therapies are explained in more details in the next section. 
1.9.1 Agents that impact the renin angiotensin system (RAS) 
Several investigations highlighted the important role of RAS in the pathogenesis of cardiovascular 
diseases (Sadoshima 2000, Mezzano, Ruiz-Ortega et al. 2001, Ruiz-Ortega, Lorenzo et al. 2001). 
Previously, angiotensin II was defined as a regulatory hormone that monitors blood pressure (Ruiz-
Ortega, Lorenzo et al. 2001). Nowadays, it is accepted that angiotensin II could stimulate the cells 
regulating the expression of growth factors, cytokines, and adhesion molecules, which are engaged 
in cell apoptosis, inflammation and fibrosis (Egido 1996, Mezzano, Ruiz-Ortega et al. 2001, Ruiz-
Ortega, Lorenzo et al. 2001). Moreover, RAS was demonstrated to have vital roles in activation of 




antihypertensive classes of drugs, such as β and calcium channel blockers, which did not show 
consistent positive results in humans, RAS inhibitors, such as ACE inhibitors, aldosterone 
antagonists and angiotensin II receptor blockers have been reported to have positive results in the 
treatment of cardiac fibrosis in both animals and humans (Roubille, Busseuil et al. 2014, Reilly 
2015).  
Fibrotic hearts express elevated levels of angiotensin II, which is an oligopeptide that causes 
vasoconstriction and increased blood pressure. Angiotensin II receptors (which are widely 
expressed in cardiac fibroblasts) have regulatory roles in the ECM production, adhesion and 
proliferation (Villarreal, Kim et al. 1993, Crabos, Roth et al. 1994).  Moreover, lisinopril (ACE 
inhibitor) repressed myocardial fibrosis significantly (Brilla, Funck et al. 2000). Interestingly, 
cardiac fibroblasts express RAS components, and RAS signalling in these cells facilitates cell 
proliferation and migration. Hence, the effect of RAS blockers to treat cardiac fibrosis could be due 
to their anti-proliferative effects (Pinter and Jain 2017). 
Furthermore, inhibition of the angiotensin I receptors in rat and mouse cell lines is anti-fibrotic by 
indirect activation of angiotensin II receptors and programmed cell death (Yamada, Horiuchi et al. 
1996). 
In contrast, angiotensin II heightens the activity of MAPK in human cardiac fibroblasts increasing 
the mRNA level of TGF-β and inhibiting the degradation of the ECM. All of which would further 
increase cardiac fibrosis (Kawano, Do et al. 2000).  Moreover, clinical trials have shown that RAS 
inhibitors can decrease cardiac fibrosis in humans, although the study populations were rather small 
(Fang, Murphy et al. 2017). 
1.9.2 TGF-β inhibitors 
As mentioned before, TGF-β is a key cytokine with pro-fibrotic effects that regulates cardiac 
fibrosis, implying that inhibiting its action can have anti-fibrotic effects. TGF-β provokes fibrosis 
by retarding the degradation rate and heightening the production of ECM components (Edgley, 
Krum et al. 2012). TGF-β can be activated by a variety of stimuli such as: angiotensin II, MMP2 
and MMP9. Interestingly, levels of MMP2 and TGF-β are increased in the cardiac tissues of human 
and animal heart failure. Moreover, TGF-β stimulates the expression of fibrillar collagen and 
fibronectin by cardiac fibroblasts (Edgley, Krum et al. 2012). Hence, inhibition of this cytokine is 
demonstrated to be a potential target for cardiac fibrosis (Reilly 2015). However, mice which 
received an anti-TGF-β antibody had a significant higher mortality rate after MI compared with the 




MI. Although the production of collagen in mice treated with the TGF-β inhibitor was reduced, the 
expression of TGF pro-inflammatory cytokines were also increased (Frantz, Hu et al. 2008). Even 
though TGF-β promotes cardiac fibrosis, it also inhibits inflammation, which is essential for tissue 
repair.  Hence, broad targeting and inhibiting TGF-β might not be a viable approach (Fang, Murphy 
et al. 2017). TGF-β inhibiting agents, such as pirfenidone and tranilast have been available clinically 
to affect the downstream targets of TGF-β, but both have adverse effects, such as liver dysfunction 
and liver failure (Fang, Murphy et al. 2017, Verma, Kumar et al. 2018). 
1.9.3 Histone deacetylase inhibitors 
One of the important groups of enzymes that play a crucial role in regulating and monitoring gene 
expression throughout are known as histone deacetylases (HDACs). The link between HDACs and 
cardiac fibrosis was first suggested by the discovery that these enzymes interact with members of 
the myocyte enhancer factor-2 (MEF2) transcription factor family (Konno, Chen et al. 2010). MEF2 
regulates several genes that are involved cardiac hypertrophy. Konno and co-workers showed that 
levels of phosphorylated class II HDACs that activate MEF2 were increased in fibrotic rat hearts. 
It was also suggested that there is a link between MEF2-dependent gene activation and fibrosis 
(Konno, Chen et al. 2010). 
Another investigation in mice demonstrated that silencing of the gene encoding HDAC9 heightens 
the activity of MEF2 (Zhang, McKinsey et al. 2002). In addition, mouse knockouts for HDAC5/9 
develop exaggerated cardiac fibrosis by aging (Zhang, McKinsey et al. 2002, Chang, McKinsey et 
al. 2004). In contrast, overexpression of HDACs 4, 5 and 9 in cultured rat cardiomyocytes decreased 
the incidence of cardiac hypertrophy (Zhang, McKinsey et al. 2002, Bush, Fielitz et al. 2004, Backs, 
Song et al. 2006). 
A later study in mice showed that HDAC inhibitors reverse cardiac remodelling and reduce cardiac 
fibrosis independent of angiotensin II in cardiac hypertrophy (Liu, Levin et al. 2008). 
Since there are currently no Food and Drug Administration approved treatments for cardiac fibrosis, 
the pre-clinical results that highlight the roles of HDAC inhibitors in cardiac fibrosis could have 
significant clinical implications (Schuetze, Stratton et al. 2017). 
1.9.4 Adenosine secretion and adenosine2B receptor stimulation 
Adenosine has antimitogenic effects on isolated rat cardiac fibroblasts through the adenosine-2B 
receptor (A2BR),  the receptor subtype, which is responsible for the inhibitory actions of adenosine 
on foetal calf serum (FCS) stimulated proliferation, collagen production and protein synthesis  




total protein synthesis in rat left ventricular cardiac fibroblasts, implicating the potentially important 
role of adenosine against cardiac fibrosis (Dubey, Gillespie et al. 1998). 
The antifibrotic role of A2BRs (via adenosine) was further confirmed when anti-sense 
oligonucleotide to the A2BR induced DNA synthesis, collagen synthesis and cell proliferation. This 
demonstrates the potential inhibitory characteristics of adenosine and A2BR in the regulation of 
cardiac remodelling correlated by the proliferation of cardiac fibroblasts (Dubey, Gillespie et al. 
2001). In contrast, over expression of A2BR in cardiac fibroblasts resulted in a significant reduction 
of protein and collagen synthesis associated with upregulation in cAMP. Conversely, significant 
upregulation of protein and collagen synthesis were observed when A2BRs were under expressed 
(Chen, Epperson et al. 2004). Over and above the effects on collagen synthesis, A2BR attenuates 
the mRNA expression of profibrotic gene markers, such as collagen 1 and connective tissue growth 
factor (CTGF) in neonatal rat cardiac fibroblasts pre-treated by angiotensin I or TGF-β (Vecchio, 
Chuo et al. 2016). 
Additionally, in vivo experiments showed that, genetic over expression of A2BR in mice is 
antifibrotic, attenuates cardiac remodelling and is cardiac protective against pressure-induced heart 
failure (Hamad, Zhu et al. 2012, Vecchio, White et al. 2017). Likewise, extracellular cAMP protects 
the heart from adrenergically induced cardiac fibrosis and remodelling, an effect which was opposed 
when A2BR were antagonised pharmacologically. Together, these observations imply antifibrotic 
roles for cAMP and A2BRs (Sassi, Ahles et al. 2014). Moreover, an investigation in rats 
demonstrated long-term administration of adenosine uptake inhibitor and a stable adenosine 
analogue post MI had antifibrotic effects on hearts and attenuated cardiac remodelling by inducing 
a downregulation on the mRNA levels of ANF and BNP genes, both of which are useful markers 
of cardiac hypertrophy. Additionally, pharmacological agents that upregulate intracellular 
adenosine levels or stimulate A2BRs can reduce the markers of cardiac fibrosis, such as 
downregulation in the mRNA levels of MMPs and reduction in the collagen volume (Wakeno, 
Minamino et al. 2006). On the other hand, the antifibrotic effects of A2BR agonists were inhibited 
in the presence of A2BR antagonist (MRS1754), but the antifibrotic effects remained unchanged 
when other ARs were selectively antagonised (Wakeno, Minamino et al. 2006).  
Studies on human myocardium demonstrated that, there is a significant reduction in the gene 
expression of all A2A, A2Bs and A3A adenosine receptors during heart failure.  It was also shown 
that, pharmacological increase of plasma adenosine levels would reduce the severity of chronic 




role of adenosine and A2BRs against cardiac fibrosis. However, this salutary effect might not be 
present in patients with chronic heart failure due to decreased receptor expression (Asakura, 
Asanuma et al. 2007, Vecchio, White et al. 2017). 
The second messenger downstream of adenosine receptors, cAMP, has also been shown to have 
important roles in the inhibition of the activity of cardiac fibroblasts (Swaney, Roth et al. 2005, Lu, 
Aroonsakool et al. 2013). Consistent with this, investigations in adult rat cardiac fibroblasts 
demonstrated that, the expression of SMA (a marker of cardiac fibroblasts) was increased after 
incubation with TGF-β and angiotensin II, but this was inhibited following forskolin (adenyl cyclase 
activator) and cAMP analogue stimulation. Moreover, treatment with forskolin blunted the collagen 
synthesis induced by TGF-β and angiotensin II and inhibited the transformation of cardiac 
fibroblasts to myofibroblasts. These results could demonstrate the important role of cAMP in 
inhibiting ECM production and could imply antifibrotic effects (Swaney, Roth et al. 2005).  
In addition to direct effects mediated through cAMP, adenosine has been shown to have antifibrotic 
effects via inhibiting the secretion of noradrenaline, attenuating the metabolism of endothelin and 
decreasing the production of renin-angiotensin system (Kitakaze and Hori 2000).  
Taking all these results together implies that actions of adenosine, especially via A2BRs, is 
beneficial in the treatment of cardiac fibrosis. However, it has been reported that adenosine and its 
action via A2BRs can also have deleterious effects (Borea, Gessi et al. 2017). 
For example, formation of foam cells and development of atherosclerosis are among the main 
factors of many cardiovascular diseases (Borea, Gessi et al. 2017) and can lead eventually to heart 
failure. An investigation carried out by Gessi and colleagues demonstrated that, in hypoxic 
conditions, adenosine through the stimulation of ARs (specially A2BRs), induces hypoxia inducible 
factor-1α (HIF-1α) accumulation. This is important because HIF-1α induces the development of 
foam cells and intraplaque angiogenesis, all of which could lead to atherosclerotic plaques (Gessi, 
Fogli et al. 2010). In contrast, genetic modifications of A2BRs or their pharmacological inhibition 
retarded the effects of adenosine on HIF-1α accumulation (Gessi, Fogli et al. 2010). Therefore, it 
was concluded that, adenosine and its receptors (mainly adenosine A2B receptors) play crucial roles 
in the development of coronary disease (Gessi, Fogli et al. 2010). 
Adenosine might also play detrimental roles in different chronic pulmonary inflammatory 
conditions, such as; chronic obstructive pulmonary disease (COPD) and asthma (Borea, Gessi et al. 
2017). Recently, an investigation in mouse models of pulmonary fibrosis reported that, extracellular 




adenosine levels by blocking its reuptake exacerbated the pulmonary fibrosis in these models (Luo, 
Le et al. 2016). Adenosine promotes the proliferation of a specific type of macrophages that is 
shown to be associated with pulmonary fibrosis. In another investigation, mice lacking A2BRs 
demonstrated lower pulmonary fibrosis and had their lungs function improved. These results were 
followed by a reduction in the expression of CD206 macrophages and arginase-1 (markers for 
alternatively activated macrophages). The author suggested that, adenosine and A2BRs play crucial 
roles towards the progression of lung fibrosis by having effects on the activation of macrophages 
(Karmouty-Quintana, Philip et al. 2015). 
Since adenosine stimulation and activation of A2BRs can express both stimulatory and inhibitory 
effects on cardiac fibrosis, further clinical investigations are required to design a related treatment 
for cardiac fibrosis. 
1.10 Adenosine 
Adenosine is a ubiquitous nucleoside that is produced from the breakdown of adenosine 
triphosphate (ATP) (Newby 1984). The antiarrhythmic and vasodilatory properties of adenosine 
were the first to be discovered. Since then, it became clear that besides its role as an intermediate in 
cellular metabolism on nucleotides, extracellular adenosine plays multiple important physiological 
roles in cardiovascular system (Drury and Szent-Gyorgyi 1929, Mubagwa, Mullane et al. 1996). 
Most roles are homeostatic and salutary in nature (Mubagwa, Mullane et al. 1996) but exceptions 
have been noted. For example, adenosine directly increases the rate of myocardial blood flow and 
oxygen supply (Adair 2005), whereas the antiadrenergic effects of adenosine could reduce the 
supply of oxygen in those tissues (Dobson and Fenton 1997, Adair 2005). Therefore, adenosine 
may act as a positive and negative feedback signal to tightly control the levels of oxygen in the 
tissues within the normal range (Adair 2005). Moreover, the well characterised cardioprotective 
actions of adenosine have made it a focus for clinical trials for ischaemia reperfusion injury after 
MI (Vecchio, White et al. 2017). Adenosine also plays important roles in the regulation of cardiac 
remodelling and cardiac fibrosis (Vecchio, White et al. 2017).  
1.10.1 Metabolism of adenosine 
Unlike other hormones or neurotransmitters, adenosine can be produced by any cell type and act 
locally whenever it is needed. The short half-life of adenosine extracellularly (a few seconds) would 
indicate that, it would be able to diffuse several millimetres form its production site, implying its 




The main site of adenosine production in the heart are cardiac vascular endothelium and 
cardiomyocytes.  Adenosine can be metabolised by two main pathways: the production of adenosine 
from AMP via dephosphorylation and the hydrolysis of S-adenosylhomocysteine (SAH) to 
adenosine and homocysteine (Mubagwa, Mullane et al. 1996, Adair 2005). Figure 2 shows the 
synthesis of adenosine. 
1.10.1.1 Dephosphorylation of adenosine monophosphate 
The main source of adenosine synthesis during hypoxia is by the dephosphorylation of intracellular 
adenosine monophosphate (5’-AMP), the concentration of which is dependent on adenosine 
triphosphate (ATP) and energy demand (Zimmer, Trendelenburg et al. 1973, Headrick, Peart et al. 
2011). The intracellular production of adenosine under hypoxic/ischaemia conditions takes place 
by the dephosphorylation of 5’-AMP via cytosolic-5’-nuclotidase or via cd73/ecto-5’-nucleotidase 
extracellularly (Berne 1980, Bruns 1990, Adair 2005).  
1.10.1.2 Hydrolysis of SAH 
Adenosine can also be produced through the transmethylation pathway, where SAH is broken down 
to adenosine and homocysteine by hydrolysis, a reaction that is catalysed by an enzyme known as 
SAH-hydrolase (Mubagwa, Mullane et al. 1996). In guinea pig hearts the rate of adenosine 
production via the hydrolysis of SAH is almost equal to the rate of the adenosine synthesis from the 
heart in normoxia, but it does not increase when there is a demand for oxygen (Lloyd and Schrader 
1993). 
1.10.2 Adenosine signalling 
Adenosine exerts its cardiovascular effects through the stimulation of adenosine receptors (ARs) 
family, which are G-protein coupled receptors (GPCRs) located on the cell surface membrane 
(Vecchio, White et al. 2017). This family consists of 4 class A receptors: A1, A2A, A2B and A3. 
Each one of these sub-members exerts a specific pharmacological action via coupling to 
intracellular G proteins. The A1 and A3ARs tend to activate Gi/o proteins to inhibit the activity of 
the adenyl cyclase (AC) enzyme and hence cAMP production. In contrast, the A2A and A2BR sub-
types preferentially activate Gs proteins to activate AC and increase the intracellular levels of cAMP 
(Fredholm, AP et al. 2001, Vecchio, White et al. 2017). Synchronous activation of different ARs 
could therefore have complementary or opposing signalling effects to regulate cardiac function 




1.10.3 Adenosine breakdown 
Adenosine can be broken down via two ways. It can be deaminated to inosine by an enzyme known 
as adenosine deaminase. Moreover, it can also get re-phosphorylated (using ATP as a donor) into 
AMP by adenosine kinase. Furthermore, diffusion plays an important role in the equilibration of 
adenosine. The nucleoside transporter is capable of transporting adenosine down its concentration 
gradient by diffusion (Adair 2005). Figure 1.2 demonstrates the breakdown of adenosine. 
 
Figure 1.2: Adenosine synthesis and breakdown inside and outside the cell. 





1.11 Mechanisms of cardiac fibroblasts proliferation 
As mentioned earlier, one of the therapeutic ways to target cardiac fibrosis, is to inhibit their 
proliferation rate. Therefore, it is important to look at the steps involved in cell cycle and how 
cardiac fibroblasts divide. 
1.11.1 Regulation of the cell cycle, including the importance of actin polymerisation 
The proliferation of all diploid (double sets of chromosomes) cells, including cardiac fibroblasts, is 
controlled by progression through a mitotic cell cycle. Non-dividing (quiescent) cardiac fibroblasts 
are maintained in the G0 phase, but they can be stimulated by suitable mitogenic signals to enter the 
first Gap period (G1). It is this stage where the necessary factors for DNA replication are assembled, 
proteins and organelles are made and dividing cells spend most of their time (Vermeulen, Van 
Bockstaele et al. 2003). G1 phase has a restriction point which divides it into 2 sub-phases. Prior to 
this point, the cell cycle is dependent on the growth factors, in other words, once the growth factors 
are removed, the cell cycle is forced back to G0 phase. However, after this point, the cell cycle 
progression is independent of the growth factors (Blagosklonny and Pardee 2002). Synthetic (S) 
phase is the stage where DNA is replicated, which is then followed by a second Gap (G2) phase. In 
G2 cells are prepared for mitosis (M). M phase itself is sub-divided into 4 stages known as: prophase, 
metaphase, anaphase and telophase (Vermeulen, Van Bockstaele et al. 2003). To make sure that 
cell cycle progresses correctly, there are various check points. For example: any sort of damage to 
the DNA molecule would stimulate a replication arrest either in G1 phase (when DNA repair occurs 
before replication) or in G2 (to allow DNA repair prior to chromosome separation in M phase). 
Moreover, there are checkpoints in S phase to control DNA replication and M phase to monitor 
spindle assembly (Stark and Taylor 2004, Houtgraaf, Versmissen et al. 2006). 
1.11.2 Positive regulation of the cell cycle 
The transition of phases in the cell cycle are monitored by regulatory proteins known as cycle 
dependent kinases (CDKs). CDKs belong to the family of serine/threonine kinases. They are 
enzymes that phosphorylate their specific targets, in other words, addition of an extra phosphate 
group causes a change in the structure and shape of the target protein. The protein levels of CDKs 
remain stable during the cell cycle, however, the levels of their activating proteins (cyclins) can 
vary. 
Up till now, 9 different CDKs (CDK1-9) along with 12 cyclins (A, B1-3, C, D1-3, E, F, G and H) 
have been discovered and identified in mammalian cells (Johnson and Walker 1999, Vermeulen, 




of cell division. For example: CDK2, CDK4, and CDK6 during the G1 phase, CDK2 during the S 
phase and CDK1 during the G2 and M phases (Vermeulen, Van Bockstaele et al. 2003). In contrast, 
the crucial roles of the remaining CDKs have not been reported (Rickert, Seghezzi et al. 1996). 
Upon activation, CDKs require cyclins to form enzymes which phosphorylate specific proteins to 
control the progression of the cell cycle (Vermeulen, Van Bockstaele et al. 2003). Importantly 
CDK2/4/6 activation results in the inactivation by hyperphosphorylation of the retinoblastoma 
tumour suppressor protein (Rb) (Sherr 1995, Rubin 2013). When Rb is active 
(hypophosphorylated), it binds to a family of transcription factors, known as E2F and inhibits their 
activity, which maintains cells in the quiescence state. In contrast, once Rb is hyperphosphorylated 
by the activity of CDKs, they are no longer able to bind to E2F family of transcription factors, which 
can now be released, allowing the expression of the genes involved in S phase (Burke, Deshong et 
al. 2010). 
In mammalian cells, there are important regulators that play key roles in the transition of G1 phase 
to S phase, such as all D-type cyclins and cyclin E. The three D-type cyclins bind to CDK4 and 
CDK6, whereas cyclin E makes a complex only with CDK2 (Sherr 1994). Cyclin E-CDK2 
complexes further phosphorylate Rb gene at different sites, which would result in the synthesis of 
cyclin A. Cyclin A promotes passage via the restriction point to the S phase. Once S phase starts, 
cyclin E gets degraded and CDK2 makes a complex with cyclin A to phosphorylate the proteins 
involved in DNA replication. In the next stages of the cell cycle (late stages of G2 phase and early 
M phase), cyclin A complexes with CDK1 to promote mitosis. Also, the levels of cyclin B along 
with its CDK1 complex increase at the late stages of phase G2, which regulates cell division and 
mitosis (Vermeulen, Van Bockstaele et al. 2003). 
1.11.3 Negative regulation of the cell cycle 
In addition, CDK activities are also controlled by other mechanisms, such as phosphorylation on 
conserved threonine and tyrosine residues brought about by CDK activating kinase (CAK) 
(Vermeulen, Van Bockstaele et al. 2003). Phosphorylation on these residues introduces 
conformational changes which enhances the binding of the cyclins to CDKs (Jeffrey, Russo et al. 
1995). In contrast, phosphorylation can also be a negative regulator and halt the cell cycle. For 
example, phosphorylation of CDK1 by Wee1 (at tyrosine-15) and Myt1 (at threonine-14) 
inactivates this kinase. On the other hand, dephosphorylation of these sites on CDK1 (which is 
brought about by an enzyme known as Cdc25) is necessary for its reactivation (Lew and Kornbluth 




Furthermore, the activity of the CDKs can also be inhibited by cell cycle inhibitory proteins, known 
as CDK inhibitors (CKI). CKIs bind to CDKs alone or to the cyclin-CDK complexes and inhibit 
the CDK activity (Vermeulen, Van Bockstaele et al. 2003). CKIs are divided into two families: the 
INK4 and the Cip/Kip families (Sherr and Roberts 1995). 
Briefly, the INK4 family is made up of 4 different proteins, namely p15, p16, p18 and p19. This 
family of CKIs specifically inhibits CDKs involved in the G1 phase of the cell cycle, such as: CDK4 
and CDK6. Their mechanism of inhibition is by making stable complexes with CDKs and stopping 
them from making complexes with cyclin D (Carnero and Hannon 1998, Canepa, Scassa et al. 
2007). 
On the other hand, the Cip/Kip family is made up of three different proteins: p21, p27 and p57. 
Unlike the INK4 family, they have a broader range of specificity. In addition to the inhibition of the 
cyclin D-CDK4 and cyclin D-CDK6, they can also inhibit cyclin B-CDK1 and DNA synthesis 
(Hengst and Reed 1998). 
1.11.4 Regulation of CDKs in the cell cycle of cardiac fibroblasts 
Literature evidence suggested important roles of CDKs, cyclins and CKIs in the regulation of the 
cardiac fibroblast cell cycle (Qi, Liu et al. 2017, Valkov, King et al. 2019). Recently, an 
investigation in rats demonstrated that inhibition of CDK2 and cyclin E halted the progression of 
cell cycle in cardiac fibroblasts. In addition, increased expression of CKIs, such as p21 (in rat hearts) 
and p27 (in cultured cardiac fibroblasts) downregulated the interstitial cardiac fibrosis. In contrast, 
inhibiting the activities of CKIs by gene therapy induced DNA synthesis, suggesting the 
involvement of these CKIs in the inhibition of cardiac fibroblast proliferation (Qi, Liu et al. 2017). 
Several cytokines and growth factors are implicated in the regulation of myocardial growth during 
developmental and pathologic conditions (Koudssi, Lopez et al. 1998). Interleukin-1β is a 
polypeptide secreted by different types of cells, such as smooth muscle cells, epithelial cells and 
fibroblasts (Dinarello 1994). The expression of this polypeptide by myocardial cells has been 
detected in several clinical circumstances characterised by inflammatory myocardial injuries. 
Cardiac fibroblasts are important sources of interleukin-1β, which upregulates the protein content 
of myocytes but downregulates the DNA synthesis in cardiac fibroblasts (Koudssi, Lopez et al. 
1998). Investigations on isolated rat cardiac fibroblasts have shown that interleukin-1β inhibits the 
progression of the cell cycle by preventing entry into S phase and arresting them in the G1/S 
interface. Moreover, interleukin-1β also decreases the phosphorylation state of Rb in these cells, 




and cyclins, such as: A, D2, D3 and E (Koudssi, Lopez et al. 1998). These findings demonstrate the 
roles of these proteins in the cell cycle of cardiac fibroblasts and emphasise the potential importance 
of targeting them for future treatments. 
As mentioned previously, once cardiac fibroblasts are activated, they can migrate to different areas 
within the tissue. Consequently, it is important to delve deeper into the mechanism of cardiac 
fibroblast migration.   
1.12 Mechanisms of cardiac fibroblasts migration 
Cell migration plays essential roles in health and diseases states, such as embryogenesis, tissue 
development, immune response and wound healing (Lauffenburger and Horwitz 1996, Mitchison 
and Cramer 1996, Kole, Tseng et al. 2005). Directional motility consists of different steps: 
protrusion of lamellipodia (parts of the cellular cortex) at the leading edge; attachment (adhesion) 
at the leading edge; deadhesion of the rear (trailing edge); and movement of the cell (Kole, Tseng 
et al. 2005, Petrie, Gavara et al. 2012). Cell migration occurs by the assembly, disassembly and 
reformation of filament structures (also known as the actin cytoskeleton), that are regulated by 
members of Rho family of small GTPases, such as Rac, Cdc42 and RhoA (Nobes and Hall 1999). 
Genetic modifications have demonstrated that Rac is important for membrane protrusion and Cdc42 
is necessary for the maintenance of cell polarity (Nobes and Hall 1999). RhoA, on the other hand, 
plays important roles in the regulation of actin dynamics, encouraging the contraction of acto-
myosin by controlling myosin II and formins (Sixt 2012, Zhou and Zheng 2013). 
Actin is among the most abundant proteins in eukaryotic cells; and actin filaments are the dominant 
structural components in lamellipodia. Actin filaments are structures made up of double helical 
polymers of globular subunits, with head to tail arrangements. The structure has two ends: the 
barbed end and the pointed end (Pollard and Borisy 2003). Polymerisation of actin at the leading 
edge leads to the formation of sheet like (lamellipodia) and rod like (filopodia) protrusion at the cell 
membrane (Nobes and Hall 1995). In lamellipodia, actin filaments cross together and form a 
meshwork-like network, while in filopodia, they are arranged into bundles of ropes (Lauffenburger 
and Horwitz 1996). 
At the leading edge of the cell, polymerisation of actin filaments provides the cells with the 
necessary pushing force. This requires the addition of actin monomers (G-monomers) to the plus or 
barbed end of actin filaments via formins, such as: mDia1 and mDia2, which involves the interaction 
with G-actin-bound-profilin. In addition to this, a stronger force can either be achieved by the 




the help of an enzyme known as cofilin, which increases actin polymerisation by producing 
additional free barbed ends (Mogilner and Oster 1996). Cell migration is also dependent on 
contractile forces at the trailing edge of the cell. Behind the leading edge, actin filaments are 
arranged into bundles to form stress fibres that criss-cross the cell and associate with myosin II to 
enhance the movement of the rear end of the cell. Force production at the leading and the trailing 
edge of the cell is dependent on the adhesion with ECM (Webb, Parsons et al. 2002). These contacts 
are facilitated by integrin adhesions, shaped at the leading edge and matured into focal adhesions. 
The focal adhesions are structures where F-actin fibres are attached; and they finally get 
disassembled at the trailing edge of the cells. Due to multiple protein interactions present in focal 
adhesions, such as: PI3K; focal adhesion kinase (FAK); and MAPKs; focal adhesions can also act 
as signalling complexes (Wozniak, Modzelewska et al. 2004). Figure 1.3 summarise the steps 






Figure 1.3: Steps involved in the migration of cardiac fibroblasts 
There are distinctive steps involved in the migration of cells with mesenchymal origin. Once the 
direction of the movement of the cell is determined, actin polymerisation at the front of the cell 
forms membrane protrusions via two means: filopodia and lamellipodia. Following the extension 
of the cell membrane, it connects its leading edge to the surface (ECM) over which it is moving by 
the formation of integrin-based complexes. Eventually, the resulting focal adhesions get matured 
and F-actin fibres are attached. Contractile forces are applied to the focal connections via myosin II 
motors to enhance the migration of the cells. As the cell migrates, it detaches from the ECM at the 
cell body and the rear, inducing cell contraction and facilitating the movement of the cell. Finally, 





1.12.1 Regulation of migration by Rho-GTPases 
Rho-GTPases regulate the coordination of cell migration and actin polymerisation. Guanine 
nucleotide exchange factors (GEF proteins), exchange GDP (inactive form) to GTP (active form) 
(Jaffe and Hall 2005). In humans, the Rho family consists of 20 different members. Among the 
members, RhoA, RhoB, Rac1, Rac2 and Cdc42 have been among the most widely investigated for 
their roles and effects on cell migration (Ridley 2001). Rho-GTPases can get inactivated via two 
ways: guanine nucleotide (GDP) dissociation inhibitors (GDIs) and GTPase activating proteins 
(GAPs). GDI binds to the inactive form of RhoA and prevents the exchange of GDP for GTP; and 
also inhibits the interaction with cell membrane (Carpenter, Tolias et al. 1999, Hansen and Nelson 
2001). On the other hand, GAPs can catalyse the dephosphorylation of GTP to GDP (Cherfils and 
Zeghouf 2013). Among the members of the Rho-GTPases, RhoA, Rac1 and Cdc42 can regulate the 
activity of proteins modulating actin polymerisation in order to control the formation of F-actin 
fibres, lamellipodia and filopodia (Nobes and Hall 1995, Tapon and Hall 1997, Hall 1998). As noted 
above, actin polymerisation at the leading edge of cardiac fibroblasts (eukaryotic cells) arises from 
the well-coordinated activities of different nucleating proteins, such as: Formins (mDia1 and 
mDia2) and Arp2/3 (Swaney and Li 2016). 
Rac1, Cdc42 and RhoA regulate the assembly of cytoskeleton in different ways (Hall 2005, Sit and 
Manser 2011). Rac1 activates Arp2/3 through the activation of WASP family verprolin-homologous 
protein (WAVE) and it regulates the formation of lamellipodia (Takenawa and Miki 2001, Hall 
2005). Like Rac1, Cdc42 also activates Arp2/3 via Wiskott-Aldrich syndrome protein (WASP) and 
N-WASP (Higgs and Pollard 2000). In addition, Cdc42 also activates mDia2, resulting in the 
regulation of filopodia (Hall 2005). On the other hand, mDia1 gets activated by RhoA to enhance 
linear actin polymerisation and regulate the formation of stress fibres (Hall 2005, Lammers, Meyer 
et al. 2008). Moreover, the activation of RhoA by Rac1 results in the development of new sites of 
adhesion and the formation of contractile filament assembly with an advancing lamellipodium 
(Nobes and Hall 1995).  
Importantly, the two GTPases, Rac1 and RhoA have antagonistic effects on actin-myosin 
contraction (Kirfel, Rigort et al. 2004, Martin, Ouellette et al. 2016). RhoA activity results in the 
activation of a kinase known as Rho-kinase (ROCK), which is induced by the binding of Rho to the 
Rho-binding domain on the COOH terminal (Phrommintikul, Tran et al. 2008). ROCK has two 
isoforms: ROCK1 and ROCK2 (Zhang, Bo et al. 2006). Upon activation, ROCK phosphorylates 
and inactivates an enzyme known as myosin light chain phosphatase (MLCP), which regulates 




necessary contractility force and induces RhoA-mediated reformation of actin stress fibres, an 
important mechanism in cell migration that is depended on ROCK (Totsukawa, Yamakita et al. 
2000). One of the other protein targets of ROCK is LIM-kinase (LIMK), which contributes to the 
actin polymerisation by inhibiting cofilin and stabilising F-actin fibres (Amano, Nakayama et al. 
2010). Equally, MLC kinase can get phosphorylated and inactivated by the activation of p21-
activated kinase (PAK1) via Rac1. This results in the downregulation of contractile forces and 
upregulation of cell migration (Martin, Bollag et al. 1995). Cell polarity is a necessary process for 
cell migration. Polarity is regulated not only via the contractile forces mediated by the arrangement 
of actin filaments and deadhesion at the rear end of the cell, but also via proper orientation 
positioning microtubule organising centre (MTOC) at the leading edge of the cell (Gomes, Jani et 
al. 2005). 
Rho-GTPases were initially recognised as a molecular switches, which associate integrin receptors 
on the cell membrane to rearrangements of the actin cytoskeleton and have emerged as crucial 
targets for cardiovascular disease (Budzyn, Marley et al. 2006). As cells change the arrangements 
of their actin cytoskeleton in response to stimuli, such as growth factors, or during mitosis and cell 
migration, they alter the localization of their intracellular proteins by regulating Rho-GTPases 
(Rajagopalan, Kurz et al. 1996). Rho-GTPases can also influence cellular processes, such as 
membrane trafficking, mRNA stability and gene transcription (Laufs and Liao 2000). Elevated 
RhoA and Rac1 activities induce cardiac hypertrophy atrial fibrillation (Clerk and Sugden 2000, 
Adam, Frost et al. 2007).  In contrast, inhibiting RhoA either by gene expression or using selective 
inhibitor for RhoA (by Clostridium botulitum C3 coenzymes) retards cardiac remodelling effects 
caused by angiotensin II (Aikawa, Komuro et al. 1999).  
Like the Rho-GTPases, the Rho-ROCK pathway plays important roles in regulating different 
cellular functions, such as organisation of F-actin filaments, cell adhesion, proliferation and 
migration, which are all involved in the pathogenesis of cardiac fibrosis (Shimokawa and Rashid 
2007, Haudek, Gupta et al. 2009). Consistent with this, studies in mice demonstrated that the mRNA 
and protein levels of ROCK1 were increased in fibrotic hearts induced by pressure overload (aortic 
constriction). Conversely, ROCK1 knockout mice demonstrated reduced non-adaptive cardiac 
fibrosis and lower differentiation of cells into cardiac myofibroblasts (Zhang, Bo et al. 2006). 
Moreover, ROCK haplo-insufficient mice had lower perivascular fibrosis induced by pressure 
overload and MI (Rikitake, Oyama et al. 2005). One way that ROCK promotes fibrosis is by 
promoting cardiac fibroblast proliferation. ROCK promotes proliferation via its actions on MKL1/2 




MKL1/2 and thereby promotes the transcription of SRF/MKLs target genes (Fan, Sebe et al. 2007, 
Elberg, Chen et al. 2008). Hence, Rho-GTPases, and at least in some cases ROCK, therefore have 
important roles in the regulation of cardiac fibroblasts and dysregulation of the Rho-ROCK-actin 
pathway can be a crucial mediator of cardiac fibrosis (Rikitake, Oyama et al. 2005). However, the 
role of ROCK in regulating cardiac fibroblast migration is less clear. Investigations in Gerbil 
fibroblasts demonstrated that these cells migrated faster upon the inhibition of ROCK by a specific 
ROCK inhibitor, Y27632 (Totsukawa, Wu et al. 2004).  
1.13 Transcriptional regulation of cardiac fibroblasts 
Following any cardiac injury, the sum of all the transcriptional modifications of cardiac fibroblasts 
could lead to pathological changes in their behaviour (Lighthouse and Small 2016). The 
transcriptional regulations of cardiac fibroblasts could be affected by different pathological stimuli, 
such as stimulation of the receptors on the cell surface membrane or/and modifications in their 
mechanical tensions (Lighthouse and Small 2016). Mechanisms which target the phenotypic 
plasticity of cardiac fibroblasts are discussed below. 
1.13.1 SRF/MKL/RhoA 
Serum response factor (SRF) is a conserved transcription factor that is important for life. It was first 
discovered in investigations on proliferative responses to serum (Esnault, Stewart et al. 2014). 
However, the binding site of SRF (CArG) is also important for myocardial (and other muscle cell) 
expression of differentiation genes, such as the sodium calcium exchanger and cardiac alpha actin 
(Cheng, Hagen et al. 1999, Latinkic, Cooper et al. 2002). The selection of SRF target genes and the 
scale of their transcriptional activation depend on the interactions with co-factors (Norman, 
Runswick et al. 1988). For example, the expression of genes encoding for SMC contractile proteins, 
which is also mediated by the CArG element, is effectively regulated by the interaction of SRF and 
members of the family of transcription cofactors related to myocardin (Miano 2003).  
This family of cofactors consists of different members, such as myocardin, megakaryoblastic 
leukemia1 (MKL1) and MKL2 (Pipes, Creemers et al. 2006, Gau, Veon et al. 2017). Myocardin 
functions primarily in SMC and cardiomyocytes. It mediates the transcription of SMC 
differentiation genes and plays important roles in heart development (Wang, Chang et al. 2001, Du, 
Ip et al. 2003). On the other hand, MKL1 and MKL2 are widely expressed and can be translocated 
from nucleus to cytoplasm by Rho activation (Miralles, Posern et al. 2003). The shuttling 
mechanism between nucleus and cytoplasm is defined by their RPEL domain i.e. amino acids 




basal conditions, the regulation of MKL localisation and its interaction with SRF is controlled by 
the interaction of its RPEL domain with monomeric G-actin. 
In other words, when F-actin is polymerised, the amount of monomeric G-actin is reduced, allowing 
the translocation of MKL into the nucleus where it binds to SRF and increase the transcription of 
SRF target genes (e.g. CCN1 and CTGF), resulting in more proliferation and migration (Cen, 
Selvaraj et al. 2003, Selvaraj and Prywes 2004). In contrast, depolymerisation of F-actin filaments 
causes an increase in the pool of G-actin, meaning more interaction and lesser translocation of 
MKL1/2 into the nucleus, inducing lesser transcription of SRF target genes (Guettler, Vartiainen et 
al. 2008). It implies that MKL1/2 regulate the phenotypic responses of fibroblasts by linking 
modifications in the actin filaments to the regulation of SRF target genes (Guettler, Vartiainen et al. 






Figure 1.4: Structures of myocardin, MKL1 and MKL2 with their different domains 
Myocardin-related transcription factors (MRTFs) share conserved domains, namely RPEL, NLS, 
basic, glutamine rich (Q), scaffold-attachment factor A/B, Acinus, PIAS (SAP), leucine zipper (LZ) 
and transcription activation (TAD) domains. The RPEL domains regulate actin binding in MKL1 
and MKL2. This domain also contains an NLS sequence, meaning that actin binding can alter the 
subcellular localisation of MKL1 and MKL2. In contrast, in myocardin these domains have 
diverged to the point that myocardin does not associate with G-actin. The basic, glutamine rich and 
transcription activation domains are required for SRF-binding. The LZ domain regulates homo- and 
heterodimerisation with other MRTF family members. The numbers to the right indicate the number 





1.13.2 The function of SRF/MKLs/RhoA 
Chromatin immunoprecipitation assays and microarray studies documented groups of SRF-target 
early growth response genes, including c-fos and Egr1, which are co-regulated by MKL1 in 
fibroblasts (Selvaraj and Prywes 2004). These genes regulate proliferation in the cell cycle by 
promoting the transition of G0 to G1. Fibroblasts gene ontology analysis of the SRF/MKL target 
genes also uncovered additional genes associated with dynamics of actin filaments, proliferation 
and migration (Esnault, Stewart et al. 2014).  
In the light of the roles of MKL1/2 as downstream mediators of ROCK signalling, other recent 
investigations also uncovered the importance of regulating MKL1/2 in fibroblast activation. For 
example, MKL1 knockout mice showed lower cardiac fibrosis post MI and displayed lower fibrosis 
in response to angiotensin II (a mediator of post-MI fibrosis). It was implied that the protective 
effects of MKL1 deletion were linked with reduction in expression of genes associated with fibrosis, 
such as collagen 1α2 (Small, Thatcher et al. 2010). Moreover, pulmonary fibrosis caused by 
bleomycin was ameliorated in MKL1 knockout mice via reduced myofibroblast proliferation 
(Bernau, Ngam et al. 2015). MKL1 may therefore play important roles in the regulation of 
myofibroblast phenotype (Lighthouse and Small 2016). In contrast, global genetic deletion of 
MKL2 or SRF in mice resulted in structural cardiac abnormalities and induced embryonic lethality 
(Arsenian, Weinhold et al. 1998, Mokalled, Carroll et al. 2015).  
Recent investigations have identified MKL1/2 as potential therapeutic targets to regulate fibroblast 
responses (Lighthouse and Small 2016). Studies in human dermal fibroblasts demonstrated that 
MKL1 mediates fibroblast contractility, whereas MKL1 deficient fibroblasts failed to express genes 
encoding for SMC contractile proteins i.e. impaired myofibroblast transformation. The authors also 
identified, N-cyclopropyl-5-(thiophen-2-yl)-isoxazole-3-carboxamide (ISX) as a stimulator of 
fibroblast activation in a MKL1 dependent manner. ISX induces the differentiation of human 
fibroblasts to myofibroblasts (which is dependent on MKL1/SRF) in vitro and it also accelerates 
cutaneous wound healing in vivo (Velasquez, Sutherland et al. 2013). On the other hand, MKL1/2 
can be pharmacologically inhibited, as their RPEL domains are the molecular targets for CCG-
1423, an inhibitor of Rho signalling (Hayashi, Watanabe et al. 2014). Pharmacological inhibition 
of MKL1/2 can suppress lung, colonic and dermal fibrosis in vivo (Evelyn, Bell et al. 2010, Haak, 




1.13.3 Hippo pathway/YAP/TAZ/TEAD 
The hippo pathway, is the most recently discovered family of signalling pathways that controls the 
size of the organs by mediating cell differentiation, proliferation and migration (Del Re 2018). It is 
an evolutionary conserved Serine/Threonine signalling pathway first discovered in fruit flies 
(Harvey, Pfleger et al. 2003). The core component of this signalling pathway are mammalian sterile 
20-like kinases (MST1 and MST2), the regulatory protein salvador (SAV1), large tumour 
suppressor kinases (LATS1 and LATS2) and Mps one binder kinase activator-like 1A (MOB1A 
and MOB1B) (Rognoni and Walko 2019). Upon activation, MST1 and MST2 attach to SAV1 to 
produce an active enzyme that activates LATS1 and LATS2 kinases via phosphorylation at Thr1079 
and Thr1041 respectively (Chan, Nousiainen et al. 2005). MST1 and MST2 can also phosphorylate 
MOB1A/B (which are regulatory subunits of LATS1 and LATS2) at Thr35 and Thr12 respectively 
(Praskova, Xia et al. 2008). In addition, phosphorylation at MOB1A and MOB1B leads to the auto-
phosphorylation of LATS1 and LATS2 (Boopathy and Hong 2019). In order for LATS kinases to 
be active, both phosphorylation of MST1/2 and auto-phosphorylation of LATS1/2 kinases are 
required (Galan and Avruch 2016). 
Activated LATS1/2-MOB1A/B can then phosphorylate the two major cofactors of transcriptional 
enhancer factor domain (TEAD1-4), known as yes associated protein (YAP) and transcriptional 
coactivator with PDZ-binding domain (TAZ). YAP has two tryptophan domains (WW1 and WW2) 
and can be phosphorylated at 5 different serine/threonine sites: Ser61, 109, 127, 164 and 381. On 
the other hand, TAZ has one WW domain and can be phosphorylated at 4 serine/threonine sites: 
Ser66, 89, 117 and 311 (Zhao, Wei et al. 2007, Hao, Chun et al. 2008, Lei, Zhang et al. 2008). Once 
YAP and TAZ are phosphorylated, they either get recruited to14-3-3 proteins leading to cytoplasmic 
localisation (Zhao, Wei et al. 2007, Lei, Zhang et al. 2008) or get ubiquitinated leading to their 
proteolytic degradation (Zhao, Li et al. 2010). Any mutation on the serine residues of YAP and TAZ 
(mentioned above) makes these TEAD cofactors unresponsive to the hippo pathway (Piccolo, 
Dupont et al. 2014). Figure 1.5 demonstrates the structure of YAP and TAZ. 
In contrast, when LATS1/2 kinases are not active, YAP/TAZ are no longer phosphorylated and are 
not bound to 14-3-3 proteins. They get translocated into the nucleus, where they can bind to the 
TEAD transcription factors to regulate the transcription of TEAD target genes, such as: connective 
tissue growth factor (CTGF); cysteine-rich angiogenic inducer 61 (CYR61) also known as cellular 
communication network factor (CCN1); plasminogen activator inhibitor 1 (PAI1); zyxin (ZYX); 
and others to regulate cell survival, growth, proliferation and migration (Chen, Chen et al. 2001, 




Sessions et al. 2019). Figure 1.6 demonstrates the hippo signalling pathway. Studies in mice 
demonstrated that active YAP (a mutation on YAP that increases its nuclear localisation and 
activity) resulted in an increase in liver size and proliferation rate (Camargo, Gokhale et al. 2007). 
Furthermore, YAP activation in mice induced tumorigenesis, which might be due to the increase in 
the transcription rate of CCN1 and CTGF genes (Dong, Feldmann et al. 2007, Zhao, Ye et al. 2008). 
Overall, loss of any of the main components of the hippo pathway, such as MSTs, SAV1, 
MOB1A/B and LATS1/2 kinases, should turn off this signalling pathway. This increases the 
transcription rate of the YAP/TAZ/TEAD target genes that are required for cell growth, 
proliferation and migration (Boopathy and Hong 2019).  However, an important thing to discuss is 








Figure 1.5: Schematic representation of YAP and TAZ proteins with their domains and 
posttranslational modification sites 
The phosphorylation sites (serine) targeted by different kinases are demonstrated with circles in 
different colours. BD: Binding domain; TAD: Transcriptional activation domain; PDZ BD: Small 
COOH-terminal domain that is capable of interaction with proteins having the PDZ domains in their 







Figure 1.6: Schematic diagram representing the Hippo signalling pathway in mammalian cells 
Left, When the signalling pathway is active, upstream signals mediate the phosphorylation of 
MST1/2, LATS1/2, YAP and TAZ proteins. Upon YAP and TAZ phosphorylation, they either get 
bound to 14-3-3 proteins and localised in cytoplasm or get proteolytically degraded. Right, when 
the signalling pathway is off, YAP and TAZ are not phosphorylated. They get translocated into the 
nucleus, where they bind to the TEAD element to mediate the transcription of TEAD target genes 





1.13.4 Mechanical signals regulating YAP/TAZ/TEAD  
Like other cell types, cardiac fibroblasts are subjected to different mechanical forces, such as stress 
and strain (Boopathy and Hong 2019). These mechanical inputs are produced by the stiffness of the 
ECM and by the pulling force generated by the neighbouring cells (Piccolo, Dupont et al. 2014). 
The mechanics of the cells and the organisation of their actin cytoskeleton are central inputs that 
cells use control their proliferation and migration in response to growth factors (Piccolo, Dupont et 
al. 2014). Importantly, the localisation (activity) of YAP/TAZ in response to these mechanical 
inputs is dependent on the status of cytoskeleton and the activity of Rho-GTPases (Zhao, Wei et al. 
2007, Piccolo, Dupont et al. 2014, Boopathy and Hong 2019).  
When a cell is stretched over a matrix, the formation of F-actin filaments induces the nuclear 
localisation and activation of YAP/TAZ, encouraging cell proliferation and migration (Dupont, 
Morsut et al. 2011). In contrast, when the morphology of the cell is changed into a rod shape, the 
F-actin filament are disturbed, resulting in the cytoplasmic translocation of YAP/TAZ, inhibiting 
their transcriptional activation capacity and retarding cell proliferation and migration (Rajkumar, 
Qureshi et al. 2017).  
1.13.5 The function of YAP/TAZ/TEAD in the heart 
YAP/TAZ/TEAD play crucial roles in the development of heart. Studies introducing mutation in 
TEAD1 gene in mice showed cardiac abnormalities, such as thinning of the cardiac ventricular walls 
and oedema. Also, it was suggested that TEAD1 plays central roles in the maturation stages of 
cardiogenesis (Chen, Friedrich et al. 1994) 
Several lines of evidence suggested that YAP/TAZ-TEAD complex plays crucial roles in promoting 
fibrosis. For example, YAP activation has been shown to enhance cardiac fibroblast activation and 
in matrix remodelling of dilated cardiomyopathy (Jin, Zhu et al. 2018). Also, investigations in 
rodents demonstrated that conditional deletion of LATS1 and LATS2 in cardiac fibroblasts, which 
normally repress YAP and TAZ activity, induced cardiac fibrosis in mice (Xiao, Hill et al. 2019). 
In Zebrafish models of cardiac injury, hearts with YAP mutants demonstrated lower collagen 
synthesis at seven days post-cryoinjury, implying important roles of YAP in scar formation during 
heart regeneration (Flinn, Jeffery et al. 2019). Moreover, YAP knockout in primary rat cardiac cells 
revealed a fibroblast-specific role for YAP in regulating pro-inflammatory cytokines and 
chemokines, implying that YAP-TEAD-mediated gene expression may also have crucial roles in 
promoting inflammation, which is also an important factor prompting the fibrotic response (Flinn, 




However, the role of YAP-TEAD in cardiac fibrosis is controversial. Some studies suggest an anti-
fibrotic role of YAP. For example, over expression of YAP in the hearts of mice reduces scarring 
and fibrosis after MI. Moreover, quantification of fibrotic area displayed higher cardiac fibrosis in 
hearts of the control mice compared to YAP overexpressed mice. Furthermore, hearts of wildtype 
mice injured at postnatal day 2, were fully healed within 26 days, displaying minimal scarring. On 
the other hand, mice with YAP knockout hearts, showed a deficiency of healthy myocardial tissues 
along with large fibrotic area (Xin, Kim et al. 2013). Also, homozygous deletion of YAP elicits 
myocardial fibrosis compared to a sham group and a heterozygous YAP deleted group, leading to 
ventricular remodelling. It is not clear why these studies suggest opposite roles of YAP in regulating 
cardiac fibrosis. However, this may reflect different functions of YAP in cardiac fibroblasts and 
cardiomyocytes. For example, heterozygous YAP inactivated mice hearts displayed enhanced 
myocyte apoptosis (Del Re, Yang et al. 2013), which may exacerbate myocardial injury and 
indirectly promote fibrosis. 
1.14 cAMP: synthesis, degradation and signalling 
1.14.1 cAMP synthesis 
The 3’-5’ cyclic nucleotide, cAMP, is derived from ATP catalysed by adenylate cyclase (AC). The 
structure of an AC comprises two groups of transmembrane helices. This enzyme belongs to a larger 
family consisting of six different classes. In mammals, cAMP is produced by the third group of this 
family (class III ACs), consisting of ten members, nine of which belong to the transmembrane AC 
(tmAC) sub-family and one belongs to soluble AC (sAC). Cardiomyocytes do not express all the 
members. In fact, the expression of tmACs 1, 5, 6, 8 and sAC have been confirmed and most of 
them modulate inotropic and chronotropic outputs from β-adrenergic receptors.  The activity of 
tmAC is modulated by neurotransmitters and hormones, and the mechanisms responsible for the 
activation and inhibition of tmACs are similar between all the nine members. Stimulation and 
inhibition are controlled via Gs and Gi proteins respectively, although there are some differences 
between them in their regulation by different PKAs. The other source of ACs, sAC, does not have 
any transmembrane domain and exists throughout the cell (i.e. mitochondria and nucleus). This 
cAMP source has the ability to produce cAMP molecules in the vicinity of the specific targets 








Figure 1.7: Structure of an AC 
The structures of ACs are made up of two transmembrane regions comprising six helices each 
(represented by TM1 and TM2) and to cytoplasmic (C1 and C2) domains. NH2: N-terminal; COOH: 





1.14.2 cAMP degradation 
The intracellular concentration of cAMP is maintained and controlled via two mechanisms: 
hydrolysis by phosphodiesterase (PDE); and efflux transportation by nucleotide efflux transporters 
(Boularan and Gales 2015). PDEs are encoded by twenty-one different genes and classified into 
eleven families. They are made up of two catalytic domains. Eight families of PDEs have been 
reported to be expressed in heart: PDE 1, 2, 3, 4, 5, 7, 8 and 9 (Omori and Kotera 2007, Boularan 
and Gales 2015). The important role of PDEs in forming the intracellular cAMP gradient in rat 
neonatal cardiomyocytes was first elucidated with the help of imaging approaches where it was also 
demonstrated that the gradient of cAMP might also activate PKA molecules (Zaccolo and Pozzan 
2002). Certain PDE isoforms are responsible for selectively hydrolysing cAMP to 5-AMP, or in 







Figure 1.8: The structures of PDEs 
The catalytic domain shown on the figure is conserved between all PDEs, whereas the regulatory 
domain varies between them. Calm BD: Binding site of calmodulin; GAF: cGMP-specific PDE, 
adenylate cyclase and FhIA; NHR: N-terminal; UVCR: Upstream conserved region; PAS: Per-





One of the other ways by which the concentration of intracellular cAMP is controlled is its extrusion 
out of the cells via a transport system known as Multi Drug Resistant Protein (MRP). This 
transporter belongs to the super family of ATP-Binding Cassette  (ABC) transporters (Cheepala, 
Hulot et al. 2013). MRP4 which is the most abundant isoform in the plasma membrane of 
cardiomyocytes (Sassi, Abi-Gerges et al. 2012) has been documented to regulate cAMP 
homeostasis in cardiac myocytes by efflux transportation. MRP4 deficient adult rat cardiomyocytes 
showed an increase in cAMP formation and were more prone to cardiac hypertrophy compared the 
sham group, an effect which was then compensated by an increase in PDEs expression (Sassi, Abi-
Gerges et al. 2012). 
cAMP signalling exerts its effects via different effectors. Its production activates two main 
downstream effectors: Protein Kinase A (PKA); and Exchange Protein Activated by cAMP 
(EPAC). 
1.14.3 cAMP/PKA/EPAC signalling 
Following β-adrenergic receptor stimulation (sympathetic) of heart cells, cAMP levels increase and 
activate cAMP dependent PKA/EPAC pathways to increase the force of contraction. This occurs as 
a result of PKA phosphorylating target proteins including Ca2+ channels and RyR to increase 
cytosolic Ca2+ which will activate greater interaction between actin and myosin because more Ca2+ 
would bind to troponin C during the systolic phase, promoting higher force of contraction (Cazorla, 
Lucas et al. 2009, Grimm and Brown 2010).  
1.14.3.1 Protein kinase A 
In an inactive state, PKA consists of a complex of two catalytic subunits and two regulatory 
subunits. The binding of two cAMP molecules to each regulatory subunit alters their conformation 
and liberates the catalytic subunits (which are now active) allowing them to phosphorylate their 
target proteins. Also, PKA phosphorylates other proteins that can accelerate relaxation which 
include phospholamban (PLN) (Figure 8).  
On the other hand, phosphorylation of troponin I (which is the inhibitory unit of troponin complex) 
via PKA activation, enhances the relaxation during diastolic phase. It has been suggested that, 
phosphorylation at these sites could be the crucial mechanism responsible for cardiac relaxation and 
contraction (Okumura, Fujita et al. 2014) 
In addition to altering excitation-contraction coupling,  the activated PKA catalytic subunits enter 
the nucleus, where they phosphorylate a transcription factor known as cAMP Response Element 




Johannessen et al. 2005, Sassone-Corsi 2012). Phosphorylated CREB then recruits a CREB binding 
protein forming a complex, which by binding to a specific regulatory region that is present in the 
promotor known as CREB Regulatory Element (CRE) regulates the transcription of the specific 
target genes (Figure 6), such as: cAMP Responsive Element Modulator (CREM), which is involved 
in insulin secretion and spermatogenesis; Hyaluronic Acid Synthase 1 (HAS1), which maintains 
tissue homeostasis and accelerates healing; and Nuclear Receptor subfamily 4 group A member 1 
(NR4A), which is involved in vascular cell proliferation (Martinez-Gonzalez and Badimon 2005, 
Dwivedi and Pandey 2008, He, Song et al. 2014, Salvi and Abderrahmani 2014, Siiskonen, Oikari 
et al. 2015) 
1.14.3.2 Exchange protein directly activated by cAMP 
More recently described cAMP sensors are exchange proteins activated directly by cAMP (EPACs), 
which were discovered in 1998 (Kawasaki, Springett et al. 1998). Unlike PKA, EPAC is not a kinase 
but is a guanine exchange factor (GEF), exchanging GDP (inactive form) to GTP (active form) for 
the Ras family of G proteins, Rap1 and Rap2 (Borland, Smith et al. 2009). Figure 1.9 demonstrates 
the activation of Rap. 
There are two isoforms of EPAC proteins, EPAC1 and EPAC2. Whereas, EPAC1 is abundantly 
distributed in heart, blood vessels and kidneys, the expression of EPAC2 is more restricted to 
pancreas, adrenal glands and central nervous system (Bos, de Rooij et al. 2001). 
EPAC1 is encoded by RAPGEF3 gene and EPAC2 is encoded by RAPGEF4 gene (Lezoualc'h, 
Fazal et al. 2016). EPAC1 and EPAC2 share similar motifs in their structures. They both have an 
N-terminal regulatory a C-terminal region (de Rooij, Rehmann et al. 2000), which contains the 
following domains: a dishevelled, Egr-10, pleckstrin (DEP) domain; and cyclic nucleotide binding 
(CNB) domain. DEP domain is involved in EPAC membrane localisation, whereas the CNB domain 
binds to cAMP with high affinity (Lezoualc'h, Fazal et al. 2016, Ramos and Antonetti 2017). On 
the other hand, the C-terminal catalytic regions contain the following domains: the Ras exchange 
motif (REM) domain; Ras associated (RA) domain; and a cell division cycle 25, CDC, homology 
(CDC25H) domain. The REM domain is need for biological responses, the RA domain is required 
for perinuclear localisation of EPAC and the CDC25H domain is necessary for RAP activation and 
nuclear localisation of EPAC (Lezoualc'h, Fazal et al. 2016, Ramos and Antonetti 2017). 
Importantly, EPAC2 has an extra CNB domain. This additional CNB domain has a lower affinity 
for cAMP and it is not essential for the activation of EPAC2 (Lezoualc'h, Fazal et al. 2016). Figure 




Elevated cAMP interacts with the phosphate binding cassette of Cyclic Nucleotide-Binding Domain 
(CNBD-B) of EPAC. This interaction results in a conformational change of EPAC (Fujita, 
Umemura et al. 2017), liberates its catalytic domain and catalyses the exchange of Rap GDP 
(inactive form) for Rap GTP (active form). Figure 1.9 shows the activation of EPAC in response to 
elevated levels of cAMP. 
The discovery of EPAC, as a cAMP sensor, raised questions regarding its mechanism of actions. 
PKA and EPAC are two distinctive cAMP signalling mediated pathways, the net effects of cAMP 
on cells could be mediated by PKA, EPAC or a cross talk between them (Cheng, Ji et al. 2008). 
Like PKA, EPAC signalling is controlled in a spatiotemporal manner by A kinase anchoring 
proteins (AKAPs), found in many different cell types (Poppinga, Munoz-Llancao et al. 2014). 
AKAP complexes highlight the importance of crosstalk existing between the effectors of cAMP. In 
vitro studies demonstrated opposing effects of PKA and EPAC activation on PKB regulation, where 
PKB is activated by EPAC stimulation, but PKA activation inhibits the activity of PKB (Mei, Qiao 






Figure 1.9: EPAC isoforms structures and their activations in response to elevated cAMP 
A. Rap proteins which are GTPases, exchange GDP to GTP.  GAPs catalyse the formation of GDP 
from GTP (via hydrolysis) to inactivate Rap. In contrast, GEF proteins, such as EPACs, increase 
the exchange rate of GDP for GTP, enhancing the activation of Rap. B. EPAC1 and EPAC2 are the 
two isoforms of EPAC. The regulatory region of EPACs contains CNB and DEP domains. The 
catalytic region contains REM, RA and CDC25H domains. C. EPAC is normally inactive, with its 
regulatory region folded over blocking the function of catalytic region. Once the intracellular levels 
of cAMP increase, cAMP binds to CNB domain, which induces a conformational change, 
whereupon the regulatory region is folded back, allowing access of catalytic region to Rap GTPases. 





1.14.4 Mechanisms underlying the anti-fibrotic effects of cAMP and its effectors 
The anti-cardio-fibrotic effects of cAMP are brought about in cardiac fibroblasts via: inhibition of 
action of growth factors that promote cardiac fibrosis; decrease in the proliferation rate; decrease in 
the migration rate; reduction in their differentiation to their active (myofibroblast) form; promotion 
of apoptosis; and minimising their ECM production (Heusinger-Ribeiro, Eberlein et al. 2001, Liu, 
Thangavel et al. 2008, Kohyama, Yamauchi et al. 2009, Sandbo, Kregel et al. 2009, Zhang, Yun et 
al. 2011, Insel, Murray et al. 2012). 
Intracellular levels of cAMP can be elevated via different means, such as ligand stimulation of 
GPCRs (agonists or antagonists) coupled to activation of ACs, direct activation of ACs with 
forskolin, use of cAMP analogues (which diffuse into the cells) and inhibition of PDEs (Insel, 
Murray et al. 2012). 
Studies carried out in rat cardiac fibroblasts suggested cAMP elevation as a potential way of 
inhibiting ECM production and collagen synthesis induced by TGF-β. The effect was accompanied 
by reduction in the protein levels of α-SMA, following the  blockade of cardiac myofibroblast 
activation (Masur, Dewal et al. 1996, Swaney, Roth et al. 2005, Yokoyama, Patel et al. 2008). 
Further investigations implicated EPAC1 as a main reason for reduction in collagen synthesis 
(Yokoyama, Patel et al. 2008).  
Further studies on human cardiac fibroblasts demonstrated that downregulation of cAMP (via 
inhibiting ACs) increased the levels of fibrotic proteins, such as collagen 1, PAI 1 and α-SMA. In 
contrast, elevation of the cAMP levels inhibited the scarring phenotypes of human cardiac 
fibroblasts (Clancy, Zheng et al. 2007). 
The proliferation rate of cardiac fibroblasts is also regulated by cAMP signalling pathways. For 
example, cAMP production via the stimulation of A2BRs inhibits the proliferation of rat cardiac 
fibroblasts (Phosri, Arieyawong et al. 2017). Moreover, cAMP has been reported to have apoptotic 
effects on mice cardiac fibroblasts, an effect that was mediated by PKA activation (Zhang, Yun et 
al. 2011). 
Signalling by cAMP has effects on fibroblast migration too. Investigations carried out on rat cardiac 
fibroblasts displayed complex effects of cAMP signalling on migration: agents that increase the 
levels of cAMP inside cardiac fibroblasts are pro-migratory at low concentrations, but have anti-
migratory effects at higher concentrations (Yokoyama, Patel et al. 2008). PKA activation is 
documented to downregulate the migration rate of cardiac fibroblasts, whereas activation of EPACs 




1.15 Rationale for thesis and hypothesis 
Cardiac fibrosis is a key aspect of heart failure, which is a prevalent, life-threatening condition for 
which current treatments are inadequate. Proliferation and migration of cardiac fibroblasts promote 
cardiac fibrosis after any type of damage, including post myocardial infarction and because of other 
cardiomyopathies that lead to heart failure. Whilst the current generation of anti-cardiac fibrosis 
drugs, such as ACE inhibitors (e.g. lisinopril), have beneficial effects, they only have modest effects 
on mortality but can also exert negative side effects (Packer, Poole-Wilson et al. 1999). Therefore, 
identifying signalling pathways that selectively inhibit cardiac fibroblasts proliferation and 
migration could lead to significantly improved treatments. This thesis focuses on the cAMP 
signalling pathway, which potently inhibits cardiac fibroblasts proliferation and migration in vitro. 
Crucially, cAMP also induces vascular protective effects in ECs, promoting barrier function and 
inhibiting inflammation and monocyte adhesion. Elevation of cAMP also inhibits VSMC 
proliferation by downregulating multiple key cell-cycle intermediates and may therefore retard 
atherosclerosis progression. However, cAMP elevation by PDE3 inhibitors has unwanted inotropic 
and chronotropic effects on the heart that have been associated with poorer survival in heart failure 
patients. Targeting downstream aspects of cAMP signalling that selectively reduce cardiac fibrosis 
would therefore be an advantage. 
Recent data from our group link the anti-mitotic and anti-migratory activity of cAMP in SMCs to 
actin-cytoskeleton remodelling in response to inhibition of members of the Rho-GTPase family. 
We investigated whether similar mechanisms apply to cardiac fibroblasts and sought to elucidate 
the components of the regulatory pathways in sufficient detail to identify novel druggable targets. 
In this thesis the following hypotheses were tested, cAMP elevating stimuli inhibit cardiac fibroblast 
proliferation and migration via remodelling of the actin-cytoskeleton and regulation of actin-


















2.1.1 General materials 
All general reagents, except those stated otherwise, were purchased from Sigma-Aldrich Co. (Poole 
UK). 
2.1.2 Cell Culture Reagents 
Dulbecco’s Modified Eagle Medium (DMEM), Advanced DMEM/F12 (1X), 1.0 g/L glucose, L-
Glutamine (200 mM), foetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 µg/ml), 
Dulbecco’s Phosphate Buffered Saline (DPBS: Ca2+ and Mg2+ free) and 10x trypsin-
ethylenediametetraacetic acid (EDTA) were acquired from Life Technologies.  
2.1.3 Immunological reagents 
Below are the details of primary and secondary antibodies used in our investigations (Tables 1 and 
2). 
Target protein Host species Dilution Supplier Catalogue 
number 
EPAC1 Mouse 1:700 Cell signalling 4155 
EPAC2 Mouse  1:700 Cell signalling 4156 
MKL1 Mouse 1:1000 Cell signalling 14760 
MKL2 Mouse 1:1000 Cell signalling 14613 
GAPDH Mouse 1:10000 Millipore MAB374 
Beta-actin (β-
actin) 
Mouse 1:1000 Sigma A5316 
BrdU Goat 1:1000 Sigma B2531 
Phospho-MYPT 
(Thr853) 
Rabbit 1:1000 Cell signalling 4563 
phospho-MYPT 
(Thr696) 
Rabbit 1:1000 Cell signalling 5163 












Rabbit 1:8000 Sigma P0161 
Anti-rabbit Goat 1:8000 Sigma P0217 
Table 2. Secondary antibodies with their details 
2.1.4 Chemicals 
Working concentrations of drugs were determined by dose-response optimisation experiments. 
Stimulations were performed in serum free DMEM (serum starvation media) unless otherwise 













Forskolin Sigma 25 µM F6886 DMSO 
Db-cAMP Sigma 200 µM F5978 Water 
BAY60-6583 TOCRIS 5 µg/ml 4472 DMSO 
Latrunculin B TOCRIS 0.5 µg/ml 3974 DMSO 
Cytochalasin D TOCRIS 2 µM 1233/1 DMSO 
ROCK inhibitor 
(Y27632) Cell signalling 10 µM S1049 DMSO 
CCG203971 CAYMEN 20 µM 15075 DMSO 
MG-132 Cell signalling 10 µM 2194S DMSO 
PKA inhibitor 
(H89) Sigma 20 µM B1427 DMSO 
Lactacystin TOCRIS 10 µM 2267 DMSO 
Acetoxymethyl 
ester of N 6-
benzoyl-cAMP 
(6-BNZ-cAMP-
AM) Biolog 20 µM B079 DMSO 
8-(4-
Chlorophenylthio) 





cAMP-AM) Biolog 20 µM C056 DMSO 
Verteporfin Sigma 10 µM SML0534 DMSO 
I-942 MOLPORT 20 µM  DMSO 
Cycloheximide Sigma  100 µg/ml C7698 DMSO 
Entinostat (MS-
275) Selleckchem 5 µM S1053 DMSO 






2.2.1 Isolation and culture of primary rat cardiac fibroblasts, rat H9C2 cells and human cardiac 
fibroblasts 
Male Sprague Dawley rat pups were killed by cervical dislocation in accordance with the Directive 
2010/63/EU of the European Parliament, under schedule 1 of the United Kingdom Home Office 
Animal Scientific Procedures Act 1986 and performed in accordance with guidelines, regulations 
and approval of the University of Bristol. Approval was granted by the University of Bristol ethical 
review board. Cultures of rat cardiac fibroblasts were prepared as previously described (Sala-
Newby, Freeman et al. 2003). Briefly, hearts from 2- to 3-day-old rats were digested with four 
cycles of incubation in 0.1% (v/v) trypsin containing 0.02% (v/v) EDTA in PBS. Digestion was 
stopped by the addition of FCS to 20% (v/v). The dispersed cells were resuspended in DMEM 
supplemented with 10% (v/v) FCS, 100 µg/ml streptomycin, and 100 U/ml penicillin and plated for 
1 hour to allow fibroblasts to adhere. The unattached myocytes were removed with two washes in 
PBS. Cardiac fibroblasts and neonatal myocytes were cultured in Advanced DMEM/F12 
supplemented with 100 µg/ml streptomycin and 100 U/ml penicillin, 10% (v/v) FCS and 2 mM L-
glutamine. 
Human cardiac fibroblasts were purchased from Promocell (Heidelberg, Germany) and cultured in 
DMEM/F12 supplemented with 100 µg/ml streptomycin and 100 U/ml penicillin, 10% (v/v) FCS 
and 2 mM L-glutamine. 
H9C2 cells were cultured in DMEM supplemented with 2 mM L-glutamine, 100 µg/ml 
streptomycin and 100 U/ml penicillin.  
2.2.2 Cell passage 
On reaching confluence, cells were washed twice in PBS and incubated with 1x trypsin EDTA 
solution at 37oC until cells had detached from the tissue culture flask. Trypsinisation was terminated 
by addition of an equal volume of 10% (v/v) FCS/DMEM and the resulting cell suspension was 
centrifuged at 259 g for 5 minutes. The cell pellet was resuspended in 10% (v/v) FCS/DMEM at 
37oC with 5% (v/v) CO2, with regular renewal of medium. Cells of passage 2-19 were used for 
experiments. 
2.2.3 Cell counting, cryopreservation and resuscitation 
Cells were counted using a Neubauer haemocytometer and the concentration of cells per ml was 
calculated using the formula: Average cell count per 1 mm2 = number of cells × 104 per ml. Prior 




FCS culture media and placed at -80oC in a freezing chamber and cooled at -1oC /min, before 
transfer to liquid nitrogen the following day. To resuscitate cells, cryovials were thawed rapidly at 
37oC and diluted 1:10 with 10% (v/v) FCS culture media. Cells were centrifuged at 259 g for 5 
minutes and resuspended in growth medium before transfer to a culture flask.  
2.2.4 Induction of cell quiescence  
All cell types were serum starved by incubation for 24 hours with serum free medium, unless 
otherwise stated (DMEM containing 2 mM L-glutamine, 100 µg/ml streptomycin and 100 U/ml 
penicillin). 
2.2.5 Molecular biology 
The bench, instruments and racks involved in RNA or DNA studies were cleaned by 70% (v/v) 
alcohol and then RNaseZap or DNAZap (Ambion Inc., Cambridgeshire, UK) to remove 
contaminating nucleases and DNA. All tubes, pipette tips and bottles used in the studies were 
purchased from suppliers with guarantee of being nuclease-free. 
2.2.5.1 Total RNA extraction and quantification  
Total RNA was extracted from all cell types using the PureLink RNA Mini Kit (Ambion) as per 
manufacturer’s instructions. RNA was eluted from purification columns in 40 µl of nuclease-free 
water. RNA was then quantified using Nanodrop spectrophotometer technology (LabTech; model 
number: ND-1000).  RNA concentration was obtained by measuring absorbance at 260 nm and 
260/230 and 260/280 ratios determined the extent of ethanol and protein contamination, 
respectively. Only samples with sufficient purity were used for subsequent experiments. 
2.2.5.2 Reverse transcription 
First-strand cDNA was synthesised from 150 ng of total RNA by random hexamer priming using 
Quantinova reverse transcription kit (Qiagen) according to manufacturer’s instructions except that 
a 10 µl reaction was performed. cDNA was then diluted to 5 ng/µl by the addition of 20 µl RNAase 
free water and stored at -20oC. 
2.2.5.3 Quantitative PCR 
Quantitative qPCR was performed using Rotor-Gene Q (Qiagen) with Lightcycler 480 SYBR Green 
1 Master PCR system (Roche Diagnostics, Ltd). Briefly, 1 µl template cDNA from the reverse 
transcription reaction was mixed with gene specific primers (0.5 µM) and enzyme mixture as stated 
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Table 4. Summary of the reactions needed in qPCR. 
Cycles of Threshold (Ct) values were determined for each reaction. This represents the cycle 
number where the fluorescent signal from amplified PCR product reaches the threshold of detection 
and is thus a relative measure of target concentration.  Ct values were then used to determine the 
differential expression of mRNA between control and treated conditions.  
Fold change = 2-ΔCt where ΔCt = Ct (treated) - Ct (control).  
Melt curve analysis was used as an indicator of single product amplification, with the number of 
peaks directly equated the number of distinct amplicons. Data was analysed from reaction were only 
a single melt-curve analysis peak was observed. 
2.2.5.4 Primer design 
Primers for qPCR analysis were designed using the NCBI Primer online application 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). This application includes a BLAST analysis to 
refine primer selection and avoid targeting of non-specific products. Filters included a PCR product 
size of 90-150 base pairs, optimal melting temperature (Tm) of 65oC, optimal primer size of 22 base 
pairs and requisite for exon-exon or exon-intron junctions for spliced and pre-spliced mRNA 
respectively. Further specifications of primer size and GC content were also included to ensure 
optimal specificity. Sequences of quantitative PCR primes are available in the Appendix. 
2.2.5.5 Agarose gel electrophoresis of DNA  
PCR products were isolated from other DNA molecules (e.g. template DNA) by agarose gel 
electrophoresis and purification of the DNA product from excised gel slices. Negatively charged 
DNA molecules migrate towards the anode when a voltage is applied across the gel. Mobility of a 




gel, but proportional to the applied voltage. The gel was prepared by addition of an appropriate 
amount of agarose to 1x TAE electrophoresis buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.0) 
containing 0.2 µg/ml ethidium bromide. Agarose was dissolved in a microwave oven, allowed to 
cool and solidified into a clean gel tray and comb apparatus. DNA samples were mixed with 1/6 
volume of 6x loading buffer (30% (v/v) glycerol, 0.25% (v/v) orange G, 0.25% (v/v) xylene cyanol 
FF) and then loaded into the wells of the gel. Electrophoresis was performed in 1x TAE buffer at 
75-150 V depending on the size of gel until optimal separation of the DNA segment of interest was 
obtained. Gels were viewed under UV light illumination. Digital images were acquired and densities 
of the bands on gels quantified using a densitometric program (Alphalmager v5.5, Alpha Innotec 
Co. San Leandro, CA, USA). Required DNA bands were excised from the gel using a sterile scalpel. 
2.2.5.6 DNA restriction, digestion and ligation  
Purified DNA fragments were digested with specific restriction endonucleases (New England 
Biolabs) to generate ‘sticky ends’ that facilitate their ligation into plasmid vectors with compatible 
sticky ends. DNA was mixed with 1 x of the appropriate enzyme specific buffer and digested at 
37oC for 8 hours. Digested DNA was purified using DNA clean up columns (Qiagen) according to 
the manufacturer’s instructions or by agarose gel purification, as described in section 2.2.5.5. 
Purified digested DNA was the ligated into the desired vector using a rapid ligation kit (Roche) 
according to the manufacturer’s instructions. 
2.2.5.7 Transformation of competent bacteria  
Plasmids containing cloned cDNAs generated by ligation reactions were amplified by 
transformation into chemically competent DH5 bacteria (Invitrogen Ltd., Paisley, UK). 
Renewable stocks of plasmids were also prepared by transformation of DH5 bacteria. Competent 
bacteria were removed from -80 ºC and thawed on ice. 10 ng of stock plasmid solution or 2 µl of a 
ligation reaction described in 2.2.5.6 was added into 20 l of competent cells with gentle mixing. 
Cells were incubated on ice for 20 minutes followed by a 45 second heat shock in a 42oC water 
bath. Cells were then returned to ice for 5 minutes. Cells were incubated with 250 l of SOC 
medium (Invitrogen Ltd., Paisley, UK) at 37oC with shaking for an hour to allow cells to recover. 
50 l of cells was spread onto LB/Amp agar plates (15 g/l bacto-agar, 10 g/l bacto-tryptone, 5 g/l 
NaCl, 5 g/l bacto-yeast extract and 100 g/ml ampicillin, pH 7.5). Plates were inverted and cultured 
at 37oC for 16 hours to allow colonies to develop. Isolated colonies were picked using sterile pipette 




2.2.5.8 Preparation of plasmid DNA  
Each confirmed colony or bacteria from a glycerol stock was added into 5 ml LB broth (10 g/l 
bacto-tryptone, 5 g/l bacto-yeast extract, 5 g/l NaCl, 100 g/ml ampicillin, pH 7.5) and the mixture 
was incubated overnight at 37oC in a rotatory incubator. The pellet from 4 ml of the mixture was 
obtained by micro-centrifugation at 10000 g for 3 minutes and the plasmid DNA was extracted from 
the cell pellet using QIAprep Spin Miniprep Kit (Qiagen Ltd., West Sussex, UK) according 
manufacturer’s instruction. Briefly, 4 ml of bacterial overnight culture was pelleted by 
centrifugation at 10000 g for 3 minutes then resuspended in 250 µl of resuspension buffer containing 
RNase. Cells were lysed, neutralised and centrifuged for 10 minutes at 10000 g. The resulting 
supernatant was transferred to a separate spin column, centrifuged briefly, washed and finally the 
DNA was eluted in 50 µL elution buffer. Plasmid DNA was quantified using the Nanodrop 
spectrophotometer. Large scale preparations of endotoxin-free plasmid were made using GenElute 
HP endotoxin-free plasmid maxiprep kits (Sigma). 
2.2.5.9 Plasmids adenoviral vectors and gene silencing 
Plasmid pSRF-luciferase (#219079) containing five copies of the serum response element (SRE; 
5’-AGG ATG TCC ATA TTA GGA CAT CT-3’) upstream of the firefly luciferase gene was 
obtained from Stratagene. CREB-luciferase plasmid (α168) was gifted by Prof. G. S. McKnight 
(University of Washington) and has been described previously (Mellon, Clegg et al. 1989). TEAD-
LUC luciferase reporter gene containing eight tandem copies of a TEAD binding element and a 
minimal TNT promoter was obtained from Addgene. 
EPAC1 promoter fragments were generated by PCR using KOD polymerase from human genomic 
DNA. The location of the 800 bp promoter fragment is chr12:48152755-48153554 (Hg19).  The 
proximal TEAD element (5’-GCATTCCTC-3’) was mutated to (5’-GCgTgtCTC-3’) by PCR with 
a reverse primer incorporating the mutated element. Promoter fragments were cloned into the Nhe1 
sites of the secreted nano-luciferase reporter gene plasmid pNL3.3 [secNluc/minP] (Promega).  The 
synthetic TEAD luciferase reporter plasmid containing eight copies of a TEAD binding element has 
been described previously (Dupont, Morsut et al. 2011) and was obtained from Addgene (plasmid 
#34615). Luciferase reporter plasmid containing the minimal TNT promoter was generated by Bgl 
II and Kpn1 digestion of the TEAD-LUC vector to remove the eight TEAD elements, leaving just 
the minimal TNT promoter. Plasmid expressing dominant-negative TEAD in which the YAP-
binding domain of TEAD is replaced with the repressor domain of Engrailed (TEAD-ENRD) was 
a gift from Prof Domenico Flagiello (University of Paris Diderot) and has been described previously 




(Ad:YAPS127A), constitutively active TAZ (Ad:TAZ5SA) or control virus lacking a transgene 
(Ad:Control) have been described previous (Kimura, Duggirala et al. 2016). Cardiac fibroblasts 
were infected with 1x107 pfu/ml of recombinant adenovirus for 18 hours. 
For gene silencing, cells were transfected with 100 pmoles of Silencer Select siRNA (Life 
Technologies) targeting rat MKL1 (s163756), rat MKL2 (ABX00O2), YAP1 (ID:s170198 and 
ID:s170200), TAZ/WWTR1 (ID: s148961) using the standard Nucleofector program A-024.  Cells 
were stimulated with the indicated agents 24 hours post transfection. The next day cell lysates were 
assayed for firefly luciferase activity and cell culture media assayed for secreted nano-luciferase. 
Firefly luciferase was quantified using the luciferase assay system (Promega) and secreted 
nanoluciferase activity assayed using the NanoGlo assay system (Promega) according to the 
manufactures instructions using Glomax Discover luminometer (Promega). 
2.2.5.10 Reporter gene assays 
EPAC1 promoter activity was determined by quantifying the secreted nano-luciferase reporter 
activity in cells transfected with EPAC1-NLUC.  Plasmid transfection was performed by 
electroporation of 1x106 cardiac fibroblasts with 5 µg of plasmid DNA using an Amaxa 
Nucleofector-1.5 (program A-024). Cultured media were conditioned for the indicated times. 10 µl 
of this lysate was mixed with 90 µl of RNase free water and assayed for EPAC-NLUC activity using 
a white 96-well plate micro-titre dish and Glomax Discover luminometer (Promega) according to 
the manufacturer instructions. 
SRF and TEAD promoter activities were determined by quantifying the firefly luciferase reporter 
activities in cells transfected with SRF-LUC and TEAD-LUC. Plasmid transfection was performed 
by electroporation of 1x106 cardiac fibroblasts with 5 µg of plasmid DNA using an Amaxa 
Nucleofector-1.5 (program A-024). Cells were lysed in 100 µl of ice cold 1x Promega reporter gene 
lysis buffer. 10 µl of this lysate was mixed with 90 µl of RNase free water and assayed for luciferase 
activity using a white 96-well plate micro-titre dish and Glomax Discover luminometer (Promega) 
according to the manufacturer instructions. 
2.2.5.11 Chromatin Immunoprecipitation (CHIP) assay 
Rat cardiac fibroblasts (approximately 8x106 cells) were washed in PBS and fixed in 11% (v/v) 
formaldehyde in PBS for eight minutes at room temperature. Formaldehyde was quenched by 
addition of glycine to a final concentration of 250 mM. Chromatin was prepared using the iDeal 
ChIP-qPCRkit (Diagenode) according to the manufacturer’s instructions. Chromatin was sheared 




Bioruptor sonnicator (Diagenode). Sheared chromatin was immunoprecipitated overnight at 4oC 
with either 1 µg of anti-H3K27 acetylation antibody (#C15410174; Diagenode) or an equal amount 
of rabbit non-immune IgG (#C15410206; Diagenode) according to the iDeal Chip-qPCR kit 
instructions. Following washing and elution, immunoprecipitated EPAC1 promoter DNA was 
quantified using qPCR with primers (Forward 5’- CCT CTG GAC TTG GAC TGG TCA TGC-3’ 
and Reverse 5’- GCC GAA TTC CAG CCA GAA CTG AGA-3’)  
2.2.5.12 RAP1GTP activity assays 
Levels of cellular RAP1GTP were quantified using the Cell Signalling Active Rap1 detection kit 
according to the manufacturer’s instructions. Briefly, cells were seeded at 5x106 cells/well in 6 well 
plates. Cells were pre-treated with 25 µM forskolin for 24 hours, as indicated before an acute 
stimulation the following day. RAP1GTP present in cell lysates was bound to 20 µg of GST-RAL-
GDS protein and affinity isolated using glutathione resin. Following washing to remove non-
specifically bound protein, specifically bound RAP1GTP as eluted in Laemmli sample buffer and 
analysed for RAP1 protein levels by Western blotting.  
2.2.5.13 Electromobility shift assays 
Electromobility shift assays (EMSA) were performed using the Lightshift EMSA kit (Thermo 
Fisher), according to the manufacturer’s instructions. Nuclear extracts from 5x106 control or pRK-
myc-TEAD1 (Addgene #33109) transfected cells were prepared using the NE-PER nuclear 
extraction kit (Thermo Fisher). Double stranded 5’ biotinylated probes corresponding to the wild-
type or TEAD element mutant human EPAC1 promoter TEAD element (Wild-type sense 5’-Biotin- 
TTC CCC TAC GCA TTC CTC TAC CGT AA-3’; Wild-type antisense 5’-Biotin-TTA CGG TAG 
AGG AAT GCG TAG GGG AA-3’; TEAD-mutant sense 5’-Biotin- TTC CCC TAC GCg Tgt CTC 
TAC CGT AA-5’ and TEAD mutant antisense 5’-Biotin-TTA CGG TAG Aga cAc GCG TAG 
GGG AA-3’) were synthesised by Sigma Aldrich. 20 fmol of double stranded DNA oligo was used 
in 20 uL binding reactions according to the Lightshift assay kit protocol. DNA complexes were 
resolved on 5% (v/v) non-denaturing polyacrylamide/0.5xTBE gels at 100V. Oligonucleotides were 
transferred to Hybond-N nylon membrane (Amersham) in 0.5 x TBE at 400 mA for 1 hour at 4oC. 
Oligonucleotides were detected using the Lightshift kit Extravidin-HRP detection system. 
 
2.2.6 Visualisation of F-actin fibres 
For detection of F-actin cells were cultured on sterile glass 13 mm diameter coverslips. F-actin 




Briefly, cells were fixed in 4% (v/v) paraformaldehyde for 10 minutes at room temperature before 
being permeabilised in 0.1% (v/v) Triton-X-100 in PBS for 5 minutes. Cells were then stained with 
phalloidin for 30 minutes in accordance with the manufacturer’s instructions. Following staining, 
cells were washed in PBS and mounted onto glass microscope slides in Slow-Fade Gold Antifade 
mounting medium (Life Technologies). Images were acquired using an Olympus fluorescence 
microscope using an oil immersion x50 objective.  
2.2.7 Visualisation of GFP-MKL in cardiac fibroblasts 
Cardiac fibroblasts (1x105) were seeded in 24 well plate dishes. The next day, cells were infected 
with 1x107ρfu/ml Ad:GFP-MKL1 in the presence of 10% (v/v) serum. The next day, cells were 
serum starved for 24 hours and then stimulated with specific cAMP elevating stimuli and/or 
mitogens for indicated times (as mentioned in each figure legend). Cellular localisation of GFP-
MKL1 was quantified by capturing live cell fluorescence images using a EVOS live cell imaging 
system. Cells were counted as having nuclear MKL1 if the nuclear GFP signal was visibly more 
intense than the cytoplasmic signal. In contrast, cells were counted as having cytosolic MKL1 if the 
cytosolic GFP signal was visible more intense than the nuclear signal. 
2.2.8 Quantification of F-actin:G-actin ratio 
F-actin and G-actin were separated by Triton-X-100 solubility essentially as previously described 
(Parreno, Raju et al. 2014). (Parreno, Raju et al.) with slight modifications. Following treatment, G-
actin was extracted by incubation with slight agitation at room temperature for 5 minutes in G-actin 
extraction buffer (PBS, 10% (v/v) glycerol, 0.1% (v/v) triton X-100, 1 mM ATP and complete 
protease inhibitor). Samples were centrifuged at 15,000 g at 4oC for 5 min. The supernatant (soluble 
G-actin) was collected. Titon-X-100 insoluble material (F-actin) remaining in the wells and pelleted 
from the soluble fraction was lysed in reducing Laemmli SDS sample buffer. Samples were 
analysed by western blotting using a -actin specific antibody (Sigma). 
2.2.9 Western blotting 
2.2.9.1 Preparation of cell lysates 
Cells were seeded either at 5 x 105 cells in 6 well plates, or at 2.5 x 105 in 12 well plates and 
incubated overnight in growth medium at 37°C, 5% (v/v) CO2. The following day cells were serum 
starved for 1 day. The next day, cells were stimulated with a specific agent for the indicated duration. 
Following stimulations, cells were washed in PBS and lysed in either 200 µL or 150 µL 1 x SDS 
lysis buffer respectively (2% (v/v) SDS, 50 mM Tris pH 6.8, 10% (v/v) glycerol) plus 25 µl/ml β-




well to ensure complete lysis of all cells and then transferred to an eppendorf and repeatedly passed 
through a 200 µl pipette to shear genomic DNA and reduce viscosity. Following a brief vortex, 
lysates were placed on a 95oC hot block for 5 minutes to reduce the samples. 
2.2.9.2 Protein concentration quantification 
The concentration of the protein lysate was determined using the micro BSA protein assay. A 
solution of 1 µg/µl BSA in from the 2 µl BSA standard provided with the BSA kit was made (60µl 
of the 2µl/BSA from the kit added to 60 µl of double distilled water in a 0.5 ml Eppendorf tube. 
The standards were made by mixing the reagents shown in the table 5. The standards were made by 
mixing the reagents shown in the table 5. 
Table 5. Protein concentration quantification 
Samples (lysates) were thawed from -20 °C storage. 5 µl of the lysates was added to 95 µl of water 
in a 0.5ml Eppendorf tube and mixed by repeated pipetting up and down. BCA assay reagent was 
prepared by mixing 500 parts of reagent A, 480 parts of reagent B and 20 parts of reagent C. An 
equal volume of reagent mixture was added to all the tubes (samples and standards), and samples 
mixed thoroughly by vertexing. Samples were incubated at 37°C for 20 minutes for a purple colour 
to be developed. 150µl of each sample was transferred to the wells of a 96 well plate the optical 
density read at 540 nm with a spectrophotometer (Bibby Scientific Limited).  The protein 
concentration of each sample was determined by plotting the standard curve of BSA standard using 
Excel and linear interpolation. Equal concentrations of reduced and denatured protein samples were 
loaded into Mini-PROTEAN TGX 4-20% (v/v) gradient precast gels (BIO-RAD) and run in a Mini-
PROTEAN Tetra Cell (BIO-RAD) filled with 1 x PAGE buffer [25 mM Tris-HCl (pH 8.3), 250 
mM glycine, 0.1% (w/v) SDS] at 90 V until the bromophenol blue marker reached the bottom of 
the plates. A pre-stained molecular weight protein marker (Geneflow Limited) was also loaded to 
allow estimation of molecular weights. 
Standards 1 2 3 4 5 6 7 8 9 10 11 
1µg/µl BSA 
(aqueous) 
0 0.5 1 2 3 4 6 8 10 15 25 
Lysis buffer(µl) 5 5 5 5 5 5 5 5 5 5 5 
Double distilled 
water (µl) 




2.2.9.3 Protein transfer and protein detection 
Following electrophoresis, the gel plates were opened, the gel was trimmed and equilibrated in Tris-
buffered saline-tween (TBST; 20 mM Tris pH 7.6, 137 mM NaCl, 0.1% (v/v) Tween-20). The gel 
was then placed on a PVDF membrane and packed with filter paper and sponges to form a transfer 
sandwich structure. Figure 2.1 shows the arrangement of the transfer package. The gel membrane 
sandwich was placed vertically in a transfer tank, ensuring that the PVDF membrane was on the 
anode side of the gel. A magnetic stirrer and an ice block were placed inside the tank to maintain 
an even temperature and prevent overheating respectively. The electrodes were connected to the 
electric supply at a constant voltage of 100 V for 90 minutes at 4 °C. The membrane was then 
blocked with Tris-buffered saline-tween containing 5% (w/v) skimmed milk powder for at least 60 
minutes at room temperature with rocking, to block non-specific binding. The blots were briefly 
washed in TBST and incubated with primary antibodies on a rocking table at 4oC overnight. After 
removal of excess unbound primary antibody, blots were washed 4 times in TBST (each wash lasted 
for 5 minutes) and then incubated with 1:8000 HRP-conjugated secondary antibodies (Sigma) 
diluted in TBST containing 2.5% (w/v) skimmed milk powder for 60 minutes at room temperature, 
with rocking. This was followed by washing 4 times in TBST (each wash lasted for 5 minutes). To 
detect the bound antibodies, the blots were incubated with 1 ml Immobilon Western 
Chemiluminescent HRP substrate (Millipore) for 1 minute and luminescence was detected with 







Figure 2.1: The arrangement of gel and membrane before going into the Bio-Rad semi-dry turbo 
blotter 
The gel is placed on top pf the membrane because the proteins travelled from the Cathode to Anode 
(A). The assembly of the sandwich: from top to bottom: Cathode, 2 layers of filter paper, gel, PVDF 






2.2.10 BrdU proliferation assay 
To quantify cell proliferation, a 5-Bromo-2′-deoxyuridine (BrdU) incorporation assay (Sigma) was 
conducted. Rat cardiac fibroblasts were seeded on 13 mm gelatin coated glass coverslips (placed in 
the wells of a 24 well plate dish) were incubated overnight in 10% (v/v) FCS/DMEM. The following 
day cells were serum starved and stimulated as indicated. Rat cardiac fibroblasts were then treated 
with 10 μM BrdU for 6 hours and then washed in PBS and fixed in 70% (v/v) ethanol. After a brief 
wash in de-ionised water cell were incubated with pre-warmed 2.0 M HCl at 37oC for 40 minutes. 
Following PBS washing, blocking buffer (5% (w/v) BSA/PBS) was added at room temperature for 
30 minutes, washed again in PBS and incubated with anti-BrdU overnight at 4oC. Washing in tap 
water caused the haematoxylin stained nuclei to stain blue. The following morning, wells were 
washed 5 times in PBS and treated with biotinylated goat-anti-mouse diluted 1:200 in 1% (w/v) 
BSA/PBS for 30 minutes at room temperature. After washing in PBS, extravidin-peroxidase 
(Sigma) diluted 1:200 in 1% (w/v) BSA/PBS was added for 30 minutes at room temperature. Wells 
were washed 4 times in PBS, rinsed in distilled H20 and incubated with the HRP substrate SigmaFast 
3,3’-diaminobenzidine (DAB, Sigma) until a brown precipitate was visible. Wells were then washed 
in distilled water and stained with the nuclear stain Mayer’s Haemotoxylin for 30 seconds. Washing 
in tap water caused the haematoxylin stained nuclei to stain blue and then the coverslips were 
mounted onto glass slides coated with PVP mounting medium. Rat cardiac fibroblasts were imaged 
using an Olympus BX41 microscope and Q-capture pro 6.0 software. BrdU positive cells (brown) 
and negative cells (blue) were counted in 10 fields of view for each inhibitor concentration and the 
number of BrdU positive cells was expressed as a percentage of total cells counted. 
2.2.11 Edu proliferation assay 
To quantify cell proliferation, a 5-Ethynyl-2’-deoxyruridine (Edu) incorporation assay (Base Click) 
was conducted. Rat cardiac fibroblasts were seeded on 13 mm gelatin coated glass coverslips 
(placed in the wells of a 24 well plate dish) were incubated overnight in 10% (v/v) FCS/DMEM/F12. 
Cells were serum starved and stimulated as indicated. Rat cardiac fibroblasts were then treated with 
10 μM Edu for 6 hours and then washed in PBS and fixed in 3.7% (v/v) formaldehyde1804 (made 
in PBS) for 15 minutes at room temperature. After a brief wash in 3% (w/v) BSA (made in PBS), 
rat cardiac fibroblasts were incubated with 0.5% (v/v) Triton X-100 (made in PBS) for 20 minutes 
at room temperature (to punch holes in the cell membrane and make the cells permeable). Following 
3% (w/v) BSA in PBS wash, the reaction cocktail was made according to the manufacturer’s 
instructions. The reaction cocktail was added to every well containing the cover slip and the plate 




temperature for 30 minutes. Following 3% (w/v) BSA in PBS wash, cells had their nuclei stained. 
Briefly, Hoechst 33342 was diluted in PBS (1:5000) and was added to every well containing the 
cover slip. Rat cardiac fibroblasts were then incubated at room temperature (wrapped around the 
aluminium foil) and rocked for 20 minutes. Following 3% (w/v) BSA in PBS wash, each well 
containing the cover slip was covered with 3% (w/v) BSA in PBS. Rat cardiac fibroblasts were 
imaged using an Olympus BX41 microscope and Q-capture pro 6.0 software. Edu positive cells 
(green) and all of the cells, including the proliferative and non-proliferative (blue), were counted in 
5-6 fields of view for each condition and the number of Edu positive cells was expressed as a 
percentage of total cells counted. 
2.2.12 Statistical analysis 
Statistical analysis was performed using Graphpad Instat software. For experiments with only 2 
conditions, data was quantified by a two-tailed paired t-test. For experiments comparing means of 
more than two groups, an ANOVA multiple comparisons test with Student Newman-Keuls post-
test was used. In all statistical analysis an output of p<0.05 was accepted significantly different. 
Data is expressed as mean +/- standard error of the mean (SEM). N indicates the number of 
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Myocardial injury or insult results in cardiomyocyte death, inflammation and pathological 
remodelling of the myocardium. This is often associated with excessive synthesis of extracellular 
matrix proteins by resident cardiac fibroblasts, resulting in myocardial fibrosis. This progressively 
reduces the compliance of the myocardium, which ultimately contributes towards the development 
of heart failure (Frangogiannis 2012). Heart failure results from various forms of cardiovascular 
pathologies, including pressure overload, aortic stenosis, hypertension, hypertrophic and post viral 
dilated cardiomyopathies a major cause of mortality worldwide, representing a major economic 
burden (Bharati and Lev 1995, Asbun and Villarreal 2006, Bernaba, Chan et al. 2010, Ashrafian, 
McKenna et al. 2011). Despite improvements in the therapeutic options for patients suffering from 
heart disease, it remains a major clinical problem and interventions designed to limit fibrosis are 
limited. 
Increased proliferation and migration of cardiac fibroblasts contributes toward cardiac remodelling 
and repair following myocardial injury (Kong, Christia et al. 2014). However, excessive or 
prolonged proliferation of cardiac fibroblasts contributes towards the development of cardiac 
fibrosis and ultimately heart failure (Olson, Naugle et al. 2005, Rog-Zielinska, Norris et al. 2016). 
Proliferative expansion of the cardiac fibroblast population increases the number of ECM producing 
cells and enhances ECM deposition independently of increased ECM gene expression. The current 
generation of drugs used to treat patients suffering from cardiac fibrosis and heart failure, including 
beta blockers and PDE inhibitors, are designed to improve cardiac function. As such they do not 
treat the underlying cause of the pathology or limit fibrosis and can have serious side effects. For 
example, PDE inhibitors (milrinone) increased mortality in patients (Packer, Carver et al. 1991, 
Majure, Greco et al. 2013). Therefore, there is a clear clinical need to new to identify new drug 
targets for the treatment of myocardial fibrosis. To this end, it is essential that we fully characterise 
the signalling pathways that specifically regulate the proliferation and migration of cardiac 
fibroblasts (Fan and Guan 2016) to help develop novel therapies that may help limit the progression 
of cardiac fibrosis. 
The cAMP signalling pathway has been proposed as a promising therapeutic target for the treatment 
of cardiac fibrosis, due to its well characterised anti-fibrotic effects in various tissues (Hamad, Zhu 
et al. 2012, Insel, Murray et al. 2012, Travers, Kamal et al. 2016, Vecchio, White et al. 2017). These 
anti-fibrotic effects may result, at least in part, from the ability of stimuli that elevate cAMP levels 




suggested that stimuli that elevated levels of cAMP effectively reduce cardiac fibrosis, at least in 
part, by inhibiting the proliferation and migration rates of cardiac fibroblasts both in vitro and in 
vivo (Liu, Thangavel et al. 2008, Chan, Dusting et al. 2010, Miller, Cai et al. 2011, Insel, Murray et 
al. 2012). Moreover, activation of cAMP signalling pathways has been shown to have anti-fibrotic 
effects in several other tissues, such as liver (Windmeier and Gressner 1997), lung (Dunkern, 
Feurstein et al. 2007, Huang, Wettlaufer et al. 2008) and kidney (Kothapalli, Hayashi et al. 1998). 
Translating cAMP elevating agents into effective therapies for cardiac fibrosis is challenging. 
Several lines of evidence demonstrate that, increased levels of cAMP, enhance cardiac contractility 
(ionotropy), rate (chronotropy) and the speed of conduction (Haikala, Kaheinen et al. 1997, 
Nakahara, Kawada et al. 1998, Sogabe, Sasaki et al. 2009, Zaccolo 2009),  implying the cAMP 
elevating therapies would have undesirable off-target effects that affect myocyte function. 
Efficiently delivering cAMP analogues to cardiac cells is also challenging due to their poor 
membrane permeability (Fantidis 2010). Recently developed cAMP analogues modified with 
acetoxymethyl ester groups demonstrate improved membrane permeability. However, rapid 
esterase cleavage of this group in vivo limits their clinical usefulness (Saerens, Delvaux et al. 2010). 
The efficacy of cAMP elevation with the PDE inhibitor Milrinone in patients with severe chronic 
heart failure has been tested in clinical trials (Packer, Carver et al. 1991, Knight and Yan 2013, 
Leroy and Fischmeister 2018). However, despite its beneficial hemodynamic effects, long term 
therapy with milrinone has been shown to increase patient morbidity and mortality (Packer, Carver 
et al. 1991, Majure, Greco et al. 2013). Moreover, cAMP elevation induced by the GPCR agonist, 
adenosine, was documented to enhance the progression of liver, skin, lung and peritoneal fibrosis 
(Schneider, Lindsay et al. 2010, Cronstein 2011, Karmouty-Quintana, Zhong et al. 2012, Burnstock, 
Vaughn et al. 2014, Wirsdorfer, de Leve et al. 2016, Liu, Bing et al. 2019). Furthermore, adenosine 
administration demonstrated fatal consequences (Edlund, Straat et al. 1989, Straat, Henriksson et 
al. 1991, Mallet 2004, Rajkumar, Qureshi et al. 2017). As a result, there is a need to characterise 
specific downstream cAMP signalling pathways that could be targeted therapeutically to exploit the 
anti-fibrotic properties of cAMP while avoiding the undesirable effects of long term cAMP 
modulation on cardiac function. As mentioned previously, although stimuli that elevate levels of 
cAMP are believed to have the ability to reduce cardiac fibroblast proliferation (Dubey, Gillespie 
et al. 1997, Insel, Murray et al. 2012), the underlying signalling mechanisms are not yet fully 
understood. A better understanding of these mechanisms may help identify novel drug targets that 
allow us to harness he beneficial effects of cAMP for treatment of cardiac fibrosis and cardiac 




Recent research in vascular smooth muscle cells has highlighted the important role of actin 
cytoskeleton remodelling in mediating the anti-proliferative and anti-migratory effects of cAMP. In 
these cells, cAMP-dependent inhibition of members of the Rho-GTPases has been implicated in 
mediating the anti-mitogenic and anti-migratory effects of cAMP in these cells (Bond, Wu et al. 
2008, Hewer, Sala-Newby et al. 2011, Kimura, Duggirala et al. 2014, Smith, Hudson et al. 2017).  
In this chapter, we test the hypothesis that cAMP-elevating stimuli inhibit cardiac fibroblast 
proliferation and migration and that this is associated with remodelling of the actin cytoskeleton 
3.2 HYPOTHESIS 
1. Elevation of cAMP inhibits proliferation and migration in cardiac fibroblasts 
2. Elevation of cAMP inhibits actin polymerisation in cardiac fibroblasts  
These hypotheses were tested via: 
• BrdU and EdU to investigate the effects of different cAMP stimuli on the proliferation of 
cardiac fibroblasts 
• Real-time scratch wound assay to determine the effects of cAMP stimuli on the migration 
of cardiac fibroblasts 







3.3.1 Elevated cAMP inhibits serum stimulated proliferation in cardiac fibroblasts 
We initially tested if elevated cAMP levels inhibited proliferation of rat cardiac fibroblasts in vitro. 
To elevate the intracellular levels of cAMP, cells were treated with 5 µg/ml of the A2BR synthetic 
agonist BAY60-6583, 200 µM of Dibutyryl-cAMP (cAMP analogue, Db-cAMP) or 25 µM of the 
adenylate cyclase activator, forskolin for 18 hours in the presence of serum mitogens. Proliferation 
was detected and quantified by incorporation of the thymidine analogue BrdU by pulse labelling 
the cells for the final 6 hours of the stimulation period. Stimulation of cardiac fibroblasts with 
BAY60-6583, Db-cAMP or forskolin significantly inhibited proliferation (to 6.55 ± 1.02%, 
p<0.001; 10.2 ± 0.82%, p<0.001; and to 2.16 ± 0.46%, p<0.001 respectively (Figure 3.1).  
3.3.2 PKA and EPAC selective agonists synergistically inhibit serum-stimulated proliferation of 
cardiac fibroblasts 
The cAMP sensors PKA and EPAC, have been implicated in mediating many of the biological 
effects of cAMP (Zaccolo 2009, Olmedo, Munoz et al. 2013, Fujita, Umemura et al. 2017, Laudette, 
Zuo et al. 2018, Zhang, Wang et al. 2019). 
In order to investigate the relative contribution of PKA and EPAC signalling in the anti-mitogenic 
effects of cAMP in cardiac fibroblasts, cells were stimulated with the selective PKA agonist (6-
BNZ-cAMP-AM) or the selective EPAC agonist (8-pCPT-2′-O-Me-cAMP-AM; abbreviated herein 
to 8-CPT-cAMP-AM), alone or in combination, for 18 hours, followed by staining of incorporated 
EdU. Due to serum esterase mediated cleavage of the acetoxymethyl ester group on these selective 
cAMP analogues, cell proliferation in this experiment was stimulated using 50 ng/ml of the 
physiological growth factor PDGF, instead of serum. PDGF-stimulated proliferation of cardiac 
fibroblasts was significantly inhibited by PKA activation (from 20.64±1.67% in controls to 
14.0±2.19% EdU incorporation p<0.01) and by EPAC activation (to 14.8 ± 2.46% EdU 
incorporation p<0.05) alone. Furthermore, a combination of 6-BNZ-cAMP-AM plus 8-CPT-
cAMP-AM acted additively to suppress PDGF-stimulated proliferation (to 9.77 ± 3.44% EdU 
incorporation p<0.01) of cardiac fibroblasts to levels that were significantly lower than in either 6-








Figure 3.1: Elevated cAMP inhibits serum-stimulated proliferation of rat cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated for 18 hours with BAY60-6583 (BAY; 5 µg/ml), dibutyryl-
cAMP (200 µM) or forskolin (25 µM) in 5% (v/v) serum, as indicated. Cells were labelled with 10 
µM BrdU for further 6 hours and proliferation quantified by immuno-histochemical staining of 
incorporated BrdU. Representative images of each condition are shown below. ***: p<0.001 and 
Db-cAMP: dibutyryl-cAMP analogue (Db-cAMP analogue). Data are expressed as mean ±SEM 





Figure 3.2: Elevated cAMP inhibits PDGF stimulated rat cardiac fibroblast proliferation 
Rat cardiac fibroblasts were stimulated for 18 hours with 6-BNZ-cAMP-AM (20 µM) and 8-CPT-
cAMP-AM (20 µM) in the presence of 50 ng/ml PDGF. Cells were labelled with 10 µM Edu for 
further 6 hours and proliferation was quantified as the percentage of by EdU-positive cells.  PDGF: 
Platelet-derived growth factor; *: p<0.05 and **: p<0.01. Data are expressed as mean ±SEM and 





3.3.3 Elevated cAMP increases the migration of cardiac fibroblasts 
Elevated cAMP signalling has been shown to inhibit cell migration in several cells types, including 
vascular smooth muscle cells (Hewer, Sala-Newby et al. 2011, Smith, Hudson et al. 2017). To 
investigate the effects of cAMP stimuli on migration of cardiac fibroblasts, cells were stimulated 
with 25 µM of forskolin or 200 µM of Db-cAMP analogue in the presence of 5% (v/v) serum and 
real-time migration rates were quantified over 24 hours using InnuCyte ZOOM scratch wound 
migration assays. Interestingly, elevation of cAMP with either forskolin or Db-cAMP analogue, 
resulted in a small increase of cardiac fibroblasts migration (Figure 3.3). 
3.3.4 Effects of elevated cAMP levels on the morphology and actin cytoskeleton remodelling of 
cardiac fibroblasts 
Whilst analysing the effects of cAMP on rat cardiac fibroblast proliferation and migration, it was 
noted that cAMP elevating stimuli induced a dramatic change in cell morphology similar to the 
stellate morphology previously reported in vascular smooth muscle cell (Pelletier, Julien et al. 2005, 
Bond, Wu et al. 2008, Hewer, Sala-Newby et al. 2011, Smith, Hudson et al. 2017). To gain an 
insight into the possible functional significance of cAMP-induced morphological changes on 
proliferation and migration of cardiac fibroblasts, detailed time-course experiments were 
performed. Stimulation of serum starved cardiac fibroblasts with 25 µM forskolin or 5 µg/ml 
BAY60-6583 resulted in a rapid induction of a rounded, condensed stellate (star-like) cell 
morphology (Figure 3.4 and 3.6), characterised by reduced cell spreading (Figure 3.5 and 3.7). 
Phase contrast images were taken at regular time intervals and average cell area was determined 
using ImageJ software, from 10-16 fields of view per condition. Acquisition of stellate morphology, 
characterised by reduced cell spreading, was evident only after 20 minutes (from 0.040 ± 0.006 
mm2 in control to 0.014 ± 0.001 mm2, p<0.001) for forskolin (Figure3.4 and 3.5) and after 40 
minutes (from 0.039 ± 0.008 mm2 in control to 0.0197 ± 0.002 mm2, p<0.05) for BAY60-6583 











Figure 3.3: cAMP elevation does not have any effect on the migration of cardiac fibroblasts 
Real-time scratch-wound migration analysis of rat cardiac fibroblasts stimulated with 25 µM 
forskolin (top panel) or 200 µM db-cAMP analogue (bottom panel) in 5% (v/v) FCS was performed 
using an IncuCyte ZOOM live-cell analysis system. FSK: forskolin; Db-cAMP analogue: dibutyryl-





Figure 3.4: Forskolin induces morphological changes in cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated in serum-free conditions with 25 µM forskolin and phase 







Figure 3.5: Forskolin inhibits cell spreading in cardiac fibroblasts 
Rat cardiac fibroblasts were serum-starved overnight before being stimulated with 10% (v/v) FCS 
in the presence of 25 µM forskolin for the indicated times and total cell area assessed by image 
analysis of phase contrast images using ImageJ software. ***: p<0.001. Data are expressed as mean 







Figure 3.6: BAY60-6583 induces morphological changes in cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated in serum-free conditions with 5 µg/ml BAY60-6583 and 






Figure 3.7: BAY60-6583 inhibits cell spreading in cardiac fibroblasts 
Rat cardiac fibroblasts were serum starved overnight before being stimulated with 10% (v/v) FCS 
in the presence of 5 µg/ml BAY60-6583 for the indicated times and total cell area assessed by image 
analysis of phase contrast images using ImageJ software. *: p<0.05 and **: p<0.01. Data are 







3.3.5 PKA and EPAC specific activation synergistically inhibit cell spreading in cardiac 
fibroblasts 
cAMP elevation activates both PKA and EPAC signalling. In order to determine which of these 
cAMP effectors is responsible for the cAMP-induced morphological changes, cardiac fibroblasts 
were stimulated with the cell permeable EPAC selective cAMP analogues, 8-CPT-cAMP-AM and 
I-942 alone, or in combination with the PKA selective agonist 6-BNZ-cAMP-AM. In cardiac 
fibroblasts, stimulation with the PKA selective agonist 6-BNZ-cAMP-AM alone induced a 
detectable change in morphology that was further enhanced by co-stimulation with 8-CPT-cAMP-
AM or I-942 (Figures 3.8 and 3.9). 
3.3.6 Elevated cAMP decreases F-actin and increases G-actin levels in cardiac fibroblasts 
To determine the effects of cAMP elevation on actin cytoskeleton remodelling, cardiac fibroblasts 
were treated with either 25 µM forskolin or 5 µg/ml BAY60-6583 and stained with Alexa-fluor-
488-conjugated phalloidin which detects F-actin fibres. Analysis of F-actin fibres in cardiac 
fibroblasts using Alexa-fluor-488-conjugated phalloidin staining demonstrated a rapid loss of F-
actin stress fibres within 20 minutes of 25 µM forskolin stimulation. This loss of F-actin stress fibres 
persisted for at least 60 minutes (Figures 3.10 and 3.11). Loss of phalloidin stained F-actin fibres 
implies impaired actin polymerisation and increased levels of G-actin monomer. To further confirm 
these changes in the actin polymerisation in cardiac fibroblasts, levels of F-actin and G-actin were 
quantified using selective solubilisation of G-actin in Triton-X-100, as explained in the methods 
chapter. Consistent with phalloidin data indicating a reduction in actin polymerisation in response 
to elevated cAMP, stimulation of cardiac fibroblasts with forskolin or BAY60-6583 resulted in a 
significant reduction in the levels of F-actin and an increase in the levels of G-actin (Figure 3.12). 
3.3. Y27632 induces morphological changes in cardiac fibroblasts 
We have demonstrated that elevation of cAMP levels causes significant morphological changes, 
depolymerises of the actin cytoskeleton and inhibition of cardiac fibroblast proliferation, without 
affecting cell migration. Studies in other mesenchymal cell types have linked cAMP signalling with 
inhibition of the RhoA-ROCK pathway (Laudanna, Campbell et al. 1997, Tamma, Klussmann et 
al. 2003, Oishi, Makita et al. 2012, Akakpo, Musicki et al. 2017, Yu, Zhang et al. 2017). Previously, 
our group suggested that the effects of cAMP on proliferation and migration of vascular smooth 
muscle cells is due, at least in part, to its inhibitory effects on Rho GTPase signalling (Bond, Wu et 
al. 2008, Duggirala, Kimura et al. 2015, Kimura, Duggirala et al. 2016). In order to test this 
hypothesis, cardiac fibroblasts were treated with a pharmacological ROCK inhibitor (Y27632). 




MYPT phosphorylated at Thr853, a well characterised ROCK substrate (Rana and Worthylake 
2012) after 20 (to 0.033±0.01%, p<0.001), 40 (to 0.024±0.009%, p<0.001) and 60 (to 0.01±0.002%, 
p<0.001) minutes of incubation (Figure 3.13), confirming that Y27632 at this dose (10 uM) 
effectively inhibits ROCK signalling. 
Given that RhoA-ROCK signalling has been implicated in regulation of the actin cytoskeleton 
(Narumiya, Ishizaki et al. 1997, Zeidan, Javadov et al. 2006, Amano, Nakayama et al. 2010, Gallo, 
Khan et al. 2012), we asked if inhibition of ROCK signalling induces a similar morphological 
change and actin cytoskeleton remodelling to that induced by cAMP elevation. Stimulation of serum 
starved cardiac fibroblasts with 10 µM Y27632 resulted in the rapid induction of rounded stellate 
morphology that was similar to that induced by cAMP elevating stimuli (Figure 3.14).  
3.3.9 Y27632 inhibits actin stress fibre formation in cardiac fibroblasts 
To determine the effects of ROCK inhibition on actin cytoskeleton remodelling, cardiac fibroblasts 
were treated with 10 µM Y27632 and stained with phalloidin, which binds specifically to F-actin 
stress fibres (Cooper 1987). Analysis of F-actin stress fibres in cardiac fibroblasts using Alexa-
fluor-488-conjugated phalloidin staining demonstrated a dramatic and rapid loss of phalloidin 
stained F-actin fibres after stimulation with 10 µM Y27632, implying impaired actin polymerisation 
and increased actin depolymerisation. This is consistent with previous studies in vascular smooth 
muscle cells demonstrated by our group (Duggirala, Kimura et al. 2015, Smith, Hudson et al. 2017) 
(Figure 3.15). 
3.3.10 Y27632 down regulates serum stimulated proliferation of cardiac fibroblasts 
Signalling through the RhoA-ROCK pathway is known to regulate actin polymerisation (Zeidan, 
Javadov et al. 2006, Amano, Nakayama et al. 2010, Sit and Manser 2011).Therefore, we tested if 
cAMP-mediated inhibition of cardiac fibroblast proliferation is associated with the inhibition of 
RhoA-ROCK signalling. In order to test this hypothesis, cardiac fibroblasts were treated with 10 
µM Y27632 in the presence of serum mitogens for 18 hours. Proliferation was detected and 
quantified by incorporation of the thymidine analogue BrdU by pulse labelling the cells for the final 
6 hours of the stimulation period. Stimulation of cardiac fibroblasts with Y27632 significantly 
inhibited their proliferation (to 8.76±4.54%, p<0.01) (Figure 3.16). 
3.3.11 Y27632 up regulates serum stimulated migration of cardiac fibroblasts 
While several lines of evidence demonstrate an inhibitory role of ROCK inhibitors on cellular 
migration (Sadok, McCarthy et al. 2015, Wang, Yang et al. 2016, Guerra, Oliveira et al. 2017, 




migration, with  ROCK inhibition enhancing the ability of cells to  migrate (Yang and Kim 2014, 
Piltti, Varjosalo et al. 2015, Chang, Zhang et al. 2018). To investigate the effects of ROCK 
signalling on the migration of cardiac fibroblasts, cells were stimulated with 10 µM Y27632 in the 
presence of 5% (v/v) serum and real-time migration rates were quantified over 24 hours using 
IncuCyte ZOOM scratch wound migration assay. Stimulation of cardiac fibroblasts with Y27632 





Figure 3.8: PKA and EPAC specific activation synergistically induce morphological changes in 
cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated in serum-free conditions with 20 µM 6-BNZ-cAMP-AM 
(PKA specific agonist) and 20 µM 8-CPT-cAMP-AM (EPAC specific agonist). Phase contrast 





Figure 3.9: PKA and EPAC specific activations synergistically induce morphological changes in 
cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated in serum-free conditions with 20 µM 6-BNZ-cAMP-AM 






Figure 3.10: Forskolin stimulation disrupts the F-actin fibres in cardiac fibroblasts. 
Rat cardiac fibroblasts were serum-starved for 4 hours before stimulation with 25 µM forskolin in 
serum free conditions for indicated times. Polymerised F-actin filaments were detected using 






Figure 3.11: BAY60-6583 stimulation disrupts the F-actin fibres in cardiac fibroblasts. 
Rat cardiac fibroblasts were serum-starved for 4 hours before stimulation with 5 µg/ml BAY60-
6583 in serum free conditions for indicated times. Polymerised F-actin filaments were detected 







Figure 3.12: Elevated cAMP decreases F-actin fibres but increases G-actin fibres in cardiac 
fibroblasts 
Rat cardiac fibroblasts were serum-starved for 4 hours before stimulation with 25 µM forskolin or 
5 µg/ml BAY60-6583 in serum-free conditions for the indicated times. F-actin fibres and G-actin 
fibres were quantified by western blotting. *: p<0.05; F: F-actin and G: G-actin. Data are expressed 







Figure 3.13: Y27632 suppresses phosphorylation of MYPT in cardiac fibroblasts. 
Rat cardiac fibroblasts were treated with 10 µM Y27632 for indicated times and total cell lysates 
analysed for phosphorylated MYPT and GAPDH by western blotting. ***: p<0.001. Data are 







Figure 3.14: Y27632 induces morphological changes in cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated in serum-free conditions with 10 µM Y27632 and phase 





Figure 3.15: Y27632 disrupts the F-actin fibres in cardiac fibroblasts. 
Rat cardiac fibroblasts were serum-starved for 4 hours before stimulation with 10 µM Y27632 in 
serum free conditions for indicated times. Polymerised F-actin filaments were detected using Alexa-





Figure 3.16: Y27632 inhibits serum-stimulated proliferation of rat cardiac fibroblasts 
Rat cardiac fibroblasts were incubated for 18 hours with 10 µM Y27632 in 5% (v/v) serum. Cells 
were labelled with 10 µM BrdU for further 6 hours and proliferation quantified by immuno-
histochemical staining of incorporated BrdU (A). Representative images of each condition are 
shown below (B). **: p<0.01 and Y27632: ROCK inhibitor. Data are expressed as mean ±SEM and 






Figure 3.17: Y27632 increases the migration rates of cardiac fibroblasts. 
Real-time scratch-wound migration analysis of rat cardiac fibroblasts stimulated with 10 µM 
Y27632 in 5% (v/v) FCS was performed using an IncuCyte ZOOM live-cell analysis system. 






In this chapter, the anti-proliferative and anti-migratory effects of elevated cAMP in cardiac 
fibroblasts were investigated. The data presented demonstrates that elevated cAMP, in response to 
activation of physiologically relevant GPCR receptors, such as the A2BR, or directly with synthetic 
cAMP analogues or the adenylyl cyclase activator forskolin, inhibits the proliferation but not the 
migration of rat cardiac fibroblasts. Using cAMP analogues to selectively activate either PKA or 
EPAC, it was demonstrated that both PKA and EPAC signalling have anti-mitogenic effects in these 
cells and together they act additively to inhibit cardiac fibroblast proliferation. Data is also presented 
demonstrating that the anti-mitogenic effects of cAMP in cardiac fibroblasts is associated with a 
dramatic remodelling of the actin cytoskeleton, characterised by loss of phalloidin stainable F-actin 
stress fibres, a decrease in the F-actin:G-actin ratio and a clear change in cell morphology that is 
similar to the stellate morphology reported in other cell types (Pelletier, Julien et al. 2005, Bond, 
Wu et al. 2008, Hewer, Sala-Newby et al. 2011). This actin remodelling and morphological change 
requires coordinated signalling through both PKA and EPAC. 
The data presented here demonstrate a role for adenosine signalling via the A2BR in inhibiting 
cardiac fibroblast proliferation. Extracellular nucleotides and nucleosides, such as adenosine, have 
been implicated as important regulators of cardiac physiology and cardiac fibroblasts homeostasis, 
including vasodilatation of coronary vessels, regulation of heart rate, angiogenesis, myocardial 
hypertrophy as well as modulation of cardiac fibrosis and regulation of cardiac fibroblast 
proliferation (Dubey, Gillespie et al. 1997, Dubey, Gillespie et al. 2001, Vecchio, White et al. 2017). 
Due to their central role in the cardiac fibrotic process, increased cardiac fibroblast proliferation is 
likely be an important factor in promoting cardiac fibrosis. Adenosine has been described as a 
‘retaliatory metabolite’ due to its enhanced release and production, and ability to help restore energy 
balance during times of cellular metabolic stress or injury (Newby 1984, Shryock and Belardinelli 
1997). Extracellular adenosine levels can be increased in response to tissue damage, ischemia or a 
crisis event (Hori and Kitakaze 1991, Mubagwa, Mullane et al. 1996). Damage to the cell 
membranes can cause release of ATP into the extracellular space which then can be metabolised to 
adenosine via the action of ecto-5’-nucleotidase (Fredholm 2007, Hasko, Linden et al. 2008, Ohta 
and Sitkovsky 2014, Fan and Guan 2016). The cardio protective properties of adenosine in the heart 
has led to several clinical trials for adenosine-based therapies for the treatment of ischaemia 
reperfusion injury after MI (Kopecky, Aviles et al. 2003, Ross, Gibbons et al. 2005, White, Atrasz 
et al. 2005, Forman, Stone et al. 2006, Vecchio, White et al. 2017). The diverse functions of 




all expressed in cardiac fibroblasts, with A2B receptors being the most abundant (Villarreal, 
Epperson et al. 2009). Here we demonstrated that activation of the A2BR using the selective A2BR 
agonist, BAY60-6583, inhibits cardiac fibroblast proliferation.  This data is consistent with previous 
work implicating signalling through the A2BR in limiting cardiac fibrosis (Dubey, Gillespie et al. 
1998, Dubey, Gillespie et al. 2001, Villarreal, Epperson et al. 2009).  In a rat model of MI, agents 
that elevate adenosine levels reduced tissue scar formation via the Gs-coupled A2BR and increased 
intracellular cAMP levels (Ryzhov, Sung et al. 2014). Consistent with these findings, silencing of 
the A2BR increases cardiac fibroblast proliferation and collagen synthesis whereas its 
overexpression has the opposite effects (Dubey, Gillespie et al. 2001, Chen, Epperson et al. 2004). 
Several lines of evidence suggest that these protective effects of adenosine are mediated by 
increases in intracellular cAMP. For example, over expression of adenylate cyclase or its activation 
with forskolin inhibits TGF-β or angiotensin II induced myofibroblast differentiation, collagen 
synthesis and proliferation in cardiac fibroblasts (Dubey, Gillespie et al. 2001, Swaney, Roth et al. 
2005, Giannotta, Benedetti et al. 2014). Consistent with these reports, data presented in this chapter 
confirms that cAMP elevation in response to forskolin or Db-cAMP analogues stimulation 
significantly inhibited cardiac fibroblast proliferation. 
Anti-proliferative properties of elevated cAMP have previously been reported in other 
mesenchymal cell types, including vascular smooth muscle cells (Hayashi, Morishita et al. 2000, 
Growcott, Spink et al. 2006, Smith, Hudson et al. 2017, Smith, Sessions et al. 2019). In VSMC, 
cAMP inhibits entry into S-phase of the cell cycle via a mechanism that requires the activation of 
both PKA and EPAC effectors (Hewer, Sala-Newby et al. 2011). Using PKA and EPAC selective 
cAMP analogues, work presented in this chapter demonstrates a similar requirement for PKA and 
EPAC signalling in cardiac fibroblasts. However, some key differences are evident. In VSMC, 
activation of PKA or EPAC in isolation did not significantly inhibit serum induced proliferation 
(Hewer, Sala-Newby et al. 2011). This contrasts with data presented here, which demonstrates a 
significant but submaximal inhibition of cardiac fibroblast proliferation in response to PKA or 
EPAC activation alone. In VSMC, PKA and EPAC activation acted synergistically to inhibit 
proliferation (Hewer, Sala-Newby et al. 2011), whereas in cardiac fibroblasts the effects were 
additive. The data presented here is consistent with data indicating an anti-mitogenic effect of 
selective EPAC or PKA activation (Yokoyama, Minamisawa et al. 2008). The reasons for these 
differences are not fully understood but may reflect differences in the relative expression levels of 
PKA and/or EPAC1 in these cell types or a difference in how these two cAMP effectors modulate 




implicated in mediating cAMP-dependent anti-mitogenesis in VSMC (Bond, Wu et al. 2008, 
Hewer, Sala-Newby et al. 2011). cAMP and EPAC signalling are known to have divergent effects 
on the proliferation in various cell types. For example, elevated cAMP inhibits proliferation of 
several cell types of mesenchymal origin, including VSMC (Hewer, Sala-Newby et al. 2011, 
Kimura, Duggirala et al. 2014, Smith, Hudson et al. 2017) and cardiac fibroblasts, but stimulates 
the proliferation of other cell types, including epithelial cells (Yamaguchi, Nagao et al. 2003), 
embryonic stem cells (Lee, Kim et al. 2012), endothelial cells (Smith, Hudson et al. 2017) and even 
VSMC under some conditions (Hogarth, Sandbo et al. 2004). Interestingly, the balance of PKA and 
EPAC signalling has been reported to switch cAMP signalling from a pro-mitogenic signal into an 
anti-mitogenic signal in PC12 cells, suggesting that the interplay between these two pathways is a 
critical step in determining the proliferative response (Kiermayer, Biondi et al. 2005). 
The anti-mitogenic effects of cAMP-elevating stimuli in cardiac fibroblasts reported here were 
associated with a rapid and profound change cell morphology and disruption of the actin 
cytoskeleton. Cyclic-AMP elevating stimuli resulted in a loss of phalloidin stainable actin stress 
fibres (F-actin) and a significant reduction in the F-actin:G-actin ratio. Similar cAMP-induced 
morphological changes, described as a ‘stellate morphology’ and characterised by a condensation 
of the cell body, formation of long branching membrane processes and loss of actin stress fibres 
have been reporter previously in other cell types, including VSMC and astrocytes (Pelletier, Julien 
et al. 2005, Hewer, Sala-Newby et al. 2011, Chen, Wild et al. 2014, Smith, Hudson et al. 2017). 
These morphological changes and loss of actin stress fibres occur rapidly after cAMP elevation 
suggesting that they are an early event in the cAMP signalling mechanisms preceding changes in 
cell proliferation and occuring independently of changes in gene expression. Cell morphology and 
the integrity and the organisation of the actin cytoskeleton is known to be a critical permissive factor 
in cell-cycle progression of adhesion-dependent cell types. This is clearly demonstrated by 
numerous studies using actin binding drugs such as latrunculin-B or cytochalasin-D, which inhibit 
actin polymerisation and block progression past the G1 phase restriction point that controls entry 
into S-phase of the cell cycle (Huang, Chen et al. 1998, Wang, Li et al. 2019). The implication is 
that cAMP-induced morphological changes and inhibition of actin polymerisation are likely to 
contribute, at least in part, to the anti-mitogenic effects of cAMP in cardiac fibroblasts. The 
mechanisms underlying this are investigated in more detail in chapter 4. Consistent with a 
requirement for actin polymerisation for a pro-fibrotic cardiac fibroblast phenotype, a recent study 
reported that fibroblasts isolated from rat hearts after 4 weeks of volume overload induced by 




reduction in F-actin and a reduced F-actin:G-actin ratio, compared to controls (Childers, Sunyecz 
et al. 2019). Importantly, treatment with a ROCK inhibitor (Y27632) reduced the F-actin:G-actin 
ratio and replicated the hypo-fibrotic phenotype. Moreover, promoting actin polymerisation with 
the actin binding drug jasplakinolide, increased the F-actin:G-actin ratio and restored a more fibrotic 
response in the cells from the volume overload hearts (Childers, Sunyecz et al. 2019). Taken 
together, these observations suggest that cAMP-induced remodelling of the actin cytoskeleton plays 
an important role in regulating a pro-fibrotic and proliferative cardiac fibroblast phenotype. The 
data presented in this chapter demonstrates that elevation of cAMP using either BAY60-6583, or 
directly with forskolin, induced disruption of actin polymerisation. A similar morphological change 
and actin disruption was observed in response to selective PKA activation with 6-BNZ-cAMP-AM, 
which also inhibited proliferation. Similar PKA-induced changes in morphology, actin cytoskeleton 
remodelling and growth arrest have been reported previously in vascular smooth muscle cells 
(Hewer, Sala-Newby et al. 2011, Kimura, Duggirala et al. 2014). However, no morphological 
change or disruption of actin stress fibres in cardiac fibroblasts was detected in response to selective 
EPAC activation, using either 8-pCPT-cAMP-AM or a non-cyclic nucleotide EPAC agonist I-942, 
despite selective EPAC activation resulting in a significant, albeit submaximal, inhibition of 
proliferation. This lack of EPAC-dependent morphological or actin change is similar to effects 
reported in VSMC, although in VSMC, selective EPAC activation does not result in growth arrest, 
in contrast to the growth inhibitory effects in cardiac fibroblasts reported here. This implies that 
EPAC-mediated growth arrest in cardiac fibroblasts occurs independently of actin cytoskeleton 
changes. This may reflect activation of actin-independent EPAC-effector signalling pathways that 
contribute towards the growth inhibitor properties of cAMP in cardiac fibroblasts. For example, 
EPAC activates RAP1 (Chapter 5), independently of changes in actin remodelling. Importantly, the 
Rap1 gene was originally identified by its ability to revert Ras-mediated cellular transformation 
(Kitayama, Sugimoto et al. 1989), suggesting that EPAC-Rap1 signalling may underly the actin-
independent growth inhibitory effects of EPAC signalling in cardiac fibroblasts. However, EPAC 
activation also enhances PKA-mediated morphological change, actin disruption and growth arrest, 
implying that at least some of the effects of EPAC signalling may be mediated via enhancement of 
PKA-induced actin remodelling.  
Although there are several similarities between the effects of cAMP signalling reported here in 
cardiac fibroblasts and those reported previously in vascular smooth muscle cells, a major difference 
is the effects of cAMP elevation on migration in these two cell types. In vascular smooth muscle 




Murai et al. 2015, McKean, Murray et al. 2015, Smith, Hudson et al. 2017). The data presented here 
demonstrates that cAMP elevation in cardiac fibroblasts using forskolin or Db-cAMP analogue has 
the opposite effect, increasing the migration of cardiac fibroblasts. This implies that distinct 
signalling mechanisms are involved in the regulation of proliferation and migration in these cells. 
Moreover, several lines of evidence reported the actin-sensitive transcription factor:co-factor 
complexes, MKL-SRF and YAP/TAZ-TEAD, to have crucial roles in the regulation of cellular 
proliferation and migration (Parmacek 2010, Yu and Guan 2013, Vasudevan and Soriano 2014, 
Duggirala, Kimura et al. 2015, Kimura, Duggirala et al. 2016, Joy, Gau et al. 2017, Smith, Hudson 
et al. 2017, Boopathy and Hong 2019). The regulation of these transcription factor complexes by 
cAMP in cardiac fibroblasts is presented in chapters 4 and 5 of this thesis and demonstrates that 
both are negatively regulated by cAMP. This clearly implies that cardiac fibroblasts migration can 
occur independently of MKL-SRF and YAP/TAZ-TEAD activity, which contrasts with the role of 
the factors in vascular smooth muscle cells. 
The importance of actin remodelling for cell migration and motility is widely accepted. Cell 
migration requires continuous dynamic reorganisation of actin, including increased actin 
polymerisation to promote lamellipodia formation and strengthen new focal adhesions at the leading 
edge but at the same time requires actin depolymerisation and focal adhesion disassembly at the 
rear, allowing for retraction of the trailing edge driven by actomyosin contractility (Pollard and 
Cooper 2009). Rho-GTPase activity plays a key role in promoting actin polymerisation at the 
leading edge and is essential for migration of cardiac fibroblasts in two-dimensional migration 
assays . Silencing of RhoA in cardiac fibroblasts inhibits their migration in 2D scratch wound assay 
(Jatho, Hartmann et al. 2015), consistent with a requirement for RhoA-mediated actin 
polymerisation. However, silencing of RhoA enhances the migration of cardiac fibroblast through 
a three-dimensional collagen gel by allowing and promoting an amoeboid mode of migration (Jatho, 
Hartmann et al. 2015). This suggests that cardiac fibroblasts use two mechanistically distinct modes 
of migration, a RhoA and actin-dependent mesenchymal mode of migration and a RhoA and actin 
independent amoeboid mode of migration. The data presented here demonstrates that cAMP 
elevation with forskolin, Db-cAMP analogue or Y27632 does not inhibit cardiac fibroblast 
migration despite clear inhibitory effects on actin polymerisation. This may indicate that cardiac 
fibroblasts adopt an amoeboid mode of migration under conditions of elevated cAMP and impaired 
actin polymerisation. Yokoyama et al also reported enhanced cardiac fibroblast migration in 
response to elevated cAMP. However, this enhancement was only evident with low but not high 




forskolin reported by Yokoyama may be due to migration assays being performed under serum free 
conditions, which contrasts with the migration assay data presented in this chapter. Serum mitogens 
activate Rho-GTPase activity (Toksoz and Merdek 2002, Maddala, Reddy et al. 2003, Ravi, 
Kaushik et al. 2015), suggesting that these differences may reflect the magnitude of inhibition of 
Rho-GTPase activity and actin polymerisation. In this chapter we present data quantifying the 
reduction in the F-actin:G-actin ratio in response to forskolin. These data demonstrate that cAMP 
elevation reduces the percentage of F-actin from 40% to 30%. Importantly, similar analyses in 
vascular smooth muscle cells demonstrate a much larger reduction in F-actin content (from 57% to 
9%). This larger inhibition of actin polymerisation by cAMP in VSMC may explain the different 
effects of cAMP in vascular smooth muscle cells and cardiac fibroblasts. The physiological 
significance of the divergent effects of cAMP on cardiac fibroblast migration is unknown. However, 
the ability of cardiac fibroblast to migrate under conditions of elevated cAMP and impaired actin 
polymerisation, possibly by adopting an amoeboid mode of migration, may reflect that critical 
importance of rapid cardiac repair following acute myocardial injury, such as following MI.  
Furthermore, we also showed that cAMP elevating stimuli induce significant morphological 
changes, actin depolymerisation and downregulation of proliferation of cardiac fibroblasts, but a 
small increase in their migration. Previous investigations have linked cAMP signalling with 
inhibition of the RhoA-ROCK pathway (Gao, Li et al. 2004). Also our group suggested that, the 
effects induced by cAMP in vascular smooth muscle cells is due to its inhibitory effects on 
Rho/ROCK signalling (Smith, Hudson et al. 2017). In order to test the hypothesis that cAMP-
mediated inhibition of ROCK may contribute towards the inhibitory effects of cAMP on cardiac 
fibroblast proliferation, cells were treated with the ROCK inhibitor Y27632. This effectively 
inhibited ROCK activity indicated by a large reduction in phosphorylation of the ROCK substrate 
MYPT. Importantly, pharmacological ROCK inhibition replicated the effects of elevated cAMP, 
inducing a stellate morphology, loss of actin stress fibres and inhibition of cell proliferation, without 
inhibiting cell migration. In fact, ROCK inhibition actually stimulated migration of cardiac 
fibroblasts in the experiments presented here. The role of ROCK activity on cell migration is 
controversial. Several lines of evidence have demonstrated that ROCK inhibition reduces cell 
migration (Sadok, McCarthy et al. 2015, Wang, Yang et al. 2016, Guerra, Oliveira et al. 2017, 
Smith, Hudson et al. 2017). However, other studies indicate that ROCK signalling represses 
migration (Totsukawa, Wu et al. 2004, Yang and Kim 2014, Piltti, Varjosalo et al. 2015, Chang, 
Zhang et al. 2018). This may reflect cell type specific differences. Stimulation of cardiac fibroblasts 




Again, this could imply that cardiac fibroblasts adopt an amoeboid mode of migration under 
conditions when ROCK is inhibited, or their actin filaments are depolymerised. 
In summary, data presented in this chapter demonstrates that the physiological GPCR agonist 
adenosine and elevated levels of cAMP inhibits cardiac fibroblast proliferation but not migration 
and that this inhibitory action is associated with a rapid change in cell morphology and inhibition 
of actin polymerisation. These data suggest that increases in adenosine following cardiac injury may 
play an important role in retraining cardiac fibroblast proliferation and fibrosis following cardiac 
injury. The proliferative expansion of the cardiac fibroblast population, the main extracellular 
producing cell type in the myocardium, enhances the deposition of extracellular proteins and hence 
contributes to fibrosis. Therefore, limiting cardiac fibroblast proliferation may be a physiological 
response to prevent excessive fibrosis and may represent a potential therapeutic avenue to reduce 
pathological myocardial fibrosis. The data of this chapter is summarised in figure 3.18. 
The underlying signalling mechanisms mediating these anti-mitogenic properties of cAMP will be 






Figure 3.18. Schematic representation of regulation cardiac fibroblast proliferation by adenosine 
induced cAMP signalling.  
Adenosine signalling via the adenosine A2B receptor induces cAMP levels in cardiac fibroblast. 
This inhibits RhoA-ROCK signalling and actin polymerisation, resulting in a change in cell 










ROLE OF MKL1-SRF AND YAP/TAZ-
TEAD IN THE  ANTI-MITOGENIC 







In chapter 3, data was presented demonstrating that cAMP-elevating stimuli inhibit cardiac 
fibroblast proliferation. This anti-mitogenic effect was associated with a rapid and dramatic change 
in cell morphology and a reduction in actin polymerisation. However, it was not clear if these anti-
mitogenic effects were mediated by the associated changes in actin polymerisation. Furthermore, it 
was not determined what the underlying mechanisms might be that link cAMP-dependent actin 
remodelling to changes in cardiac fibroblast proliferation. 
As discussed in chapter 3, morphological changes and loss of actin stress fibres occur rapidly after 
cAMP elevation, suggesting that they are an early event in the cAMP signalling mechanisms and 
precede changes in cell proliferation. The rapid onset of these morphological and actin changes also 
imply that they probably occur independently of changes in gene expression. Cell morphology, cell 
spreading and the polymerisation of the actin cytoskeleton are known to be critical factors in 
allowing cell proliferation of many adhesion-dependent cell types (Smith, Sessions et al. 2019). 
Studies using actin binding drugs such as cytochalasin-D or latrunculin-B, which directly inhibit 
actin polymerisation clearly demonstrate that the integrity of the actin cytoskeleton is essential for 
cell cycle progression in many different adhesion-dependent cell types (Huang, Chen et al. 1998, 
Wang, Li et al. 2019). Several mechanisms have been proposed to be involved in mediating the 
actin-dependence of cell proliferation. Early studies highlighted effects on the MAPK signalling 
pathway (Aplin, Howe et al. 1999, Schwartz and Assoian 2001). However, several lines of evidence 
reported that the ability of a polymerised actin cytoskeleton to support cell proliferation is not 
mediated simply via the MAPK signalling pathway. In fact, MAPK signalling is only important in 
the early G1 phase of the cell-cycle while a properly organised actin cytoskeleton is essential 
throughout most of the G1 phase up until the restriction point that controls entry into S-phase (Wang, 
Li et al. 2019). These studies imply that effects of the actin cytoskeleton on proliferation can be 
separated from actin-dependent effects on MAPK activity. Interestingly, the anti-mitogenic effects 
of cAMP signalling on cell proliferation have also been shown to be dissociated from the inhibitory 
effects of cAMP on MAPK signalling (Cospedal, Lobo et al. 1999). These data imply that additional 
mechanisms are involved in mediating the anti-mitogenic effects of cAMP and actin disruption. 
Early work from our lab implicated remodelling of the actin cytoskeleton as playing an important 
functional role in mediating the anti-mitogenic effects of cAMP in VSMC (Bond, Wu et al. 2008, 
Hewer, Sala-Newby et al. 2011, Kimura, Duggirala et al. 2014). Consistent with this, data presented 
in chapter 3 demonstrates that cAMP is also anti-mitogenic in cardiac fibroblasts and that this is 




mechanisms involving actin cytoskeleton remodelling and changes in gene expression are therefore 
likely to be important in allowing cells to sense and respond to cAMP-elevating stimuli, in addition 
to various other micro-environmental signals that regulate the polymerisation of actin cytoskeleton. 
A large body of research has focussed on characterising these mechanisms. Early research studying 
the regulation of the FOS gene helped to identify a key regulatory mechanism that links the actin-
cytoskeleton to changes in gene expression (Graham and Gilman 1991, Hill, Wynne et al. 1995). 
The FOS gene is controlled by binding of the SRF transcription factor to a serum-response element 
(SRE) in its proximal promoter region. Mitogen stimulation was shown to be able to induce the 
FOS gene, via activation of the MAPK signalling pathway, by inducing the binding of ternary 
complex factor (TCF) binding to SRF.  However, mutated SRF elements in the FOS promoter that 
were incapable of binding TCFs remained responsive to signals that modulated Rho-GTPase 
activity or induced remodelling of the actin cytoskeleton (Graham and Gilman 1991, Hill, Wynne 
et al. 1995). This work ultimately established that SRF activity is also sensitive to actin 
polymerisation via a TCF-independent mechanism (Posern, Miralles et al. 2004). As mentioned in 
chapter 1, regulation of SRF activity following actin remodelling is regulated by SRF co-
transcription factors, known as MKL1 and MKL2 (Miralles, Posern et al. 2003). As discussed in 
the introduction chapter, MKL1 and MKL2 translocate between the cytosol and the nucleus, where 
they interact with and stimulate SRF-dependent gene expression (Miralles, Posern et al. 2003). The 
cellular localisation of MKL proteins is regulated by interaction with G-actin monomers, which 
bind to MKL1/2 via their N-terminal RPEL domains. It follows that signals that reduce actin 
polymerisation, such as cAMP-elevating stimuli, increase the association of actin monomer with 
the MKL1/2. Inhibition of actin polymerisation using actin binding drugs has been shown to induce 
nuclear export of MKL1/2 and hence reduced SRF-dependent gene expression (Esnault, Stewart et 
al. 2014). In contrast, stimuli such as mitogens that increased RhoA-mediated actin-polymerisation 
and hence depletion of G-actin monomer levels cause MKL1/2 to translocate into the nucleus, where 
they enhances SRF-dependent gene expression (Guettler, Vartiainen et al. 2008, Hirano and 
Matsuura 2011, Smith, Hudson et al. 2017). Through investigating the effects of cAMP stimulation 
on actin cytoskeleton remodelling in cardiac fibroblasts (which was discussed in chapter 3), it 
became a point of interest to study whether MKL1 and MKL2 are also regulated by cAMP in cardiac 
fibroblasts and if this mechanism is involved in mediating the anti-mitogenic effects of cAMP in 
these cells. Our group has previously reported that RhoA inhibition downregulates the expression 
of SRF-dependent genes in VSMCs (Duggirala, Kimura et al. 2015). Furthermore, forskolin 
stimulation was demonstrated to inhibit the expression of pro-proliferative and pro-migratory genes: 




Duggirala et al. 2016, Smith, Hudson et al. 2017). These results indicate that cAMP signalling 
represses the expression of SRF-dependent genes by regulating MKL1 activation. This mechanism 
may contribute towards the anti-mitotic effects of cAMP in fibroblasts, given that pharmacological 
inhibition or genetic deletion of MKL1/2 reduced intestinal fibrosis (Johnson, Rodansky et al. 
2014), lung fibrosis (Sisson, Ajayi et al. 2015), skin fibrosis (Haak, Tsou et al. 2014) and inhibited 
the expression of ECM genes and smooth muscle genes associated with a myofibroblast phenotype 
(Small, Thatcher et al. 2010). 
Clearly, the effects of cAMP stimulation and actin depolymerisation are unlikely to be mediated 
solely via the MKL-SRF signalling pathway. Other actin sensitive transcription factors have also 
been described (Low, Pan et al. 2014, Meng, Moroishi et al. 2016, Qiao, Chen et al. 2017). For 
example, the transcriptional co-activators YAP and TAZ have also been implicated in linking actin 
remodelling and biomechanical signals to changes in gene expression and cellular responses in 
various cell types (Low, Pan et al. 2014, Park, Shin et al. 2018). These co-factors translocate 
between the cytoplasm and the nucleus in response to bio-mechanincal signals and stimuli that 
modulate actin organisation (Elosegui-Artola, Andreu et al. 2017, Dobrokhotov, Samsonov et al. 
2018, Shreberk-Shaked and Oren 2019). Once in the nucleus, YAP and TAZ bind to TEAD 
transcription factors (TEAD1-4) and interact with other members of the transcriptional machinery, 
including RNA polymerase II (Rognoni and Walko 2019), to mediate the expression of different 
genes required for proliferation and migration (Komuro and Yacubova 2003, Zhao, Li et al. 2010, 
Hudson, Kimura et al. 2018). Under normal conditions, YAP and TAZ are negatively regulated by 
MST and LATS (Dong, Feldmann et al. 2007, Hao, Chun et al. 2008). Once YAP and TAZ are 
phosphorylated by LATS, they are translocated out of the nucleus into the cytoplasm and get 
degraded, which decreases the expression of TEAD-dependent genes (Zhao, Wei et al. 2007, 
Gloerich and Bos 2010). Recent investigations demonstrated that the activities of YAP and TAZ 
can be affected by GPCR signalling. For example, lysophosphatidic acid (LPA) and sphingosine 1-
phosphophate (S1P) act via G12/13-coupled receptors to activate YAP and TAZ, whereas stimulation 
of Gs-coupled receptors in response to epinephrine or glucagon inhibits YAP and TAZ function 
(Yu, Zhao et al. 2012).  Consistent with this, recent research in smooth muscle cells and breast 
cancer cells has demonstrated that stimulation of cAMP signalling, which inhibits Rho-GTPase 
activity and inhibits actin polymerisation (Pelletier, Julien et al. 2005, Bond, Wu et al. 2008), 
induces YAP/TAZ phosphorylation, YAP/TAZ cytoplasmic translocation and downregulation of 
TEAD-dependent  gene expression (Bond, Wu et al. 2008, Yu, Zhang et al. 2013, Kimura, 
Duggirala et al. 2016).  This inhibition of YAP/TAZ activity has been implicated in mediating the 




their proliferation (Kimura, Duggirala et al. 2016, Wang, Li et al. 2019) and constitutively active 
mutants of YAP and TAZ are able to reverse these anti-mitogenic properties of elevated cAMP 
(Kimura, Duggirala et al. 2016). Together, these data highlight the importance of YAP and TAZ in 
promoting the proliferation of cardiovascular cells and that the inhibition of YAP and TAZ 
contributes to anti-proliferative effects of cAMP (Kimura, Duggirala et al. 2016). Several lines of 
evidence suggested that YAP-dependent activation of TEAD enhances cell  proliferation by 
increasing the expression of proliferation associated genes, such as Ccn1 and Ctgf (Zhao, Ye et al. 
2008, Stein, Bardet et al. 2015, Kimura, Duggirala et al. 2016, Wang, Li et al. 2019). Importantly, 
pro-mitotic and pro-migratory genes, such as Ccn1 and Ctgf are also subject to regulation by 
MKL1/2-SRF. This suggests that genes required for efficient proliferation of cardiac cells are 
coupled to the status of the actin network via both MKL1/2-SRF and YAP/TAZ-TEAD 
transcriptional complexes (Smith, Sessions et al. 2019). Taken together, these data suggest that 
changes in actin organisation regulates cellular responses, including proliferation and migration. 
This regulation of cellular behaviour is at least in part by controlling the activities of different 
transcription factor complexes, such as, MKL1-SRF and YAP/TAZ-TEAD (Miralles, Posern et al. 
2003, Camoretti-Mercado, Dulin et al. 2005, Ota and Sasaki 2008, Gau, Veon et al. 2017, Tsai, 
Anderson et al. 2017). Modifications in the stimulation of these transcription factor complexes, 
ultimately induce changes in cellular responses by changing gene expression (Minami, Kuwahara 
et al. 2012, Haak, Tsou et al. 2014). Notably, MKL-SRF and YAP/TAZ/TEAD have also been 
implicated in enhancing in tissue fibrosis following injuries and insults. Data presented in chapter 
3 of this thesis, presented that elevated levels of cAMP down regulated the proliferation of cardiac 
fibroblasts. An effect which is associated with a rapid actin cytoskeleton remodelling. The aims and 
hypothesis of this chapter are mentioned in the next section. 
4.2 HYPOTHESIS 
The hypotheses for this chapter were: 
1. cAMP elevation reduces SRF and TEAD-dependent transcription in cardiac fibroblasts 
2. cAMP elevation inhibits nuclear translocation of MKL1 in cardiac fibroblasts 
3. The proliferation of cardiac fibroblasts is MKL-dependent 
4. cAMP elevation inhibits nuclear translocation of YAP in cardiac fibroblasts 





4.3.1 Elevated levels of cAMP inhibit SRF and TEAD-dependent luciferase reporter gene activity 
in cardiac fibroblasts 
Cardiac fibroblasts were transiently transfected with luciferase reporter gene constructs under the 
control of promoter regions containing either five multimerised copies of a consensus SRF element 
(SRF-LUC) or eight multimerised copies of a consensus TEAD element (TEAD-LUC). These cells 
were then stimulated with the A2BR agonist BAY60-6583, forskolin or Db-cAMP analogue for 
eight hours to increase the intracellular concentrations of cAMP (Figure 4.1). Treatment of cardiac 
fibroblasts with BAY60-6583, forskolin or Db-cAMP analogue resulted in a significant down 
regulation (to 0.67±0.12-fold p<0.05, 0.3±0.035-fold p<0.01 and 0.60±0.13-fold p<0.05, 
respectively) of SRF-dependent luciferase reporter gene activity (Figure 4.1). In a similar manner, 
stimulation of cardiac fibroblasts with BAY60-6583, forskolin or Db-cAMP analogue resulted in a 
significant down regulation (to 0.44±0.056-fold p<0.001, 0.22±0.036-fold p<0.001 and 
0.41±0.054-fold p<0.001, respectively) of TEAD-dependent luciferase reporter gene activity 
(Figure 4.1). In contrast, the activity of the control luciferase reporter gene (Control-LUC), which 
was under the control of a minimal promoter region lacking any SRF or TEAD binding elements, 
was not significantly changed with these cAMP elevating agents (Figure 4.1). These data 
demonstrate that elevated cAMP inhibits SRF and TEAD-dependent luciferase reporter gene 
activities in cardiac fibroblasts.  
4.3.2 Elevated levels of cAMP down regulate the expression of SRF and TEAD-dependent target 
genes in cardiac fibroblasts 
As discussed previously, cAMP elevation has previously been linked to decreases in SRF and 
TEAD-dependent gene expression in VSMC by inducing actin remodelling and inhibiting the 
nuclear translocation of SRF transcription factors, MKL1 and MKL2 (Kimura, Duggirala et al. 
2016, Smith, Hudson et al. 2017, Smith, Sessions et al. 2019). Since cAMP elevating stimuli 
inhibited the SRF and TEAD-dependent luciferase reporter gene activity, we tested if the 
endogenous SRF and TEAD-dependent target genes were also repressed by these cAMP-elevating 
stimuli in cardiac fibroblasts, using qRT-PCR. Cardiac fibroblasts were stimulated with 5 µg/ml 
BAY60-6583 and mRNA expression of previously characterised (Smith, Hudson et al. 2017) SRF 
target genes, Ccn1, Ctgf, Serpine (Pai1), Zyx, Heyl and Thbs1 quantified. Stimulation with BAY60-
6583 rapidly and significantly inhibited the mRNA levels of Ccn1 (to 0.25±0.17-fold, p<0.05, Ccn1 
pre-spliced RNA (to 0.4±0.2-fold, p<0.05), Ctgf (to 0.25±0.17-fold, p<0.05), Ctgf pre-spliced RNA 




p<0.05), Heyl (to 0.63±0.067-fold, p<0.05) and Thbs1 (to 0.17±0.085-fold, p<0.05) after 6 hours 
respectively, while the mRNA levels of the housekeeping gene 36B4 was not affected (Figure 4.2). 
Moreover, stimulation of cardiac fibroblasts with 25 µM forskolin rapidly and significantly 
inhibited the mRNA levels of Ccn1 (to 0.092±0.05-fold  and to 0.05±0.016-fold at 2 and 6 hours 
respectively, p<0.001), Ccn1 pre-spliced RNA (to 0.069±0.01-fold and to 0.087±0.04-fold at 2 and 
6 hours respectively, p<0.001), Ctgf (to 0.26±0.11-fold and to 0.03±0.011-fold at 2 and 6 hours 
respectively, p<0.001), Ctgf pre-spliced RNA (to 0.065±0.033-fold and to 0.074±0.025-fold at 2 
and 6 hours respectively, p<0.001), Serpine/Pai1 (to 0.28±0.036-fold and to 0.015±0.006-fold at 2 
and 6 hours respectively, p<0.001), Zyx (to 0.57±0.1-fold and to 0.23±0.08-fold at 2 and 6 hours 
respectively, p<0.001), Heyl (to 0.74±0.095-fold and to 0.7±0.2-fold at 2 and 6 hours respectively, 
p<0.001) and Thbs1 (to 0.65±0.03-fold and to 0.09±0.02-fold at 2 and 6 hours respectively, 
p<0.001), while the mRNA levels of 36B4 were not affected (Figure 4.3). Taken together, these 
data indicate that cAMP elevating stimuli inhibit the expression of SRF and TEAD-dependent gene 
expression in cardiac fibroblasts. 
4.3.3 Elevated levels of cAMP activate CREB-dependent transcription in cardiac fibroblasts  
The activity of CREB-dependent gene expression was also quantified in order to examine whether 
the inhibition of SRF and TEAD-target gene mRNA expression by cAMP elevating stimuli was 
simply due to a generalised global repression of transcription or if this represented a more selective 
repression of specific transcription factor activity.  
Cardiac fibroblasts were transiently transfected with a luciferase reporter gene constructs (CREB-
LUC) under the control of a 168 bp of the endogenous glycoprotein human alpha-subunit gene 
promoter, which contains two copies of a consensus CREB gene promoter. This vector was a gift 
from Professor Stan McKnight and has previously been shown to faithfully report CREB activity 
(Mellon, Clegg et al. 1989, Smith, Hudson et al. 2017). Cardiac fibroblasts were transfected with 
CREB-LUC and stimulated with BAY60-6583, forskolin or Db-cAMP and luciferase activity 
quantified. Treatment of cardiac fibroblasts with BAY60-6583, forskolin or Db-cAMP analogue 
resulted in a significant up regulation (to 8.09±1.40-fold, p<0.001; 4.30±1.16-fold, p<0.05 and 
5.34±1.23-fold, p<0.05 respectively) of CREB-LUC (Figure 4.4). Furthermore, the mRNA 
expression levels of the endogenous CREB-target gene, Nr4A1 (Volakakis, Kadkhodaei et al. 2010, 
Medzikovic, de Vries et al. 2019), was also significantly upregulated in response to BAY60-6583 
(to 10.7±3.26-fold and 6.68±1.58-fold, p<0.05 at 2 and 6 hours of stimulation respectively, Figure 
4.5A), forskolin (to 16.3±7.91-fold, p<0.05 and 2.20±0.91-fold at 2 and 6 hours of stimulation 




2 and 6 hours of stimulation respectively, Figure 4.5C) stimulation. However, mRNA levels of the 
CREB-independent housekeeping gene 36B4 remained unaffected by any of these stimuli (Figure 
4.5 D-F). Taken together, these data indicate that cAMP-elevating stimuli selectively repress SRF- 








Figure 4.1: Elevated cAMP inhibits SRF and TEAD-dependent luciferase reporter gene 
activities in cardiac fibroblasts 
Rat cardiac fibroblasts were transfected with SRF-LUC, TEAD-LUC or Control-LUC reporter 
plasmids and stimulated with 5 µg/ml BAY60-6583, 25 µM forskolin or 200 µM Db-cAMP 
analogue for 8 hours in serum free conditions and lysates assayed for luciferase activity. *: p < 0.05; 
**: 0.01 and ***: 0.001. Data are expressed as mean ±SEM and analysed using one-way ANOVA 






Figure 4.2: BAY60-6583 inhibits the mRNA levels of SRF and TEAD-target genes in cardiac 
fibroblasts 
Rat cardiac fibroblasts were stimulated with 5 µg/ml BAY60-6583 in serum free conditions for 
6 hours and mRNA levels of indicated genes quantified by RT-qPCR. *: p<0.05. Data are expressed 






Figure 4.3: Forskolin inhibits the mRNA levels of SRF and TEAD-target genes in cardiac 
fibroblasts 
Rat cardiac fibroblasts were stimulated with 25 µM forskolin in serum free conditions for 2 and 
6 hours and mRNA levels of indicated genes quantified by RT-qPCR. **: p<0.01 and ***: p<0.001. 
Data are expressed as mean ±SEM and analysed using one-way ANOVA with Student Newman-




4.3.4 Elevated levels of cAMP suppress Rho/ROCK signalling in cardiac fibroblasts 
As demonstrated in chapter 3, elevated levels of cAMP and pharmacological inhibition of 
Rho/ROCK induced morphological changes and actin remodelling in cardiac fibroblasts. Moreover, 
our group has also shown that, elevation of cAMP levels down regulates the activity of the 
Rho/ROCK signalling pathway in vascular smooth muscle cells (Smith, Hudson et al. 2017). The 
next question was if elevated levels of cAMP also down regulate the activity of the Rho/ROCK 
signalling pathway in cardiac fibroblasts and if this is involved in the inhibition of SRF- and TEAD-
dependent gene expression. 
In order to answer this question, cardiac fibroblasts were stimulated with BAY60-6583, forskolin 
or Db-cAMP analogues at different times. At the end of each time point, the protein levels of 
phosphorylated myosin phosphatase targeting subunit (pMYPT) were quantified by Western 
blotting. Briefly, RhoA mediates activation of ROCK, which then phosphorylates its downstream 
target, MYPT, at Thr696 and Thr853. ROCK mediated phosphorylation of MYPT results in MYPT 
inactivation. Upon MYPT inactivation, MLC phosphorylation levels increase, resulting in stress 
fibre formation and cellular contraction (Kimura, Ito et al. 1996, Birukova, Smurova et al. 2004, 
Birukova, Smurova et al. 2004, Amano, Nakayama et al. 2010). Protein levels of pMYPT (Thr853) 
were significantly down regulated in response to BAY60-6583 (to 0.39±0.14-fold, p<0.05 and 
0.38±0.082-fold, p<0.05 at 40 and 60 minutes of stimulation respectively, Figure 4.6), forskolin (to 
0.32±0.11-fold, p<0.001; 0.35±0.10-fold, p<0.001 and 0.26±0.11-fold, p<0.001 at 20, 40 and 60 
minutes of stimulation respectively, Figure 4.7) or Db-cAMP analogue (to 0.20±0.01-fold, p<0.001; 
0.33±0.14-fold, p<0.001 and 0.27±0.11-fold, p<0.001 at 20, 40 and 60 minutes of stimulation 
respectively, Figure 4.8). This indicates that elevated cAMP induces inhibition of RhoA/ROCK 
signalling in cardiac fibroblasts, which is consistent with the effects previously reported in vascular 
smooth muscle cells (Smith, Hudson et al. 2017). 
4.3.5 Y27632 inhibits SRF and TEAD-dependent luciferase reporter gene activities in cardiac 
fibroblasts 
Since cAMP inhibits SRF and TEAD activity in cardiac fibroblasts and this was associated with an 
inhibition of RhoA/ROCK signalling, we next tested if SRF and TEAD activity was dependent on 
ROCK activity. In order to test this, cardiac fibroblasts were transiently transfected with either SRF-
LUC or TEAD-LUC reporter plasmids. These cells were then stimulated with 10 µM Y27632 for 
eight hours to inhibit ROCK activity (Figure 3.13), which significantly down regulated the activity 
of SRF-LUC (to 0.32±0.10-fold, p<0.05) and TEAD-LUC (to 0.44±0.09-fold, p<0.05)  (Figure 4.9). 




lacking SRF or TEAD binding elements, remained unaffected by Y27632 treatment (Figure 4.9). 
These data demonstrate that ROCK regulates the activities of SRF-LUC and TEAD-LUC in cardiac 
fibroblasts. 
4.3.6 Y27632 down regulates the expression of SRF and TEAD-target genes in cardiac fibroblasts 
Previously in this chapter (see Chapter 4, section 3.1), we showed that elevated levels of cAMP 
down regulated SRF-LUC and TEAD-LUC activity. Consistent with this, the mRNA levels of SRF 
and TEAD-target genes were also suppressed (see Chapter 4, section 3.2). Likewise, we 
demonstrated that elevated levels of cAMP inhibit Rho/ROCK signalling (see Chapter 4, section 
3.4). We therefore asked if the inhibitory effects of cAMP signalling on the SRF and TEAD-
dependent gene expression was due to cAMP-mediated ROCK inhibition. In order to answer this 
question, cardiac fibroblasts were treated with 10 µM Y27632. This resulted in a rapid and 
significant down regulation of mRNA levels of Ccn1 (to 0.76±0.15-fold and to 0.31±0.079-fold at 
2 and 6 hours respectively, p<0.01), Ccn1 pre-spliced RNA (to 0.82±0.075-fold and to 0.38±0.11-
fold at 2 and 6 hours respectively, p<0.05), Ctgf (to 0.53±0.16-fold and to 0.43±0.15-fold at 2 and 
6 hours respectively, P<0.05), Ctgf pre-spliced RNA (to 0.58±0.14-fold and to 0.46±0.19-fold at 2 
and 6 hours respectively, p<0.001), Serpine/Pai1 (to 0.20±0.02-fold at 6 hours), Zyx (to 0.75±0.14-
fold and to 0.40±0.088-fold at 2 and 6 hours respectively, p<0.001) and Heyl (to 0.33±0.046-fold 





Figure 4.4: cAMP-elevating agents stimulate CREB-LUC in cardiac fibroblasts 
Rat cardiac fibroblasts were transfected with CREB-LUC and stimulated with 5 µg/ml BAY60-
6583, 25 µM forskolin or 200 µM Db-cAMP analogue in serum free conditions for 8 hours. The 
cells were lysed and their lysates assayed for the activity of luciferase.  ***: p<0.001 and *: p<0.05. 
Data are expressed as mean ±SEM and analysed using one-way ANOVA with Student Newman-







Figure 4.5: cAMP-elevating agents stimulate CREB-target gene (Nr4a1) in cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated with 5 µg/ml BAY 60-6583 (A and D), 25 µM forskolin (B 
and E) and 200 µM Db-cAMP (C and F) analogue in serum free conditions for 2 and 6 hours. The 
mRNA levels of Nr4a1 (A, B and C) and 36B4 (D, E and F) were quantified by RT-qPCR. *: 
p<0.05. Data are expressed as mean ±SEM and analysed using one-way ANOVA with Student 





Figure 4.6: BAY60-6583 inhibits phosphorylation of MYPT in cardiac fibroblasts. 
Rat cardiac fibroblasts were treated with 5 µg/ml BAY60-6583 for indicated times and total cell 
lysates analysed for phosphorylated MYPT by western blotting. Representative images of pMYPT 
and GAPDH Western blots are shown below the graph. *: p<0.05. Data are expressed as mean 





Figure 4.7: Forskolin inhibits phosphorylation of MYPT in cardiac fibroblasts. 
Rat cardiac fibroblasts were treated with 25 µM forskolin for indicated times and total cell lysates 
analysed for phosphorylated MYPT and GAPDH by western blotting. Representative images of 
pMYPT and GAPDH Western blots are shown below the graph ***: p<0.001. Data are expressed 





Figure 4.8: Db-cAMP analogue inhibits phosphorylation of MYPT in cardiac fibroblasts. 
Rat cardiac fibroblasts were treated with 200 µM Db-cAMP analogue for indicated times and total 
cell lysates analysed for phosphorylated MYPT and GAPDH by western blotting. Representative 
images of pMYPT and GAPDH western blots are shown below the graph. ***: p<0.001. Data are 
expressed as mean ±SEM and analysed using one-way ANOVA with Student Newman-Keuls 





Figure 4.9: Y27632 inhibits SRF and TEAD-dependent luciferase reporter gene activities in 
cardiac fibroblasts 
Rat cardiac fibroblasts were transfected with SRF-LUC, TEAD-LUC or Control-LUC reporter 
plasmids and stimulated with 10 µM Y27632 for 8 hours in serum free conditions and lysates 
assayed for luciferase activity. *: p < 0.05. Data are expressed as mean ±SEM and analysed using 






Figure 4.10: Y27632 inhibits the mRNA levels of SRF and TEAD-target genes in cardiac 
fibroblasts 
Rat cardiac fibroblasts were stimulated with 10 µM Y27632 in serum free conditions for 2 and 
6 hours and mRNA levels of indicated genes quantified by RT-qPCR. *: p<0.05. Data are expressed 





4.3.7 cAMP elevating agents inhibits nuclear localisation of MKL1 in cardiac fibroblasts 
Since the elevation of cAMP inhibited SRF-LUC reporter gene activity and down regulated the 
mRNA levels of SRF and TEAD-target genes in cardiac fibroblasts, we investigated the underlying 
mechanisms. MKL1 is one of the transcriptional co-factors for the SRF transcription factor. Nuclear 
localisation of MKL1 was previously reported to be sensitive to actin polymerisation, which is 
mediated via its N-terminal RPEL actin binding domain (Miralles, Posern et al. 2003). As shown in 
chapter 3, elevated cAMP induced actin depolymerisation in cardiac fibroblasts, resulting in 
increased levels of G-actin monomer (Figure 3.12). Moreover, our group demonstrated that 
depolymerisation of actin filaments and increased levels of G-actin trigger cytoplasmic localisation 
of MKL1 in vascular smooth muscle cells (Smith, Hudson et al. 2017). Therefore, we tested if 
cAMP-dependent inhibition of SRF activity in cardiac fibroblasts is mediated by inhibition of 
MKL1 nuclear localisation. In order to study the effects of cAMP induced actin remodelling on the 
cellular localisation of MKL1 in cardiac fibroblasts, cells were infected with an adenoviral vector 
expressing GFP-tagged MKL1 (GFP-MKL1). GFP-MKL1 expressing cardiac fibroblasts were 
stimulated with cAMP elevating agents for the indicated times and the sub-cellular location of 
MKL1 quantified. In serum starved cells, GFP-MKL1 was mostly cytoplasmic (19.4±1.16% of cells 
with nuclear GFP-MKL1). However, serum (FCS) stimulation triggered a rapid and significant 
nuclear localisation of GFP-MKL1 after only 15 minutes, which was persisted at 30 and 60 minutes 
after stimulation. Importantly,  serum induced localisation of GFP-MKL1 was significantly 
inhibited by the co-stimulation of cardiac fibroblasts with BAY60-6583 at 15 (from 45.7±3.11% to 
11.8±6.01% of cells with nuclear GFP-MKL1; p<0.001), 30 (from 48.9±2.09% to 4.78±2.85% of 
cells with nuclear GFP-MKL1; p<0.001) and 60 (from 48.0±2.48% to 6.65±4.88% of cells with 
nuclear GFP-MKL1; p<0.001) minutes (Figure 4.11 and 4.12). To test these further, cardiac 
fibroblasts were stimulated with forskolin and nuclear localisation of GFP-MKL1 quantified.  
Forskolin stimulation significantly inhibited the nuclear localisation of GFP-MKL1 after 15 minutes 
(from 78.6±3.14% to 32.6±8.60% of cells with nuclear GFP-MKL1; p<0.05), 30 minutes (from 
80.5±5.45% to 11.2±2.55% of cells with nuclear GFP-MKL1; p<0.001) and 60 minutes (from 
83.1±4.48% to 8.15±2.75% of cells with nuclear GFP-MKL1; p<0.001) minutes of stimulation 
(Figure 4.13 and 4.14). 
To determine the specific roles of PKA and EPAC in the regulation of nuclear/cytoplasmic 
localisation of MKL1, cardiac fibroblasts were infected with an adenoviral vector expressing GFP-
MKL1 and stimulated with PKA and EPAC selective cAMP analogues, alone and in combination. 




nuclear GFP-MKL1). However, PDGF stimulation triggered a rapid and increase in nuclear 
localisation of GFP-MKL1 after 30, 45, 60 and 75 minutes (Figures 4.14 and 4.15). Importantly, 
nuclear localisation of GFP-MKL1 was significantly reduced by the co-stimulation of cardiac 
fibroblasts with 6-BNZ-cAMP-AM at 30 (from 71.4±4.73% to 11.6±3.34% of cells with nuclear 
GFP-MKL1; p<0.001), 45 (from 81.8±6.21% to 21.9±1.89% of cells with nuclear GFP-MKL1; 
p<0.001), 60 (from 84.2±6.79% to 29.5±2.25% of cells with nuclear GFP-MKL1;p<0.001) and 75 
(from 85.9±5.04% to 32.5±5.30%; p<0.01) minutes (Figures 4.14 and 4.15). Furthermore, nuclear 
localisation of GFP-MKL1 was also significantly reduced by the co-treatment with 8-CPT-cAMP-
AM at 30 (from 71.4±4.73% to 18.0±4.91% of cells with nuclear GFP-MKL1; p<0.001), 45 (from 
81.8±6.21% to 22.8±3.42% of cells with nuclear GFP-MKL1; p<0.001), 60 (from 84.2±6.79% to 
43.9±10.8% of cells with nuclear GFP-MKL1;p<0.01) and 75 (from 85.9±5.04% to 58.9±18.1%; 
p<0.05) minutes of stimulation significantly (Figures 4.14 and 4.15). Importantly, a combination of 
6-BNZ-cAMP-AM plus 8-CPT-cAMP-AM acted additively to reduce the nuclear localisation of 
GFP-MKL1 in cardiac fibroblasts 30 (from 71.4±4.73% to 9.85±0.43% of cells with nuclear GFP-
MKL1; p<0.001), 45 (from 81.8±6.21% to 10.6±1.09% of cells with nuclear GFP-MKL1; p<0.001), 
60 (from 84.2±6.79% to 13.4±3.54% of cells with nuclear GFP-MKL1;p<0.001) and 75 (from 
85.9±5.04% to 18.6±1.96%; p<0.01) minutes of stimulation significantly (Figures 4.14 and 4.15). 
Furthermore, stimulation with the combination of 6-BNZ-cAMP-AM plus 8-CPT-cAMP-AM 
resulted in a significantly greater inhibition of nuclear GFP-MKL1 localisation compared to either 
6-BNZ-cAMP-AM or 8-CPT-cAMP-AM alone at 60 and 75 minutes of stimulation. 
4.3.8 EPAC-selective cAMP analogue 8-CPT-cAMP-AM does not stimulate PKA-sensitive gene 
expression 
Data presented in Figure 4.16 indicates that an EPAC-selective analogues inhibit nuclear 
localisation of GFP-MKL1. Cytoplasmic localisation of MKL1 is typically associated with 
disruption of actin polymerisation and cell spreading. Interestingly, treatment of cardiac fibroblasts 
with EPAC-selective agonist did not induce any detectable change in cellular morphology. It is 
important to note that EPAC-selective cAMP analogues and their metabolites have been previously 
reported to have off-target effects, including inhibition of PDE activity and subsequent elevation of 
endogenous cAMP levels (Poppe, Rybalkin et al. 2008, Enyeart and Enyeart 2009, Sand, Grandoch 
et al. 2010, Herfindal, Nygaard et al. 2013, Herfindal, Krakstad et al. 2014). To test if stimulation 
of cardiac fibroblasts with 8-CPT-cAMP-AM may be inducing PKA activity via these potential off-
target effects, we quantified the expression levels of the classical PKA inducible gene Nr4a1. 




to PKA activation. Stimulation of cardiac fibroblasts with the PKA-selective analogues 6-BNZ-
cAMP-AM resulted in a three-fold induction of Nr4a1 mRNA levels (Figure 4.17). However, 
stimulation with the EPAC-selective analogues 8-CPT-cAMP-AM did not result in any detectable 
induction of Nr4a1 mRNA levels. Taken together, these data indicate that 8-CPT-cAMP-AM 
stimulation at the dose used in these experiments does not results in an off-target activation of PKA-
CREB signalling. 
4.3.9 Elevated levels of cAMP inhibit nuclear localisation of YAP in cardiac fibroblasts 
Since the elevation of cAMP inhibited TEAD-LUC activity and down regulated the mRNA levels 
of SRF and TEAD-target genes in cardiac fibroblasts, we investigated the underlying mechanisms. 
YAP is one of the transcriptional co-factors for TEAD transcription factor. Nuclear localisation of 
YAP was previously reported to be sensitive to actin polymerisation (Reddy, Deguchi et al. 2013, 
Das, Fischer et al. 2016, Seo and Kim 2018). As shown in chapter 3, elevated cAMP induced actin 
depolymerisation in cardiac fibroblasts, resulting in increased levels of G-actin monomer (Figure 
3.12). Moreover, studies in vascular smooth muscle cells demonstrated that depolymerisation of 
actin filaments and increased levels of G-actin trigger, YAP phosphorylation, its cytoplasmic 
localisation and degradation (Dupont, Morsut et al. 2011). Likewise, as stimulation of cAMP 
signalling pathway induced similar changes in actin cytoskeleton and levels of G-actin in cardiac 
fibroblasts, we tested if cAMP-dependent inhibition of TEAD activity in these cells is mediated by 
YAP phosphorylation, its cytoplasmic localisation and degradation. In order to study this, cardiac 
fibroblasts were stimulated with forskolin for the indicated times. Moreover, Western blot analysis 
of total cardiac fibroblasts lysates demonstrated a significant and rapid reduction of total YAP 
protein levels (Figure 4.18A and D) and confirmed an increase in the level of YAP phosphorylation 
at two phosphorylation sites, serine 172 (Figure 4.18B and D) and serine 397 (Figure 4.18C and D). 
The upregulation in the phosphorylation of YAP protein at these two phosphorylation sites have 
previously been associated with YAP nuclear extrusion and degradation (Zhao, Wei et al. 2007, 
Zhao, Li et al. 2010). Moreover, immunofluorescent staining of forskolin treated cells detected a 
significant inhibition in nuclear and cytoplasmic levels of YAP protein (Figure 4.19 and 4.20). 
Taken together, these data demonstrate that elevated cAMP inhibit TEAD activity in cardiac 








Figure 4.11: BAY60-6583 inhibits the nuclear localisation of GFP-MKL1 in cardiac fibroblasts 
Rat cardiac fibroblasts were infected with an adenoviral vector expressing GFP-MKL1. Cells were 
serum starved overnight before being stimulated for 1 hour with 10% (v/v) FCS in the presence of 
5 µg/ml BAY60-6583 (representative images, only one time point is shown). SF: serum free; FCS: 






Figure 4.12: BAY60-6583 extrudes nuclear GFP-MKL1 in cardiac fibroblasts 
Rat cardiac fibroblasts were infected with adenoviral vectors expressing GFP-MKL1. Cells were 
serum starved overnight before being stimulated for 1 hour with 10% (v/v) FCS in the presence of 
5 µg/ml BAY60-6538. Cells were analysed for cellular localisation of GFP-MKL1 by fluorescence 
microscopy. Cellular localisation of GFP-MKL1 was quantified by image analysis ***: p < 0.001 
when comparing BAY60-6538 to control at each time point. Data are expressed as mean ±SEM and 





Figure 4.13: Forskolin inhibits the nuclear localisation of GFP-MKL1 in cardiac fibroblasts 
Rat cardiac fibroblasts were infected with an adenoviral vector expressing GFP-MKL1. Cells were 
serum starved overnight before being stimulated for 1 hour with 10% (v/v) FCS in the presence of 
25 µM forskolin (representative images, only one time point is shown). FCS: Foetal calf serum; 







Figure 4.14: Forskolin extrudes nuclear GFP-MKL1 in cardiac fibroblasts 
Rat cardiac fibroblasts were infected with an adenoviral vector expressing GFP-MKL1 (Ad:GFP-
MKL1). Cells were serum starved overnight before being stimulated for 1 hour with 10% (v/v) FCS 
in the presence of 25 µM forskolin. Cells were analysed for cellular localisation of GFP-MKL1 by 
fluorescence microscopy. Cellular localisation of GFP-MKL1 was quantified by image analysis 
***: p < 0.001 with respect to nuclear localisation. Data are expressed as mean ±SEM and analysed 







Figure 4.15: 6-BNZ-cAMP-AM and 8-CPT-cAMP-AM inhibit the nuclear localisation of GFP-
MKL1 in cardiac fibroblasts 
Rat cardiac fibroblasts were infected with an adenoviral vector expressing GFP-MKL1 (Ad:GFP-
MKL1). Cells were serum starved overnight before being stimulated for 15, 30, 45, 60 and 75 
minutes with 10% (v/v) FCS in the presence of 20 µM of 6-BNZ-cAMP-AM alone, 20 µM of 8-
CPT-cAMP-AM alone and 6-BNZ-cAMP-AM and 8—CPT-cAMP-AM together (representative 
images, only one time point is shown). FCS: Foetal calf serum; Blank: No virus; White arrows: 
Nuclear GFP-MKL1 and min: minutes. Bar indicates 200 µm. Due to the shortage of space, only 







Figure 4.16: 6-BNZ-cAMP-AM and 8-CPT-cAMP-AM extrudes nuclear GFP-MKL1 in cardiac 
fibroblasts 
Cardiac fibroblasts were infected with adenoviral vectors expressing GFP-MKL1 (Ad:GFP-
MKL1). Cardiac fibroblasts were serum starved overnight before being stimulated for 1 hour with 
50 ng/ml PDGF in the presence of 20 µM 6-BNZ-cAMP-AM and 20 µM 8-CPT-cAMP-AM. Cells 
were analysed for cellular localisation of GFP-MKL1 by fluorescence microscopy and quantified 
by image analysis. *: p<0.05 control vs 6-BNZ-cAMP-AM stimulation; **: p<0.01 control vs 6-
BNZ-cAMP-AM stimulation;***: p<0.001 control vs 6-BNZ-cAMP-AM stimulation; ##: p<0.01 
control vs 8-CPT-cAMP-AM; ###: p<0.001 control vs 8-CPT-cAMP-AM; ††: p<0.01 control vs 6-
BNZ-cAMP-AM + 8-CPT-cAMP-AM; †††: p<0.001 control vs 6-BNZ-cAMP-AM + 8-CPT-
cAMP-AM. Data are expressed as mean ±SEM and analysed using one-way ANOVA with Student 





Figure 4.17: 8-CPT-cAMP-AM does not activate PKA-sensitive gene expression 
Rat cardiac fibroblasts were stimulated with 5 µg/ml BAY 60-6583, 25 µM forskolin or 200 µM 
Db-cAMP analogue in serum free conditions for 6 hours. The mRNA levels of Nr4a1 were 
quantified by RT-qPCR. Data are expressed as mean ±SEM and analysed using one-way ANOVA 






Figure 4.18: Elevated levels of cAMP inhibit total YAP protein levels in cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated with 25 µM forskolin for the indicated times (A-D). Total 
cellular YAP (A), phospho-YAPS127 (B), phospho-YAPS397 (C) were quantified by Western blotting 
(D) and densitometric analysis (A-C). ***: p<0.01. Data are expressed as mean ±SEM and analysed 





Figure 4.19: Elevated levels of cAMP inhibit nuclear localisation of YAP in cardiac fibroblasts 
Rast cardiac fibroblasts were stimulated with 25 µM forskolin for 2 hours. Cells were fixed and analysed by 








Figure 4.20: Elevated levels of cAMP inhibit total YAP protein levels in cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated with 25 µM forskolin for 2 hours. Nuclear and cytoplasmic 
YAP levels were quantified by image analysis of immunofluorescent micrographs. Data are 




4.3.10 CCG203971 down regulates the proliferation of cardiac fibroblasts 
Taken together, the data presented demonstrates that elevated levels of cAMP induce 
depolymerisation of the actin cytoskeleton, inhibit the nuclear localisation of MKL1, inhibits 
nuclear localisation of YAP, down regulate SRF/TEAD activities and SRF /TEAD-dependent gene 
expression. We therefore asked if inhibition of MKL1 nuclear localisation and SRF activity was 
involved in mediating the anti-mitogenic effects of cAMP in cardiac fibroblasts. Initially we used 
the second generation MKL1/2 inhibitor, known as CCG203971, with lower cytotoxicity compared 
to the first generation (Johnson, Rodansky et al. 2014), to test the role of MKL-SRF signalling 
(Evelyn, Bell et al. 2010, Bell, Haak et al. 2013). CCG203971 binds to the RPEL domains of 
MKL1/2, preventing their nuclear translocation, thus reducing SRF-dependent gene expression 
(Evelyn, Wade et al. 2007, Evelyn, Bell et al. 2010, Bell, Haak et al. 2013, Smith, Hudson et al. 
2017, Yu-Wai-Man, Spencer-Dene et al. 2017). Asynchronously proliferating cardiac fibroblasts 
were treated with 20 µM CCG203971 for 24 hours. Cells were labelled with EdU for the last 6 
hours of this incubation to label cells in S-phase of the cell cycle. Stimulation of cardiac fibroblasts 
with CCG203971 significantly down regulated incorporation of Edu (to 14.0±2.03%, p<0.05; 
Figure 4.21), indicating that MKL-SRF activity is essential for maximal cardiac fibroblast 
proliferation. 
4.3.11 Silencing of MKL1 and MKL2 down regulate proliferation of cardiac fibroblasts 
Inhibition of Edu incorporation with CCG203971 implies a role for MKL1/2 in the proliferation of 
cardiac fibroblasts. However, it should be noted that CCG203971 may also bind to the RPEL 
domains of other proteins RPEL-domain containing proteins (Bell, Haak et al. 2013, Hayashi, 
Watanabe et al. 2014, Johnson, Rodansky et al. 2014). Therefore, to further validate the inhibitory 
effects of CCG203971 on the proliferation of cardiac fibroblasts, MKL1 and MKL2 were silenced 
using small interfering RNAs (siRNA). Transient transfection of cardiac fibroblasts with siRNAs 
targeting MKL1 and MKL2 (siMKL1/2) significantly reduced the protein levels of MKL1 and 
MKL2 detected by Western blotting, compared to cardiac fibroblasts transfected with control 
siRNA (siNEG), without affecting the protein levels of the housekeeping gene GAPDH (Figures 
4.22 and 4.23). In the context of the reporter gene assay, silencing of MKL1 and MKL2 significantly 
reduced the SRF-reporter gene activity (to 0.44±0.86%, p<0.05), without affecting the control 
promoter activity (Figure 4.24), consistent with the large reduction in MKL1 and MKL2 protein 
levels. To test the function of MKL1 and MKL2 in cardiac fibroblast proliferation, cells were 
transfected with siRNAs targeting MKL1 and MKL2 and labelled with EdU 48 hours after 




of Edu (to 19.7±0.87%, p<0.01 EdU incorporation; Figure 4.25), indicating that MKL1/2 are 
required for maximal proliferation of cardiac fibroblasts. 
4.3.12 Pharmacological TEAD inhibition with compound 3.1 reduced cardiac fibroblast 
proliferation 
As mentioned previously in chapter 1 and demonstrated previously by our group (Kimura, 
Duggirala et al. 2016), elevated levels of cAMP inhibits the nuclear localisation of YAP and TAZ, 
two co-transcription factors of TEAD, and down regulate TEAD activity (Kimura, Duggirala et al. 
2016). Likewise, we previously showed that pharmacological inhibition of YAP-TEAD activity 
using a novel YAP-TEAD protein:protein interaction inhibitor, termed compound 3.1 (CPD3.1), 
down regulates the proliferation and migration of vascular smooth muscle and HeLa cells (Smith, 
Sessions et al. 2019). In addition, several line of evidence demonstrated that YAP/TAZ-TEAD 
regulates the transcription of genes (such as, CCN1 and CTGF) involved in proliferation and cell 
growth or various cell types (Zhang, Smolen et al. 2008, Zhao, Ye et al. 2008, Holden and 
Cunningham 2018, Smith, Sessions et al. 2019). Therefore, we hypothesised that the anti-mitogenic 
effects of cAMP in cardiac fibroblasts may, at least in part, be mediated by inhibition of YAP-
TEAD activity. To test this, we pharmacologically inhibited YAP/TAZ-TEAD activity using 
compound 3.1 (abbreviated to CPD3.1) and quantified effects on cardiac fibroblast proliferation. 
To this end, asynchronously proliferating cardiac fibroblasts were treated with 60 µM CPD3.1 for 
24 hours, in the presence of EdU for the last 6 hours to label cells progressing through S-phase of 
the cell cycle. Although we demonstrated that CPD3.1 inhibits the activity of TEAD reporter in 
vascular smooth muscle cells (Smith, Sessions et al. 2019), we also further confirmed this in cardiac 
fibroblasts (Figure 5.23). Incubation of cardiac fibroblasts with CPD3.1 significantly down 
regulated incorporation of Edu (to 7.16±1.46%, p<0.05; Figure 4.26), indicating that YAP-TEAD 








Figure 4.21: CCG203971 inhibits serum-stimulated proliferation of rat cardiac fibroblasts 
Rat cardiac fibroblasts were stimulated for 24 hours with 20 µM CCG203971 in 5% (v/v) serum, 
as indicated. Cells were labelled with 10 µM EdU for further 6 hours and proliferation quantified 
by immuno-histochemical staining of incorporated Edu. *: p<0.05 and CCG203971: MKL1/2 
pharmacological inhibitor. Data are expressed as mean ±SEM and analysed using paired Students 





Figure 4.22: siMKL1/2 down regulates protein levels of MKL1 in cardiac fibroblasts 
Rat cardiac fibroblasts were transfected with 50 pmoles of Silencer select siRNA targeting MKL1 
and MKL2 (siMKL1/2) or non-targeting control siRNA (siNEG). Total cell lysates were prepared 
48 hours post transfection and analysed by Western blotting for MKL1 and GAPDH. ***: p<0.001 





Figure 4.23: siMKL1/2 down regulates protein levels of MKL2 in cardiac fibroblasts. 
Rat cardiac fibroblasts were transfected with 50 pmoles of Silencer select siRNA targeting MKL1 
and MKL2 (siMKL1/2) simultaneously, or non-targeting control siRNA (siNEG). Total cell lysates 
were prepared 48 hours post transfection and analysed by western blotting for MKL2 and GAPDH. 
***: p<0.001 and si: siRNA. Data are expressed as mean ±SEM and analysed using paired Students 





Figure 4.24: siMKL1/2 down regulate the activity of SRF promoter 
Rat cardiac fibroblasts were transfected with 50 pmoles of Silencer select siRNA targeting MKL1 
and MKL2 (siMKL1/2) simultaneously or non-targeting control siRNA (siNEG). Total cell lysates 
were analysed for reporter gene assay. *: p<0.05 and si: siRNA. Data are expressed as mean ±SEM 






Figure 4.25: siMKL1/2 down regulates the proliferation of cardiac fibroblasts. 
Rat cardiac fibroblasts were transfected with 50 pmoles of Silencer select siRNA siRNA targeting 
MKL1 and MKL2 (siMKL1/2) simultaneously or non-targeting control siRNA (siNEG). Cells were 
labelled with EdU 48 hours after transfection. *: p<0.05 and si: siRNA. Data are expressed as mean 





Figure 4.26: Compound 3.1 down regulates serum-stimulated proliferation of rat cardiac 
fibroblasts 
Rat cardiac fibroblasts were stimulated for 24 hours with 60 µM CPD3.1 in 5% (v/v) serum, as 
indicated. Cells were labelled with 10 µM EdU for further 6 hours and proliferation quantified by 
immuno-histochemical staining of incorporated Edu. *: p<0.05 and CPD3.1: TEAD 
pharmacological inhibitor. Data are expressed as mean ±SEM and analysed using paired Students 






Numerous investigations have characterised the ability of cAMP signalling to inhibit fibrosis 
(Kothapalli, Hayashi et al. 1998, Yokoyama, Patel et al. 2008, Insel, Murray et al. 2012, Simms, 
Coward et al. 2013, Weng, Wang et al. 2015, Liu, Xu et al. 2017, Lambers, Roth et al. 2018). In 
chapter 3, it was demonstrated that cAMP elevating stimuli inhibit the proliferation of cardiac 
fibroblasts without having significant effects on their migration. This anti-mitogenic effect was 
associated with a rapid and large change in cell morphology and a loss of actin stress fibres. 
Likewise, it was demonstrated that pharmacological ROCK inhibitor depolymerised the actin 
cytoskeleton of cardiac fibroblasts, down regulated their proliferation but increased their migration. 
In chapter 4, the aforementioned findings were extended to characterise the mechanisms underlying 
the anti-mitogenic effects of cAMP signalling in cardiac fibroblasts. The data presented here 
demonstrates that elevated levels of cAMP inhibit the activity of two key transcription factors, 
known as, SRF and TEAD. Consistent with this, the mRNA levels of endogenous genes previously 
shown to be SRF and TEAD targets (Smith, Hudson et al. 2017, Smith, Sessions et al. 2019) were 
also down regulated by cAMP elevating stimuli. We also demonstrated that inhibition of SRF 
reporter gene activity is associated with nuclear exclusion of MKL1, an effect which was also 
regulated via PKA and EPAC stimulation. Moreover, we demonstrated that, stimulation of cAMP 
signalling in cardiac fibroblasts inhibited TEAD reporter gene activity by reducing the total protein 
levels of YAP and mediating its nuclear exclusion. Furthermore, work in this chapter highlight that 
of SRF and TEAD activities are functionally important in regulating the proliferation of cardiac 
fibroblasts. 
As demonstrated in this chapter, cAMP elevating stimuli down regulate the activity of SRF and 
TEAD reporter genes. SRF and TEAD have previously been shown to be actin sensitive (Schratt, 
Philippar et al. 2002, Liu, Halayko et al. 2003, Miralles, Posern et al. 2003, Beck, Flynn et al. 2012, 
Oku, Nishiya et al. 2015, Kimura, Duggirala et al. 2016, Elisi, Santucci et al. 2018). Therefore, this 
is consistent with cAMP inhibition of these transcription factors, given that elevated levels of cAMP 
depolymerise actin filaments in fibroblasts and other cell types (Howe 2004, Pelletier, Julien et al. 
2005, Gerits, Mikalsen et al. 2007, Kim, Kim et al. 2013, Chen, Yang et al. 2014, Kim, Ryu et al. 
2015, Smith, Hudson et al. 2017). Although our data is consistent with this, further work is needed 
to demonstrate the essential role of the RhoA-ROCK pathway in mediating these inhibitory effects 
of cAMP on the activity of SRF and TEAD. This could be established using constitutively active 




Moreover, we demonstrated the actin remodelling effects of cAMP is mediated by PKA and EPAC 
specific signalling. For example, we showed that selective PKA activation inhibited actin 
polymerisation and nuclear localisation of MKL1. Likewise, PKA and EPAC cooperate to induce 
morphological changes and inhibit nuclear localisation of MKL1. Interestingly, selective activation 
of EPAC also inhibited nuclear localisation of MKL1 in cardiac fibroblasts. To our knowledge, this 
is the first demonstration that EPAC regulates MKL1 localisation or SRF activity. Importantly, 
almost all studies link MKL1 regulation to remodelling of the actin cytoskeleton (Pawlowski, 
Rajakyla et al. 2010, Filippi 2015, Joy, Gau et al. 2017, Smith, Hudson et al. 2017, Sidorenko and 
Vartiainen 2019). However, we did not detect any morphological change in response to specific 
EPAC activation in cardiac fibroblasts. This may indicate the involvement of an actin-independent 
mechanism regulating nuclear localisation of MKL1 in response to EPAC signalling. However, this 
may simply reflect undetected or subtle changes in actin polymeristaion in response to EPAC 
activation that are regulating MKL localisation. Clearly, further research is required to investigate 
this further. 
Consistent with previous findings, we showed that elevated levels of cAMP down regulated TEAD 
activity (Yu, Zhang et al. 2013, Varelas 2014, Meng, Moroishi et al. 2016). An effect which is 
mediated, at least in part, by translocation of YAP from the nucleus to the cytoplasm in cardiac 
fibroblasts. These data are consistent with those reported previously in VSMC. Since YAP cellular 
localisation is typically sensitive to the organisation of the actin cytoskeleton, our data would predict 
a cooperative role for both PKA and EPAC. However, this was not determined here. It will therefore 
be important to study the effects of selective PKA and EPAC activation on the protein levels and 
cellular localisation of total YAP, levels of phosphorylated YAP and TEAD activity. 
SRF activity has a well characterised role in promoting the expression of immediate-early genes 
needed for proliferation and migration, such as, FOS (Treisman 1995). Also, it was shown that SRF 
activity in many adhesion dependent cell types, is dependent on RhoA signalling. For instance, 
expression of constitutively active RhoA mutants increase the polymerisation of actin (Liu, Halayko 
et al. 2003, Settleman 2003, Smith, Hudson et al. 2017, Gau and Roy 2018) and induce the 
expression of SRF-dependent genes, such as, Ccn1, Ctgf and Pai1 (Smith, Hudson et al. 2017). In 
contrast, inhibition of RhoA with C3 transferase, inhibits the induction SRF-dependent genes by 
mitogenic stimuli (Hill, Wynne et al. 1995). Furthermore, stimulation of fibroblasts with agents that 
promote actin polymerisation (FCS and Jasplakinolide) or inhibit actin polymerisation (Lat-B and 
Cyto-D) demonstrate the dependency of SRF and TEAD activity on the organisation and 




2010, Gualdrini, Esnault et al. 2016, Smith, Hudson et al. 2017). Several lines of evidence also 
demonstrated the important roles of MKL1/2 in regulating proliferation (Seifert and Posern 2017, 
Gau and Roy 2018, Guenther, Faisal et al. 2019). Consistent with these findings, our data 
demonstrated that elevated levels of cAMP, down regulated RhoA-ROCK signalling, induced actin 
depolymerisation, suppressed SRF activity, inhibited nuclear localisation of MKL1 and 
proliferation. This implies that some of the anti-fibrotic effects of cAMP signalling pathway could 
be mediated by the inhibition of MKL signalling in cardiac fibroblasts. A number of published 
investigations support the statement that MKL signalling is pro-fibrotic (Parmacek 2010, Sakai, 
Chun et al. 2013, Shiwen, Stratton et al. 2015). For instance, MKL1 was demonstrated to have 
crucial roles in systemic sclerosis fibrosis and inhibition of MKL1 nuclear localisation or 
knockdown of MKL1 synthesis reduced collagen I production and abolished fibrotic targets in skin 
fibrosis (Shiwen, Stratton et al. 2015). In addition, investigations in mice reported the pro-fibrotic 
role of MKL1 in kidneys and showed that MKL1-deficient mice demonstrated significantly lower 
tubulointerstitial fibrosis compared to the control group (Xu, Wu et al. 2015). Moreover, studies in 
lung fibroblasts demonstrated that knocking down MKL1 reduced collagen synthesis and 
myofibroblasts transformation (Ni, Dong et al. 2013). Interestingly, Small and colleagues reported 
important new findings demonstrating that MKL1 plays central roles in promoting cardiac fibrosis 
in response to MI and MKL1 knockout mice demonstrated a significant reduction in the conversion 
of cardiac fibroblasts to myofibroblasts and cardiac fibrosis (Small, Thatcher et al. 2010). Consistent 
with these findings, our results suggest that anti-fibrotic effects of cAMP are at least in part mediated 
via the inhibition of MKL and that pharmacological targeting of MKL therapeutic potential for 
cardiac fibrosis.  
Along these lines, pharmacological MKL inhibitors have been shown to have anti-fibrotic effects. 
For example, pharmacological inhibition of MKL reduced peritoneal fibrosis in mice (Sakai, Chun 
et al. 2013), down regulated TGF-β induced-fibrogenesis in human induced colonic myofibroblasts 
(Johnson, Rodansky et al. 2014) and decreased lung fibrosis in murine models (Sisson, Ajayi et al. 
2015). The MKL inhibitor CCG1423 has been demonstrated to have anti-fibrotic effects (Minami, 
Kuwahara et al. 2012, Sakai, Chun et al. 2013). However, this first generation of MKL inhibitor has 
been reported to have some cytotoxic effects in vitro and in vivo (Evelyn, Bell et al. 2010, Bell, 
Haak et al. 2013, Johnson, Rodansky et al. 2014). Therefore, we assayed the anti-fibrotic effects of 
CCG203971, an optimised version of the previous generation (CCG1423), which was characterised 
by high throughput screening as an effective inhibitor of RhoA-stimulated SRF/MKL gene 




regulated the proliferation of cardiac fibroblasts, implicating MKL activity in the regulation of 
cardiac fibroblast proliferation. However, data obtained using these inhibitors should be interpreted 
cautiously as their exact mechanism of action is not fully understood. It has been suggested that 
they specifically binds to the NLS domains of MKL1/2, which prevents their interactions with 
importin α/β1 and inhibits their nuclear translocation (Hayashi, Watanabe et al. 2014). However, 
another investigation reported that these MKL pharmacological inhibitors interact with CasL 
(MICAL2), a member of MICAL family of actin binding monooxygenase (Lundquist, Storaska et 
al. 2014). Furthermore, MICAL2 is suggested to increase the activity of MKL via the 
polymerisation of nuclear actin (Grintsevich, Yesilyurt et al. 2016). As a result of this, some of the 
effects of CCG1423 on MKL1/2, could be due attributed to the inhibition of MICAL proteins (Haak, 
Appleton et al. 2017). Notably, even though CCG1423 and CCG203971 have been reported to down 
regulate MKL signalling pathway in vitro and in vivo (Haak, Tsou et al. 2014, Johnson, Rodansky 
et al. 2014, Sisson, Ajayi et al. 2015, Gau, Veon et al. 2017, Joy, Gau et al. 2017, Yu-Wai-Man, 
Spencer-Dene et al. 2017), these compounds are not only specific to MKL1/2, but rather inhibit all 
proteins containing the RPEL domain, for example: phosphatase and actin regulating proteins 
(PHACTR1), which is an actin binding protein with phosphatase regulating activity expressed in 
endothelial and vascular smooth muscle cells (Allen, Greenfield et al. 2004, Wiezlak, Diring et al. 
2012, Huet, Rajakyla et al. 2013). The PHACTR1 gene is linked with different single nucleotide 
polymorphism which, have been associated with increased risk of heart diseases (Hager, Kamatani 
et al. 2012) and is expressed abundantly in human atherosclerosis plaques (Reschen, Lin et al. 2016). 
Since there are studies showing that PHACTR1 promote cellular migration and proliferation 
(Wiezlak, Diring et al. 2012, Fils-Aime, Dai et al. 2013, Jing, Zhang et al. 2019); therefore, it is 
important to note that, the inhibitory effects of CCG203791 on the proliferation of cardiac 
fibroblasts could be due to an accumulative result of global inhibition of proteins containing RPEL 
domains rather than MKL1 or MKL2 alone. However, the data presented here demonstrates that 
CCG203971 recapitulated the effects of cAMP signalling on the proliferation of cardiac fibroblasts. 
To further test the role of MKL1/2 in cardiac fibroblast proliferation, we used siRNA-mediated 
gene silencing. Consistent with the result obtained from the pharmacological inhibition of MKL1/2, 
dual silencing of both MKL1 and MKL2 (siRNA MKL1/2) proteins significantly down regulated 
the proliferation of cardiac fibroblasts. These data strengthen the conclusion that MKL1/2 are 
important regulators of cardiac fibroblast proliferation and suggest that these may be involved in 
promoting cardiac fibrosis. Studies carried out in mice demonstrated that mice lacking MKL1 




Thatcher et al. 2010). Importantly, mice lacking MKL1, did not suffer from cardiac rupturing 
following induced MI, indicating that they initially experienced sufficient scar formation to stabilise 
the injured myocardium  (Small, Thatcher et al. 2010). Although we did not actually test the effects 
of siMKL1/2 on cardiac fibrosis, but we demonstrated that, siMKL1/2 reduced the proliferation of 
cardiac fibroblasts, implying lesser cardiac fibroblasts, lesser cardiac fibrotic genes expression and 
lesser ECM production, which is consistent with other studies, reporting the fibroblasts from mice 
lacking MKL1, displaying lower collagen synthesis (Luchsinger, Patenaude et al. 2011). MKL1 has 
also been recognised to have anti-apoptotic properties. Over expression of MKL1 has been reported 
to suppress tumour necrosis factor induced cell death in rat cardiomyocytes following hypoxia-
induced injury (Zhong, Hu et al. 2016). The anti-apoptotic properties of MKL1 fits well with data 
establishing a role of MKL1 in the proliferation of cardiac fibroblasts. 
Since MKL1 or MKL2 were not individually silenced in our experiments, the specific role of each 
MKL protein on the proliferation of cardiac fibroblasts could not be demonstrated. It is perhaps not 
surprising to expect divergent effects of MKL1 and MKL2 on the proliferation of cardiac 
fibroblasts, since MKL2 has a additional 71-amino acid N-terminal region that is not present in 
MKL1 and is suggested to act as an extra regulatory domain. Similar MKL1 and MKL1 gene 
silencing investigations from our group showed that MKL1 and MKL2 have divergent effects on 
the proliferation and migration of vascular smooth muscle cells (Smith, Hudson et al. 2017). It is 
therefore important that future research focuses on characterising the specific roles played by MKL1 
and MKL2 in the regulation of cardiac fibroblast proliferation, migration and fibrosis. 
Despite the advantages of silencing MKL1/2 over their pharmacological inhibitions, the findings 
presented here, could still be subject to off-target effects. Co-transcription factors such as: MKL1 
and MKL2, are usually parts of a dynamic complex, with different interacting proteins that, 
incorporate intracellular and extracellular signals to direct gene expression accordingly. Silencing 
any of these proteins within their complexes creates the possibility to disassemble these complexes 
and inhibit the binding of other proteins. In fact, MKL1 and MKL2 have been demonstrated to 
directly interact with different proteins which regulate the transcription of SRF-target genes. For 
example, MKL1 and MKL2 have been reported to form homodimers and heterodimers with 
members of the myocardin transcription factor family via a coiled-core motif (Parmacek 2007). 
Indeed, it has been demonstrated that MKL1 binds to SRF in dimeric complexes (Miralles, Posern 
et al. 2003) and that disruption of this coiled-core domain in the structures of MKL1 and MKL2 
down regulates the transactivation by these co-transcription factors (Du, Ip et al. 2003, Selvaraj and 




their activities. In addition to these, several lines of evidence have reported the interaction of MKL1 
with other transcription factors, for instance: STAT3 (Liao, Wang et al. 2014) and TEAD (Yu, 
Miyamoto et al. 2016). Out of importance, MKL1-STAT3 complexes have been demonstrated to 
enhance the migration of breast cancer cells (Liao, Wang et al. 2014) and the interaction of MKL1 
with TEAD has been reported to be pro-mitogenic in human glioblastoma cells (Yu, Miyamoto et 
al. 2016). Furthermore, our group has also demonstrated that stimulation of the Hippo pathways in 
vascular smooth muscle cell increases proliferation (Kimura, Duggirala et al. 2016). Consequently, 
the effects on the proliferation of cardiac fibroblasts induced by MKL1/2 silencing could be a 
combined consequence of the removal of proteins and disruption of protein complexes that promote 
the proliferation of cardiac fibroblasts. Taken together, these observations suggest that the MKL-
SRF and YAP-TEAD complexes may represent attractive drug targets to limit tissue fibrosis. 
However, it should be noted that a number of studies report possible limitations of MKL-SRF 
targeting therapies. For instance, general silencing of MKL2 induces embryonical lethality due to 
cardiac defects (Oh, Richardson et al. 2005) and specific silencing of MKL1/2 induced cardiac 
dilation, death of cardiomyocytes and even cardiac fibrosis in mice (Mokalled, Carroll et al. 2015).  
Several lines of evidence report the roles of YAP/TAZ-TEAD in cellular proliferation (Camargo, 
Gokhale et al. 2007, Dong, Feldmann et al. 2007, Zhang, Smolen et al. 2008, Holden and 
Cunningham 2018). Also, the activities of YAP and TAZ were shown to be dependent on actin 
cytoskeleton and RhoGTPases (Dupont, Morsut et al. 2011, Aragona, Panciera et al. 2013, 
Reginensi, Scott et al. 2013). Consistent with these findings, our data demonstrated that elevated 
levels of cAMP, inhibited Rho-ROCK signalling, induced actin depolymerisation, suppressed 
nuclear localisation of YAP, decreased TEAD activity and proliferation. This implies that some of 
the anti-fibrotic effects of cAMP signalling pathway could be mediated at least in part via the 
inhibition of YAP/TEAD in cardiac fibroblasts. Accumulating evidence suggest that YAP/TAZ-
TEAD signalling is pro-fibrotic (Piersma, Bank et al. 2015, Noguchi, Saito et al. 2018, Kim, Choi 
et al. 2019) and that they act as the sensors of ECM stiffness. The two transcriptional coactivators 
of Hippo pathway drive the synthesis of fibrogenic factors and increase cellular contractility 
mediating tissue stiffness mechanisms. As a result of this, YAP and TAZ stimulation could create 
a feed-forward loop of fibroblast activation which eventually would lead to tissue fibrosis (Noguchi, 
Saito et al. 2018). Interestingly, several studies demonstrated that YAP/TAZ-TEAD inhibition 
reduced fibrosis. For instance, the expression levels of YAP were increased in renal fibroblasts 
following kidney injuries (Liang, Yu et al. 2017). Moreover, inhibition of YAP/TAZ signalling 




whereas YAP over expression induced ECM synthesis and myofibroblast transformation even in 
the absence of TGF-β (Liang, Yu et al. 2017). Furthermore, it was shown that pharmacological 
inhibition of YAP (using verteporfin) or cell-specific knockout of YAP and TAZ reduced interstitial 
fibrosis in mice (Liang, Yu et al. 2017). Consistent with these findings, pharmacological inhibition 
of YAP and TAZ, using dopamine receptor agonist, reduced pulmonary and hepatic fibrosis in mice 
(Schnurrbusch, Jochmann et al. 2005). Taken together, these results highlight the importance of 
Hippo pathway signalling in fibrosis. However, it is important to consider the important adverse 
effects of verteporfin, such as: body pain, shortness of breath, chest pain and etc (Schnurrbusch, 
Jochmann et al. 2005). In addition, the endogenous levels of dopamine were not measured in liver 
and lung, therefore further investigations are needed to characterise the functional roles of dopamine 
signalling pathway during tissue fibrosis (Haak, Kostallari et al. 2019).  
Consistent with a role of YAP/TAZ-TEAD in mediating cardiac fibroblast proliferation, we 
demonstrated, using a recently characterised novel TEAD inhibitor, CPD3.1 (Smith, Sessions et al. 
2019), that pharmacological inhibition of TEAD using CPD3.1 reduced the proliferation of cardiac 
fibroblasts. Previously we demonstrated that CPD3.1 down regulated the activity of TEAD, CCN1 
and CTGF promoter without affecting the control promoters, lacking the TEAD binding elements 
(Smith, Sessions et al. 2019). Moreover, we showed that, CPD3.1 down regulates the mRNA levels 
of TEAD target genes (CCN1 and CTGF) without affecting the mRNA levels of non-TEAD target 
genes (Smith, Sessions et al. 2019). All of which highlight the specificity of our novel TEAD 
inhibitor. 
However, the precise role of YAP/TAZ-TEAD in cardiac fibrosis is still controversial. For example, 
genetic cardiac deletion of YAP resulted in increased cardiac fibrosis in response to pressure 
overload (Byun, Del Re et al. 2019). However, it is not clear if cardiac YAP knockout-induced 
cardiac fibrosis was due to an effect of YAP loss in cardiac fibroblasts or the loss of YAP in 
cardiomyocytes. It has been reported that YAP can act as a survival factor in cardiomyocytes and 
its loss results in increased cardiac myocytes apoptosis during pressure overload (Xin, Kim et al. 
2013, Byun, Del Re et al. 2019). This increased cardiomyocyte death probably exacerbates the 
response to cardiac injury and in turn enhances the subsequent fibrotic response. Therefore, these 
findings imply that pharmacological inhibition of YAP may be problematic due to undesired effects 
of YAP inhibition in cardiomyocytes. Also, studies in rodents show that epicardial YAP and TAZ 
knockout induced cardiac fibrosis and death after MI in mice (Ramjee, Li et al. 2017), indicating 
the crucial roles of YAP/TAZ-TEAD for cardiac repair (Ramjee, Li et al. 2017, Liu and Martin 




required for scar formation rather than being required for cardiomyocyte proliferation, since its 
deletion was not sufficient to impair the proliferation of cardiomyocytes during cardiac regeneration 
(Flinn, Jeffery et al. 2019). 
Importantly, four different isoforms of TEAD transcription factors (TEAD1-4) (Finch-Edmondson, 
Strauss et al. 2016) and multiple transcriptional coactivators (YAP, TAZ and VGLL) have been 
described that are likely to have distinctive functions in cardiac fibroblasts (Lin, Moroishi et al. 
2018). It is therefore important that future research focusses on characterising the expression and 
function of these different TEADs and transcriptional coactivators in cardiac fibroblasts. This 
research may highlight the value of developing new TEAD isoform and/or co-factor specific 
inhibitors, which may provide anti-fibrotic effects without inducing unwanted side-effects such as 
increased cardiomyocyte death. 
During tissue fibrosis, changes to the mechanical properties of the ECM have been implicated in 
promoting increased cardiac fibroblast proliferation and further enhancement of the fibrotic process. 
Targeting the activity of MKL-SRF and YAP/TAZ-TEAD may therefore represent a way to break 
this vicious cycle of fibrosis. This could initially be tested by culturing cardiac fibroblasts on bio-
functionalised acrylamide gels of tuneable stiffness. Experiments using cultured myocardial slices 
could also explore this, with the advantage that cardiac fibroblasts are interacting with their 
endogenous natural ECM together with cardiac myocytes, which is clearly more physiologically 
relevant. Myocardial slices could provide representative in vitro models suitable model to 
investigate the proliferation (and possibly the migration) of cardiac fibroblasts in the context of 
cardiac fibrosis, as well as valuable tools to study the therapeutic interventions (Perbellini, Watson 
et al. 2018, Watson, Terracciano et al. 2019).  
Taken together, the data presented in this chapter demonstrates that cAMP-mediated inhibition of 
cardiac fibroblast proliferation is mediated via reduced activity of both MKL-SRF and YAP-TEAD-
dependent gene expression. This work implies that these transcription factor complexes may 
represent potential therapeutic targets to limit cardiac fibroblast proliferation during cardiac fibrosis. 






Figure 3.27. Schematic representation of the mechanism underlying the inhibition of cardiac 
fibroblast proliferation by adenosine induced cAMP signalling.  
Adenosine signalling via the adenosine A2B receptor induces cAMP levels in cardiac fibroblast. 
This induces PKA and EPAC1 activity, which act cooperatively to inhibit actin polymeristaion. PKA 
and EPAC1 activation acts cooperatively to inhibit MKL1 and YAP nuclear localisation. Cyclic 
AMP signalling also induced YAP phosphorylation, a marker of YAP inactivation. Elevated cAMP 
levels inhibited the activity of the MKL1 and YAP-dependent transcription factors, SRF and TEAD, 
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As mentioned in chapter 1, EPAC proteins are important cAMPs sensors that have been implicated 
in numerous physiological and pathological processes (Borland, Smith et al. 2009, Fujita, Umemura 
et al. 2017).  
The development of EPAC-selective cAMP analogues such as 8-(4-chlorophenylthio)-2′-O-methyl-
cAMP (Holz, Chepurny et al. 2008) has helped identify many important physiological functions of 
EPAC activity in cardiac cells. For example, EPAC activity has been implicated in the regulation 
of cardiac fibroblast proliferation (Phosri, Arieyawong et al. 2017), cell migration, contraction of 
cardiac myocytes (Pereira, Ruiz-Hurtado et al. 2012), regulation of inflammation (Parnell, Smith et 
al. 2012, Wiejak, Dunlop et al. 2014), cardiac myocyte hypertrophy (Metrich, Lucas et al. 2008) 
and cardiac fibrosis (Surinkaew, Aflaki et al. 2019). Although two isoforms of EPAC have been 
identified, namely EPAC1 and EPAC2, EPAC1 is more widely expressed than EPAC2, being 
ubiquitously expressed in cardiac cells (Ulucan, Wang et al. 2007, Olmedo, Munoz et al. 2013).  
Cardiac fibroblasts represent the main non-myocyte cell type in the myocardium (Liu, Wang et al. 
2017). They occupy the myocardial interstitium (Chen, Ding et al. 2013), performing various 
important functions that are required for maintenance of normal myocardial homeostasis, including 
regulation of myocardial ECM production and myocardial integrity in addition to acting as 
mechano-electric transducers (Souders, Bowers et al. 2009). In response to a range of different 
signals, including angiotensin II and TGF-, cardiac fibroblasts trans-differentiate into 
myofibroblasts, characterised by increased expression of alpha-smooth muscle cell actin and 
increased proliferation, migration and collagen synthesis (Kong, Christia et al. 2014). The switch 
in phenotype from cardiac fibroblasts to myofibroblast is important for promoting myocardial 
healing after cardiac injury (Chistiakov, Orekhov et al. 2016, Shinde, Su et al. 2018). However, 
aberrant or excessive ECM deposition and myofibroblast proliferation has been implicated in the 
development of maladaptive fibrosis, which increases the stiffness of the myocardium, impairs 
cardiac function and promotes the development of heart failure (Kong, Christia et al. 2014, 
Medzikovic, de Vries et al. 2019).  
As discussed in the introduction chapter, numerous reports have indicated that cAMP elevating 
stimuli, such as adenosine, have anti-fibrotic affects, which are believed to by mediated at least in 
part by reduced rates of cardiac fibroblast proliferation and a reduction in collagen production 
(Ryzhov, Sung et al. 2014, Phosri, Arieyawong et al. 2017, Vecchio, White et al. 2017). Importantly, 




studies have reported that specific activation of EPAC1 using selective pharmacological agonists 
or genetic over expression, reduces angiotensin II-induced cardiac fibroblast proliferation, 
migration and collagen production (Yokoyama, Minamisawa et al. 2008, Villarreal, Epperson et al. 
2009, Surinkaew, Aflaki et al. 2019) and reduces cardiac fibrosis in vivo (Surinkaew, Aflaki et al. 
2019). In contrast, pharmacological inhibition of EPAC with ESI-09 reverses the inhibitory effects 
of adenosine on angiotensin II-induced collagen synthesis and cardiac fibroblast activation (Kong, 
Christia et al. 2014, Phosri, Bunrukchai et al. 2018). Taken together, these findings imply that 
activation of EPAC1 in response to elevated cAMP inhibits cardiac fibrosis. 
Notably, several lines of evidence have suggested that levels of EPAC1 can be altered in response 
to different physiological and pathophysiological stimuli. For instance, growth factors, such as: 
angiotensin II and TGF-β enhance the reduction of EPAC1 mRNA and protein levels in cardiac 
fibroblasts (Yokoyama, Minamisawa et al. 2008, Olmedo, Munoz et al. 2013).  EPAC1 mRNA and 
protein levels are also downregulated in vivo in a rat MI model and a canine ventricular tachypacing 
model of heart failure (Yokoyama, Minamisawa et al. 2008, Surinkaew, Aflaki et al. 2019). 
Although a large body of literature documents the activation of EPAC GEF activity in response to 
cAMP, very little is known about the mechanisms that regulate EPAC1 expression levels. Since 
many cell signalling pathways are regulated by negative feedback loops that ensure transient 
signalling in response to specific stimuli, we hypothesised that EPAC1 expression may be subject 
to negative regulation in response to elevated cAMP levels. Here we characterise the regulation of 
EPAC1 gene expression in response to cAMP elevation in cardiac fibroblasts. We describe a novel 
negative feedback loop by which EPAC1 and PKA activation by cAMP reduces EPAC1 expression 
by inhibiting TEAD activity and histone-H3 lysine-27-acetylation of the EPAC1 proximal 
promoter. 
5.2 HYPOTHESIS 
The hypotheses for this chapter were: 
1. Elevated cAMP inhibits EPAC1 expression in cardiac fibroblasts 






5.3.1 Elevated cAMP inhibits EPAC1 expression in cardiac fibroblasts 
Stimulation of A2BR increases cAMP levels and has anti-fibrotic effects in cardiac fibroblasts 
(Chen, Epperson et al. 2004). We therefore stimulated cardiac fibroblasts with the A2BAR agonist 
BAY60-6583 (at 5 µg/mL as previously described (Hudson, Kimura et al. 2018)) and quantified 
effects on EPAC1 mRNA and protein levels at early timepoints (i.e. less than 8 hours) to 
characterise direct effects on EPAC1 levels and avoid the possibility of any confounding effect of 
secondary signalling mechanisms. We focused on the regulation of EPAC1 levels as the expression 
of EPAC2 protein was not detectable in cultured rat cardiac fibroblasts by Western blotting (Figure 
5.1), consistent with previous investigations (Yokoyama, Minamisawa et al. 2008). 
Stimulation or rat cardiac fibroblasts with BAY60-6583 significantly reduced EPAC1 mRNA levels 
after 2 and 8 hours (Figure 5.2A). Levels of EPAC1 pre-spliced RNA, a measure of the transcription 
rate of EPAC1 (Elferink and Reiners 1996), were similarly reduced at 2 and 8 hours (Figure 5.2A). 
Levels of the housekeeping gene 36B4 remained unaffected. BAY60-6583 stimulation also reduced 
levels of EPAC1 protein after 2, 4, 6 and 8 hours, with maximal inhibition at the 8-hour time-point 
(Figure 5.3A). A similar down regulation of EPAC1 mRNA was detected in human cardiac 
fibroblasts, stimulated with BAY-60-6583 (Figure 5.4A). 
We next tested if elevation of intracellular cAMP using the adenylate cyclase activator, forskolin 
(at 25 uM , as previously described (Smith, Hudson et al. 2017)) also inhibited EPAC1 expression. 
Stimulation with forskolin significantly inhibited EPAC1 mRNA and pre-spliced EPAC1 RNA at 
2 and 8 hours without affecting 36B4 mRNA levels (Figure 5.2B). Forskolin stimulation also 
resulted in time dependent inhibition of EPAC1 protein levels, with maximal inhibition after 8 hours 
(Figure 5.3B). Forskolin stimulation of human cardiac fibroblasts with forskolin also resulted in the 
down regulation of both EPAC1 protein and mRNA levels, after 8 hours (Figure 5.4B and 5.5). 
Finally, we tested if stimulation with the synthetic cAMP analogue, dibutyryl-cAMP (at 200 µM as 
previously described (Hewer, Sala-Newby et al. 2011)), also repressed EPAC1 expression. 
Stimulation of cardiac fibroblasts with dibutyryl-cAMP significantly suppressed EPAC1 mRNA 
and pre-spliced EPAC1 mRNA at 2 and 8 hours (Figure 5.2C) and EPAC1 protein levels (Figure 
5.3C).  
Elevated cAMP can activate both PKA and EPAC signalling. We therefore characterised if PKA 
and/or EPAC activity was involved in the inhibition of EPAC1 expression in cardiac fibroblasts. 




respectively) (Almahariq, Mei et al. 2014). Incubation of cardiac fibroblasts with H89 or ESI-09 
significantly reversed the forskolin-induced reduction in EPAC1 mRNA and pre-spliced EPAC1 
mRNA levels (Figure 5.6A). The mRNA levels of 36B4 were not altered (Figure 5.6A). These data 
imply the contribution of both PKA and EPAC activity in the regulation of EPAC1 mRNA levels. 
In order to test the roles of PKA and EPAC activation further, cardiac fibroblasts were stimulated 
with the PKA selective agonist 6-BNZ-cAMP-AM or the non-cyclic EPAC selective agonist I-942 
(Parnell, McElroy et al. 2017). Stimulation with 6-BNZ-cAMP-AM or I-942 alone induced a 
significant reduction on the mRNA levels of EPAC1 and pre-spliced EPAC mRNA without 
affecting levels of 36B4 (Figure 5.6B). Importantly, co-stimulation of cardiac fibroblasts with I-942 
and 6-BNZ-cAMP-AM acted additively to downregulate EPAC1 mRNA and pre-spliced RNA 
levels (Figure 5.6B). 
To further test the role of EPAC activation in the regulation of EPAC1 mRNA levels, we stimulated 
cells with the cell permeable EPAC selective cAMP analogue 8-pCPT-2'-O-Me-cAMP-AM 
(abbreviated to 8-CPT-cAMP-AM) alone or with the PKA selective agonist 6-BNZ-cAMP-AM.  
Specific activation of EPAC with 8-pCPT-2'-O-Me-cAMP-AM or PKA with 6-BNZ-cAMP-AM 
alone significantly suppressed EPAC1 mRNA and pre-spliced EPAC mRNA without changing the 
mRNA levels of housekeeping genes (Figure 5.7A). A combination of 6-BNZ-cAMP-AM plus 8-
pCPT-2'-O-Me-cAMP-AM acted additively to suppress EPAC1 mRNA and pre-spliced RNA 
(Figure 5.7A). Likewise, the mRNA levels of 36B4 were unaffected (Figure 5.7A).  
In addition to the suppression of EPAC1 mRNA levels, EPAC1 protein levels were significantly 
inhibited in response to 6-BNZ-cAMP-AM or a combination of 6-BNZ-cAMP-AM with 8- cAMP-








Figure 5.1: Analysis of EPAC1 and EPAC2 protein levels in cardiac fibroblasts 
Total cell lysates prepared from rat cardiac fibroblasts were analysed for EPAC1 and EPAC2 









Figure 5.2: cAMP elevating stimuli down regulate EPAC1 mRNA levels in cardiac fibroblasts 
Serum-starved rat cardiac fibroblasts were stimulated with BAY60-6583 (5 µg/mL; A), forskolin 
(25 µM; B) and dibutyryl-cAMP (200 µM; C) for 2 to 8 hours. Total RNA was extracted and 
analysed by qRT-PCR for fully spliced and pre-spliced EPAC1 and 36B4 mRNA (A, B and C). **: 
p<0.01 and ***: p<0.001. Data are expressed as mean ±SEM and analysed using one-way ANOVA 










Figure 5.3: cAMP elevating stimuli down regulate EPAC1 protein levels in cardiac fibroblasts 
Serum-starved rat cardiac fibroblasts were stimulated with BAY60-6583 (5 µg/mL; A), forskolin 
(25 µM; B) and dibutyryl-cAMP (200 µM; C) for 2, 4, 6 and 8 hours. Total cell lysates were 
analysed for the levels of EPAC1 and GAPDH protein by Western blotting and densitometric 
analysis (A, B and C). *: p<0.05; **: p<0.01 and ***: p<0.001. Data are expressed as mean ±SEM 






Figure 5.4: A2BR activation and forskolin stimulation inhibit EPAC1 mRNA in human cardiac 
fibroblasts 
Human cardiac fibroblasts were stimulated with BAY60-6583 (5 µg/mL; A) or forskolin (25 µM; 
B) for 8 hours. Total RNA was extracted and analysed by qRT-PCR for EPAC1 and 36B4 mRNA. 






Figure 5.5: Forskolin stimulation inhibits EPAC1 protein levels in human cardiac fibroblasts 
Human cardiac fibroblasts were stimulated with 25 µm forskolin for 8 hours. Total cell lysates were 
analysed for the levels of EPAC1 and GAPDH protein by Western blotting and densitometric 






Figure 5.6: PKA and EPAC activity co-ordinately regulate EPAC1 expression in cardiac 
fibroblasts 
Serum-starved CF were stimulated with forskolin (25 µM) alone or in combination with either H89 
(10 µM) or ESI-09 (10 µM), as indicated, for two hours (A) or with 6-BNZ-cAMP-AM (6-BNZ-
AM; 20 µM), I-942 (100 µM) or 8-pCPT-2'-O-Me-cAMP-AM (8-CPT-AM, 20 µM) as indicated, 
for 8 hours (B). Total RNA was extracted and analysed for EPAC1 mRNA, pre-spliced EPAC1 
mRNA and 36B4 mRNA by qRT-PCR. *: p<0.05; **: p<0.01 and ***: p<0.001. Data are expressed 



























Figure 5.7: PKA and EPAC activity synergically downregulate EPAC1 expression in cardiac 
fibroblasts. 
Serum-starved CF were stimulated with 6-BNZ-cAMP-AM (6-BNZ-AM; 20 µM), or 8-pCPT-2'-
O-Me-cAMP-AM (8-CPT-AM, 20 µM) alone or in combination as indicated, for 8 hours. Total 
RNA was extracted and analysed for EPAC1 mRNA, pre-spliced EPAC1 mRNA and 36B4 mRNA 
by qRT-PCR (A). Total cell lysates were analysed for the levels of EPAC1 and GAPDH protein by 
western blotting and densitometric analysis (B). *: p<0.05; **: p<0.01 and ***: p<0.001. Data are 
expressed as mean ±SEM and analysed by ANOVA with Student Newman Keul’s post-test, A, n=3 




5.3.2 Inhibition of EPAC1 expression by cAMP is associated with actin-cytoskeleton remodelling 
and changes in cell morphology 
cAMP elevating stimuli have previously been documented to alter cell morphology and actin 
cytoskeleton remodelling in several cell types (Hewer, Sala-Newby et al. 2011, Duggirala, Kimura 
et al. 2015, Kimura, Duggirala et al. 2016, Smith, Hudson et al. 2017) and this has been associated 
with changes in cell behaviour. It was noticed that down regulation of EPAC1 protein and mRNA 
levels in response to cAMP-elevating stimuli was associated with this reduction in cell spreading 
(Figure 5.10A) and a change in cell morphology (Figure 3.4, 3.6, 3.8, 3.9 and 5.8), characterised by 
acquisition of stellate-like morphology, loss of F-actin-stress fibres and actin depolymerisation 
(Figure 5.9). We therefore tested if this change in cell morphology and disruption of actin 
polymerisation was functionally linked to changes in the levels of EPAC1 expression in cardiac 
fibroblasts. Importantly, cAMP elevation did not induce any detectable morphological change, 
reduction in cell area, or loss of F-actin stress fibres in the embryonic cardiomyocyte H9C2 cell 
line, Moreover, elevated cAMP in these cells did not result in any reduction in  EPAC1 mRNA 
expression, suggesting a possible mechanistic link between cAMP induced actin remodelling and 
EPAC1 expression. in (Figure 5.8, 5.9, 5.10B and 5.11).  
In order to further test the functional association between actin remodelling and EPAC1 expression 
in cardiac fibroblasts, we tested if removal of cAMP stimulus would result in a reversal of the cAMP 
stellate morphology and a restoration of EPAC1 mRNA expression levels back to normal control 
levels. Stimulating cardiac fibroblasts with forskolin for 2 hours, 8 hours or 24 hours significantly 
suppressed EPAC1 mRNA expression (Figure 5.12A) and induced a characteristic stellate 
morphology (Figure 5.12B). Notably, mRNA levels of EPAC1 after a 2-hour forskolin stimulation 
followed by a 6-hour or 24-hours washout period were not significantly different from baseline 
levels. This implies that cAMP washout leads to a rapid reversal of the forskolin-induced 
morphological change and restoration of EPAC1 expression (Figure 5.12).  
The next question was whether actin polymerisation is necessary for maximal EPAC1 expression 
in cardiac fibroblast. In order to answer this question, actin cytoskeleton polymerisation was 
disrupted using multiple approaches, including incubation with the Rho kinase (ROCK) inhibitor 
Y27632, or the actin binding drugs Lat-B or Cyto-D. Treatment of cardiac fibroblasts with Y27632, 
Lat-B or Cyto-D rapidly induced stellate cell morphology and a loss of F-actin stress fibres (Figure 
5.13A), which was morphologically similar to that induced by elevated cAMP. Likewise, treatment 
with these actin depolymerising agents significantly inhibited cell spreading (Figure 5.13B) and 




of the housekeeping gene 36B4 (Figure 5.14A). Y27632, Lat-B or Cyto-D stimulation also 
significantly reduced levels of EPAC1 protein (Figure 5.14B). Taken together, these data 







Figure 5.8. Forskolin induces morphological changes in cardiac fibroblasts but not in cardiac 
myocytes. 
Rat cardiac fibroblasts and cardiac myocytes were stimulated in serum-free conditions with 25 µM 





Figure 5.9 Forskolin stimulation disrupts the F-actin fibres in cardiac fibroblasts but not in 
cardiac myocytes. 
Rat cardiac fibroblasts and cardiac myocytes were stimulated in serum-free conditions with 25 µM 
forskolin for 8 hours. Polymerised F-actin filaments were detected using Phalloidin staining of fixed 






Figure 5.10. Forskolin stimulation inhibits cell spreading in cardiac fibroblasts but not H9C2 
cells.  
Serum-starved rat cardiac fibroblasts and H9C2 cells were stimulated with 25 µM forskolin for 8 
hours. Cell spreading was analysed by phase contrast microscopy. *: p<0.05. Data are expressed as 






Figure 5.11. inhibition of EPAC1 expression by cAMP elevation. 
Serum-starved rat cardiac fibroblasts and H9C2 cells were stimulated with 25 µM forskolin or 200 
µM dibutyryl-cAMP for 8 hours, as indicated. Total RNA was extracted and analysed for EPAC1 
mRNA by qRT-PCR. Db-cAMP analogue: Dibutyryl cAMP analogue and **: p<0.01. Data are 











Figure 5.12. Washout of forskolin results in rapid reversal of stellate morphology and re-
expression of EPAC1 mRNA. 
Serum-starved rat cardiac fibroblasts were stimulated continuously with 25 µM forskolin for 2 
hours, 8 or 24 hours. Cells were also stimulated with 25 µM forskolin for 2 hours followed by 
washout of forskolin and incubation in serum free media fo a further 6 hours or 22 hours (labelled 
8 and 24 hours respectively to indicated total time from intial stimualtion). Total RNA was extracted 
and analysed for EPAC1 mRNA by RT-qPCR (A) and phase contrast microscopy (B). * and #: 






Figure 5.13: Actin cytoskeleton disruption induces stellate morphology and depolymerises actin 
fibres in cardiac fibroblasts 
Serum-starved rat cardiac fibroblasts were stimulated with 10 µM Y27632, 2 µM cytochalasin-D 
(Cyto-D) or 0.5 ug/mL latrunculin-B (Lat-B) for 8 hours. Cell morphology and F-actin stress fibres 





Figure 5.14: Actin cytoskeleton disruption inhibits EPAC1 expression. 
Serum-starved rat cardiac fibroblasts were stimulated with 10 µM Y27632, 2 µM cytochalasin-D 
(Cyto-D) or 0.5 ug/mL latrunculin-B (Lat-B) for 8 hours Total RNA was extracted and analysed for 
EPAC1 mRNA, pre-spliced EPAC1 mRNA and 36B4 mRNA by qRT-PCR (C; n=3). Total cell 
lysates were analysed for EPAC1 and GAPDH protein levels by Western blotting and densitometric 
analysis (D; n=5). *: p<0.05; **: p<0.01 and ***: p<0.001. Data are expressed as mean ±SEM and 




5.3.3 cAMP-induced down regulation of EPAC1 impairs EPAC downstream signalling and 
cardiac fibroblasts morphological changes induced by cAMP signalling 
Our next question was if cAMP-induced suppression of EPAC1 expression would result in impaired 
EPAC1 signalling and altered cellular responses induced by cAMP. To answer this question, cardiac 
fibroblasts were pre-stimulated with 25 µM forskolin for 24 hours to down regulate EPAC1 
expression, which was confirmed by Western blotting (Figure 5.15A). Cardiac fibroblasts were then 
acutely stimulated with either 20 µM 8-CPT-cAMP-AM or 25 µM forskolin for 30 minutes and 
EPAC signalling quantified using RAP1 activity assays. In non-pre-treated cardiac fibroblasts, 
acute stimulation with either 8-CPT-cAMP-AM or forskolin resulted in an increase in Rap1GTP 
(active) levels (Figures 5.15C and 5.15D). However, in cardiac fibroblasts that were pre-treated 
with forskolin (for 24 hours), acute stimulation with 8-CPT-cAMP-AM or forskolin did not result 
in an increase in Rap1GTP (Figures 5.15C and 5.15D). Moreover, the morphological changes of 
cardiac fibroblasts induced by either forskolin or a combination of 8-CPT-cAMP-AM with 6-BNZ-
cAMP-AM were significantly reduced in cells pre-stimulated with forskolin (Figures 5.16 and 
5.17). These findings imply that reduction of EPAC1 expression caused by elevating cAMP stimuli, 
impairs EPAC1 down-stream signalling and morphological changes in response to subsequent 
cAMP signalling. 
5.3.4 cAMP-induced inhibition of YAP-TEAD decreases EPAC1 promoter activity 
Cardiac fibroblasts were transfected with a secreted nano-luciferase reporter gene driven by the 
human EPAC1 proximal promoter region (EPAC1-NLUC) to investigate if elevated levels of cAMP 
and actin-cytoskeleton disruption regulates EPAC1 levels at the level of transcription. Stimulation 
of EPAC1-NLUC transfected cardiac fibroblasts with 25 µM forskolin resulted in a significant 
inhibition of promoter activity without having effects on the control reporter gene driven by a 
minimal TNT-minimal promoter region (Figure 5.18A). 
Furthermore, disruption of actin-cytoskeleton polymerisation using Y27631, Lat-B or Cyto-D also 
significantly inhibited EPAC1 promoter activity (Figure 5.18B). In order to detect potential 
transcription factors that might mediation this regulation, the human EPAC1 promoter was 
truncated into smaller fragments of 800 base pairs, 600 base pairs, 400 base pairs and 200 base pairs 
in length. Cardiac fibroblasts were transfected with these smaller human EPAC1 promoter 
truncations and stimulated with 25 µM forskolin. This resulted in a significant downregulation of 
the activities of all these smaller fragments (Figure 5.18C), suggesting the presence of a cAMP 




Sequence analysis of this proximal 200 base pair region identified a conserved binding element for 
the transcription factor (TEAD).  A large body of research has previously documented the 
association of actin-cytoskeleton organisation to regulation of TEAD activity (Dupont, Morsut et 
al. 2011, Reddy, Deguchi et al. 2013, Zhang, Lin et al. 2014, Kimura, Duggirala et al. 2016). As a 
result of this, we tested if cAMP-dependent regulation of EPAC1 expression in cardiac fibroblasts 
was regulated by TEAD activity. 
At first, we asked if elevation of cAMP levels or disruption of actin cytoskeleton polymerisation 
would result in downregulation of TEAD activity and expression of TEAD target gene mRNAs. In 
order to test this, cardiac fibroblasts were transfected with a synthetic TEAD reporter gene and 
stimulated with cAMP elevating agents. Stimulation of these cells with BAY60-6583, forskolin or 
Db-cAMP analogue all resulted in a significant inhibition of TEAD-dependent reporter gene 
activity. Importantly, the activity of the TEAD independent minimal TNT-promoter (control 
promoter) was not affected (Figure 5.19A). We also tested if direct disruption of actin-cytoskeleton 
polymerisation with latrunculin-B, cytochalasin-D or Y27632 also resulted in a reduction in TEAD 
luciferase reporter gene activity. Stimulation of TEAD-LUC transfected cells with Lat-B, Cyto-D 
or Y27632 all significantly inhibited TEAD reporter activity (Figure 5.19B). Finally, we tested in 
elevated cAMP also inhibited mRNA expression of the classical TEAD-target genes, CCN1 and 
CTGF (Kimura, Duggirala et al. 2016, Smith, Sessions et al. 2019).  Forskolin stimulation for 2 or 
8 hours resulted in a significant downregulation of both CCN1 and CTGF mRNA and pre-spliced 
RNA levels, indicating transcriptional repression of these genes by forskolin (Figure 5.19C). 
As mentioned in chapter 1, the activity of TEAD is regulated by its transcriptional co-factor YAP 
(Vassilev, Kaneko et al. 2001, Zhao, Li et al. 2010). Immunofluorescent staining of cardiac 
fibroblasts stimulated with 25 µM forskolin, identified a significant reduction in nuclear and 
cytoplasmic levels of YAP protein (Ebrahimighaei, McNeill et al. 2019). In addition, western blot 
analysis of total cardiac fibroblast lysates further demonstrated a significant and rapid 
downregulation of total YAP protein levels (Figure 4.18), and a significant upregulation in the level 
of YAP phosphorylation at serine 172 and serine 397 (Figure 4.18). Previously, it was documented 
that these modifications are associated with export of YAP from nucleus and its degradation (Zhao, 
Wei et al. 2007, Zhao, Li et al. 2010). Taken everything into consideration, these results show that 





We next asked if the TEAD element present in the EPAC1 proximal promoter is functionally 
important for the EPAC1 expression in cardiac fibroblasts. We initially tested if this TEAD element 
could bind TEAD protein using electromobility shift assay (EMSA) analysis. EMSA analysis of the 
EPAC1 TEAD element showed that nuclear extracts from Myc-TEAD1 transfected cardiac 
fibroblasts, but not control transfected cells, formed a band of reduced electrophoretic mobility 
when incubated with a biotinylated DNA probe containing the wild-type EPAC1 promoter TEAD 
element, suggesting that TEAD1 is bound to the TEAD element in the human EPAC1 promoter 
(Figure 5.20A). In contrast, this band of reduced mobility was formed when a 3 base-pair mutation 
was introduced into the TEAD element. This implies that, TEAD1 protein binds specifically to the 
consensus TEAD sequence in the human EPAC1 promoter (Figure 5.20A). 
In the context of a luciferase reporter gene, the introduction of these 3 base pair mutation in the 
consensus TEAD element significantly inhibited EPAC1 promoter activity (Figure 5.20B), 
indicating that this TEAD element is functionally important for maximal EPAC1 promoter activity 
in cardiac fibroblasts.  
In order to further test the hypothesis that the YAP-TEAD transcriptional complex is important for 
EPAC1 expression, we used siRNA-mediated gene silencing to silence the TEAD co-factors YAP 
and TAZ. Silencing these co-transcription factors resulted in a strong down regulation of YAP and 
TAZ protein expression without affecting levels of GAPDH or -actin protein (Figure 5.21A). A 
similar silencing of YAP and TAZ mRNA, but not 36B4 mRNA, was detected after transfection 
with YAP and TAZ siRNA, indicating efficient and specific gene silencing (Figure 5.21B). 
Importantly, silencing of YAP and TAZ resulted in a significant downregulation of the mRNA 
levels of the classical TEAD-target genes CCN1 and CTGF as well as significantly reducing EPAC1 
mRNA and EPAC pre-spliced RNA levels without affecting the mRNA levels of the housekeeping 
gene, 36B4 (Figure 5.21B). In the context of the reporter gene assay, silencing YAP and TAZ 
significantly reduced the TEAD-reporter gene and EPAC1 promoter activity (Figures 5.21C and 
5.21D). These findings highlight the roles of YAP/TAZ-TEAD in regulating the expression of 
EPAC1. 
In order to investigate the regulatory role of TEAD on EPAC1 expression further, we transfected 
cardiac fibroblasts with a dominant-negative TEAD1 expression vector that expresses the TEAD1 
DNA binding domain fused to the Drosophila engrailed transcriptional repressor domain (TEAD1-
Eng). Expression of TEAD1-Eng significantly reduced TEAD reporter gene activity without 




elements (Figure 5.22A), consistent with specific inhibition of TEAD activity. Importantly, 
expression of TEAD1-Eng also significantly inhibited EPAC1 reporter gene activity, without 
affecting activity of a minimal promoter reporter gene (Figure 5.22B).  
The formation of a YAP-TEAD complex is a crucial step in the transcription of TEAD-dependent 
genes. Therefore, in order to further test the roles of TEAD in the regulation of EPAC1 gene 
expression, we employed two different pharmacological inhibitors of YAP/TAZ-TEAD complex, 
namely Verteporfin (Liu-Chittenden, Huang et al. 2012) and compound 3.1 (CPD3.1) (Smith, 
Sessions et al. 2019). Stimulation of cardiac fibroblasts with Verteporfin or CPD3.1 significantly 
reduced TEAD-NLUC activity (Figure 5.23A). Likewise, treatment of cardiac fibroblasts with the 
two TEAD inhibitors significantly inhibited EPAC1 promoter activity (Figure 5.23B). In addition, 
cardiac fibroblast stimulation with Verteporfin and CPD3.1, induced a downregulation on the 
mRNA levels of the TEAD-target genes, CCN1 and CTGF, as well as retarding the levels of EPAC1 
mRNA and its pre-spliced form (Figures 5.24A and 5.24B). In contrast, levels of the TEAD-
independent housekeeping genes 36B4 or TBP were not affected by either Verteporfin or CPD3.1 
stimulation (Figures 5.24A and 5.24B). Taken together these data demonstrated that YAP/TAZ-








Figure 5.15: Chronic forskolin stimulation attenuates induction of RAP1GTP levels in response 
to subsequent cAMP-elevating stimuli. 
Serum-starved rat cardiac fibroblasts were stimulated with 25 µM forskolin for 24 hours, as 
indicated. Total cell lysates were analysed for EPAC1 and GAPDH protein levels (A). Rap1 assay 
GDP (negative) and GTPγS (positive) controls (B). Forskolin pre-treated or non-pre-treated cardiac 
fibroblast were stimulated with 20 µM 8-pCPT-2'-O-Me-cAMP-AM (C) or 25 µM forskolin (D) 
for 30 minutes. RAP1GTP (active) and total RAP1 levels were detected by RAP1 pull-down assays 






              
Figure 5.16: Chronic forskolin stimulation attenuates induction of morphological change in 
response to subsequent cAMP-elevating stimuli. 
Serum-starved rat cardiac fibroblasts were pre-treated with either serum free media or 25 µM 
forskolin for 24 hours, as indicated. Cells were then stimulated for   15, 30 or 45 minutes with 25 
µM forskolin or 20 µM 8-pCPT-2'-O-Me-cAMP-AM plus 20 µM 6-BNZ-cAMP-AM.  Cell 





Figure 5.17: Chronic forskolin stimulation attenuates induction of morphological change in 
response to subsequent cAMP-elevating stimuli. 
Serum-starved cardiac fibroblasts were pre-treated with either serum free media or 25 µM forskolin 
for 24 hours, as indicated. Cells were then stimulated for   15, 30 or 45 minutes with 25 µM forskolin 
or 20 µM 8-pCPT-2'-O-Me-cAMP-AM (CPT) plus 20 µM 6-BNZ-cAMP-AM (BNZ).  Cell area 
was quantified by image analysis of phase contrast micrographs. Data are expressed as mean ±SEM 









Figure 5.18: Elevated cAMP and inhibition of actin polymerisation reduces EPAC1 promoter 
activity and TEAD activity in cardiac fibroblasts. 
Rat cardiac fibroblasts were transfected with EPAC1-NLUC reporter (A and B) and stimulated with 
25 µM forskolin, 10 µM Y27632, 2 µM Cyto-D or 0.5 µg/mL Lat-B for 8 hours. Cells were 
transfected with a NLUC reporter vector controlled by the indicated EPAC1 promoter truncations 
or a minimal promoter, as indicated, and NLUC activity assayed 24 hours later (C). **: p<0.01 and 
***: p<0.001. Data are expressed as mean ±SEM and analysed by ANOVA with Student Newman 








Figure 5.19: Elevated cAMP and inhibition of actin polymerisation TEAD activity in cardiac 
fibroblasts. 
Rat cardiac fibroblasts were transfected with a TEAD-LUC reporter or minimal promoter-LUC 
reporter vector as indicated and stimulated with 5 µg/mL BAY65-6085, 25 µM forskolin, 200 µM 
db-cAMP and luciferase activity quantified after 8 hours (A). Cardiac fibroblasts were transfected 
with a TEAD-LUC reporter vector and stimulated with 10 µM Y27632, 2 µM Cyto-D and 0.5 µg/ml 
Lat-B and luciferase activity was quantified after 8 hours (B). Cardiac fibroblasts were stimulated 
with 25 µM forskolin for 2 and 8 hours (C). Total RNA was extracted and analysed for CCN1 
mRNA, pre-spliced CCN1 RNA, CTGF mRNA, pre-spliced CTGF RNA and 36B4 mRNA levels 
(F). **: p<0.01 and ***: p<0.001. Data are expressed as mean ±SEM and analysed by ANOVA 







Figure 20: YAP/TAZ-TEAD activity is required for the maximal expression of EPAC1. 
Electromobility shift assay (EMSA) analysis of binding of TEAD protein from nuclear extracts 
from control or myc-TEAD1 transfected rat cardiac fibroblasts to DNA probes containing either the 
wild-type or mutated TEAD element from the EPAC1 proximal promoter (A). Rat cardiac 
fibroblasts were transfected with a secreted nanoluciferase reporter (NLUC) gene plasmid under the 
control of either the wild-type EPAC1 promoter or the EPAC1 promoter containing a mutated 
TEAD element. Secreted NLUC activity was quantified 24 hours after transient transfection (B). *: 






Figure 5.21: YAP/TAZ-TEAD activity is required for maximal EPAC1 expression 
Rat cardiac fibroblasts were transfected with siRNA targeting YAP and TAZ (siYAP/TAZ) or non-
targeting control siRNA (siControl), together with TEAD-LUC or EPAC1-NLUC reporter 
plasmids. Total cell lysates were analysed for protein levels of YAP, TAZ, GAPDH or -ACTIN 
by Western blotting (A). Total RNA was extracted and analysed for the mRNA levels of YAP, 
TAZ, EPAC1, pre-spliced EPAC1 mRNA, CCN1 and 36B4 using RT-qPCR (B). Total cell lysates 
were analysed, and reporter gene activity quantified (C and D). *: p<0.05; **: p<0.01 and ***: 
p<0.01. Data are expressed as mean ±SEM and analysed by paired Students t-test (C and D) or 








Figure 5.22. YAP/TAZ-TEAD activity is required for maximum EPAC1 activity. 
Rat cardiac fibroblasts were transfected with TEAD-LUC (A), EPAC1-NLUC (B) or a minimal 
promoter reporter (A and B), together with either an empty expression vector lacking a transgene 
(Control) or a dominant-negative TEAD expression vector, as indicated (A and B). Reporter gene 
activity was quantified 24 hours after transfection. *: p<0.05. Data are expressed as mean ±SEM 






Figure 5.23: Pharmacological TEAD inhibition reduces human EPAC1 promoter. 
Rat cardiac fibroblasts were transfected with TEAD-LUC reporter (A) or EPAC1-NLUC reporter 
(B) and stimulated with either 60 µM CPD 3.1 or 10 µM verteporfin. Reporter gene activity was 
quantified 24 hours after transfection. **: p<0.01 and ***: p<0.01. Data are expressed as mean 





Figure 5.24: Pharmacological TEAD inhibition reduces EPAC1 and TEAD target genes. 
Rat cardiac fibroblasts were stimulated with 60 µM CPD3.1 for 8 or 18 hours (A) or 10 µM 
Verteporfin (B) and total RNA was extracted and analysed for the mRNA levels of EPAC1, pre-
spliced EPAC1, CCN1, CTGF, TBP and 36B4 mRNA by RT-qPCR. *: p<0.05; **: p<0.01 and 
***: p<0.01. Data are expressed as mean ±SEM and analysed by ANOVA with Student Newman 




5.3.5 YAP and TAZ are required but insufficient for EPAC1 mRNA expression  
To further test the importance of YAP and TAZ in the regulation of EPAC1 expression, we asked 
if YAP and TAZ activation is sufficient to reverse the inhibitory effects of elevated cAMP levels 
on EPAC1 expression. To test this, we over expressed the constitutively active mutants of YAP 
(YAPS127A) and TAZ (TAZ5SA) using adenoviruses. YAPS127A over expression completely rescued 
forskolin-mediated inhibition of TEAD-reporter activity, confirming efficient reversal of cAMP 
mediated inhibition of TEAD reporter activity (Figure 5.25A). Likewise, over expression of 
YAPS127A completely reversed the cAMP-mediated inhibition of EPAC1 promoter activity (Figure 
5.25B), which is consistent with our findings showing the requirement for YAP-TEAD activity for 
maximal EPAC1 expression. 
We next tested if YAP over expression could also reverse mRNA levels of TEAD target genes 
(CCN1) and EPAC1 following forskolin stimulation. Forskolin treatment of cardiac fibroblasts 
infected with a control adenovirus lacking a transgene, induced a reduction in the mRNA levels of 
CCN1 (Figure 5.26A). In addition, this downregulation was completely rescued by the over 
expression of either YAPS127A or TAZ5SA, consistent with our data on the rescue of TEAD-
dependent reporter gene activity (Figure 5.26A). Similarly, forskolin stimulation of cardiac 
fibroblasts infected with control adenovirus resulted in downregulation of EPAC1 mRNA levels 
(Figure 5.26B). However, in contrast to CCN1 mRNA levels, over expression of YAPS127A or 
TAZ5SA co-transcription factors did not reverse the forskolin-induced inhibition effects on the 
mRNA levels of EPAC1 (Figure 5.26B). 
Taken together, these data suggest that YAP or TAZ-mediated activation of TEAD alone is not 
sufficient for EPAC1 mRNA expression, despite the inhibitory effects of dominant negative TEAD 
and silencing of YAP and TAZ on the mRNA levels of EPAC1 in cardiac fibroblasts (Figures 5.21 
and 5.22). This implies the contribution of at least one additional mechanism that is necessary for 
expression of the endogenous EPAC1 gene that is not essential for regulation of the EPAC1 reporter 







Figure 5.25. YAP over expression rescues forskolin-mediated inhibition of TEAD reporter gene 
and EPAC1 promoter activity. 
Rat cardiac fibroblasts were transfected with TEAD-LUC (A) or EPAC-NLUC (B) reporter gene 
plasmids. The next day, cells were infected with either a control adenovirus (Ad:Control) or 
adenovirus expressing constitutively-active YAP. Cells were then stimulated with 25 µM forskolin 
for 8 hours and reporter gene activity quantified. *: p<0.05 and ** p<0.01. Data are expressed as 





Figure 5.26: YAP and TAZ are insufficient for EPAC1 mRNA expression. 
Rat cardiac fibroblasts were transfected with TEAD-LUC (A) or EPAC-NLUC (B) reporter gene 
plasmids. The next day, cells were infected with either a control adenovirus (Ad:Control) or 
adenovirus expressing constitutively-active YAP or TAZ, as indicated (A-D). Cells were then 
stimulated with 25 µM forskolin for 8 hours and reporter gene activity quantified (A and B) or total 
RNA analysed by qRT-PCR for EPAC1 mRNA or CCN1 mRNA levels as indicated. (C and D). *: 
p<0.05; **: p<0.01 and ***: p<0.001. Data are expressed as mean ±SEM and analysed by ANOVA 




5.3.6 HDAC1/3-mediated deacetylation of histone-3 lysine 27 contributes to cAMP-mediated 
inhibition of EPAC1 expression 
The regulation of endogenous gene expression requires transcription factor binding to the gene’s 
promoter region in addition to epigenetic remodelling of the local chromatin organisation. In 
contrast, plasmid-based reporter gene vectors are not usually packaged with histone proteins into 
chromatin and are largely regulated by transcription factor activity alone. As a result of this, we 
studied the possibility of epigenetic control in cAMP-mediated repression of EPAC1 expression. 
Since acetylation of histone-3 at lysinse-27 is associated with an open chromatin conformation and 
active gene expression, we specifically asked whether epigenetic regulation of histone3 lysine-27 
acetylation is necessary, in addition to YAP-TEAD activity, for maximal EPAC1 expression. We 
tested the hypothesis that changes in histone 3 acetylation in the vicinity of the endogenous EPAC1 
promoter is involved in the repression of EPAC1 mRNA expression in response to elevated cAMP. 
Moreover, we asked if the necessity of histone-3 lysine-27 (H3K27) acetylation explains inability 
of YAP or TAZ over expression to rescue EPAC1 mRNA levels in forskolin stimulated cardiac 
fibroblasts. In order to test this, chromatin immunoprecipitation (ChIP) was used to quantify the 
effects of cAMP elevation on H3K27 acetylation at the proximal EPAC1 promoter.  
H3K27 acetylation was detected at the EPAC1 proximal promoter region in cultures of cardiac 
fibroblasts. Also, forskolin stimulation of cardiac fibroblasts resulted in a significant reduction in 
H3K27 acetylation levels at this region (Figure 5.27A). In contrast, levels of H3K27 acetylation at 
the proximal promoter of HAS1, a CREB-target gene that is induced by cAMP, were significantly 
increased following forskolin stimulation. This suggests that changes induced by forskolin in 
H3K27 acetylation, are region-specific and do not reflect global changes in H3K27 acetylation 
levels. Notably, the inhibitory effects of forskolin on H3K27 acetylation at the EPAC1 promoter 
was partly but significantly rescued by pre-stimulation of cardiac fibroblasts with the HDAC1/3-
selective HDAC inhibitor (MS-275), which was not the case for CREB-target gene, HAS1, yet 
again showing the specificity in H3K27 acetylation mediated by HDAC1/3 (Figure 5.27B). We 
therefore tested if HDAC1/3 inhibition would cooperate with YAP overexpression to rescue 
forskolin-induced inhibition of EPAC1 mRNA. In the control group, forskolin treatment, 
significantly inhibited EPAC1 mRNA levels (Figure 5.28A). The inhibitory effects of forskolin 
were not rescued by YAPS127A over expression (Figure 5.28A). This is consistent with the data in 
Figure 5.28B. By contrast, HDAC inhibiton partially reverse the inhibitory effects induced by 
forskolin on EPAC1 mRNA. Importantly, however, a combination of MS-275 and YAPS127A 




expression of the housekeeping gene 36B4 remained unaffected by any of the treatments (Figure 
5.23B). Hence, H3K27-acetylation appeared to facilitate TEAD dependent transcription of EPAC1 







Figure 5.27. Forskolin deacetylates histone-3 lysine-27. 
Rat cardiac fibroblasts were treated with 5 µM MS275 for 18 hours followed by stimulation with 
25 µM forskolin for a further 2 hours (A and B). Cells were fixed and chromatin extracted and 
analysed for H3K27 acetylation at the proximal EPAC1 (A) or HAS1 (B) promoter regions. **: 
p<0.01 and ***: p<0.001. Data are expressed as mean ±SEM and analysed by ANOVA with Student 





Figure 5.28: HDAC1/3 mediated deacetylation of histone-3 lysine-27 contributes to cAMP-
mediated inhibition of EPAC1 mRNA expression. 
Rat cardiac fibroblasts were infected with control adenovirus (Ad:Control) or adenovirus expressing 
constitutively active YAP (Ad:YAP) (A and B). The next day, cells were treated with 5 µM MS275 
for 18 hours followed by stimulation with 25 µM forskolin for a further 2 hours. Total RNA was 
extracted and analysed by RT-qPCR for EPAC1 (A) or 36B4 (B) mRNA levels. **: p<0.01 and 
***: p<0.001. Data are expressed as mean ±SEM and analysed by ANOVA with Student Newman 





A large body of literature documents the ability of cAMP to activate EPAC signalling (de Rooij, 
Zwartkruis et al. 1998, de Rooij, Rehmann et al. 2000, Bos 2006, Hewer, Sala-Newby et al. 2011). 
However, the mechanisms responsible for regulating the expression of the EPAC gene is unknown. 
Here, we studied the mechanism responsible for the regulation of EPAC1 gene expression in cardiac 
fibroblast in normal conditions and in response to cAMP elevating stimuli.  We documented that 
protein and mRNA levels of EPAC1 are regulated by TEAD-dependent transcription and that 
H3K27 acetylation is essential for TEAD activity at the EPAC proximal promoter. 
In this chapter, it was demonstrated that elevated intracellular levels of cAMP rapidly suppress the 
protein and mRNA levels of EPAC1 via two distinctive signalling mechanisms. The first 
mechanism involves depolymerisation of actin cytoskeleton in response to cAMP, which results in 
the subsequent inactivation of YAP/TAZ-TEAD transcription factor activity. The second 
mechanism involves a cAMP-induced deacetylation of H3K27 in the vicinity of the endogenous 
EPAC1 promoter. Inhibition of EPAC1 expression via these mechanisms diminishes EPAC1 
signalling and EPAC1-dependent morphological changes in response to subsequent cAMP-
elevating stimuli. Together, these mechanisms represent a newly discovered system of crosstalk 
that controls EPAC1 expression in response to cAMP elevating stimuli and is crucial in regulating 
cellular responses to cAMP elevation (Figure 5.29). 
In detail, elevating intracellular concentrations of cAMP, using either forskolin, cAMP analogues 
or physiological agonists of the A2BR, down regulate EPAC1 expression in cardiac fibroblasts. 
Specific activation of PKA or EPAC was able to suppress the mRNA levels of EPAC1 and activated 
together they acted additively to reduce EPAC1 expression. Interestingly, specific stimulation of 
PKA was more effective compared to specific EPAC activation at down regulating mRNA levels 
of EPAC1, suggesting a dominant role for PKA-mediated negative crosstalk in controlling EPAC1 
expression. Negative crosstalk between PKA and EPAC have been reported previously, where PKA 
activation can oppose EPAC induced phosphorylation of AKT (Mei, Qiao et al. 2002). Moreover, 
PKA can antagonise the ability of the EPAC effector protein (Rap1) to form new blood vessels 
(Menon, Doebele et al. 2012). PKA can also regulate cAMP-dependent activation of EPAC by 
controlling the availability of cAMP via PDEs (Baillie, Scott et al. 2005). The novel findings 
presented here show that activation of PKA and EPAC play crucial roles in controlling the mRNA 




Inhibition of EPAC1 expression in cardiac fibroblasts in response to cAMP elevating stimuli is 
functionally linked with acquisition of a stellate morphology, which is characterised by a condensed 
cytoplasm, extended membrane protrusion and loss of F-actin stress fibres. Morphological changes 
and actin depolymerisation induced by cAMP elevation have been described in some other cell 
types, for example, smooth muscle cells (Hewer, Sala-Newby et al. 2011, Duggirala, Kimura et al. 
2015, Smith, Hudson et al. 2017), astrocytes (Hatten 1985) and mesenchymal stem cells (Zhang, 
Yun et al. 2011). Importantly, in cardiac fibroblasts, the magnitude of the stellate morphology and 
reduction in actin-cytoskeleton polymerisation induced by activation of PKA and EPAC reflects the 
repression of EPAC1 gene expression. However, cAMP-induced actin remodelling, and inhibition 
of actin polymerisation are cell-type specific. Even though, cAMP elevating stimuli causes 
pronounced actin-cytoskeleton disruption in cardiac fibroblasts and smooth muscle cells (Bond, Wu 
et al. 2008, Hewer, Sala-Newby et al. 2011, Kimura, Duggirala et al. 2014), the similar scenario is 
not repeated in endothelial cells, where cAMP signalling promotes cortical actin polymerisation via 
PKA and EPAC activation (Cullere, Shaw et al. 2005, Birukova, Zagranichnaya et al. 2007, Prasain 
and Stevens 2009). In addition to this, as demonstrated here, elevation of cAMP levels do not cause 
morphological changes or actin depolymerisation in H9C2 embryonic cardiomyocytes cell line. 
Notably, EPAC1 expression is not suppressed by cAMP signalling in these cells, indicating that 
downregulation of EPAC1 mRNA levels, at least in part, is mediated by these changes in the actin-
cytoskeleton polymerisation status. Hand in hand with this, we showed that, indirect actin 
depolymerisation, using the ROCK inhibitor Y27632, or directly targeting actin filaments with the 
actin-binding agents cytochalasin-D or latrunculin-B, also retards EPAC1 expression in cardiac 
fibroblasts. To our knowledge, this is the first time that EPAC1 expression has been linked to actin-
cytoskeleton remodelling. Our new results confirm the existence of a novel negative crosstalk 
mechanism where PKA cooperates with EPAC activity to induce actin-cytoskeleton remodelling, 
and this mediates the suppression of EPAC1 gene expression. 
Previous studies have reported the association between different signals with EPAC1 expression. 
For example: TGF- stimulation can have stimulatory or repressive effects on EPAC1 expression 
in cardiac fibroblasts or myofibroblasts respectively (Olmedo, Munoz et al. 2013). Studies in 
rodents demonstrated that, prostaglandin stimulation reduces EPAC1 protein levels in liver fibrosis 
(Schippers, Beljaars et al. 2017). Stimulation of beta-adrenoreceptors with isoproterenol up 
regulated the expression of EPAC in atrial fibroblasts (Surinkaew, Aflaki et al. 2019). On the other 
hand, the responsible mechanisms that control EPAC1 gene expression in response to physiological 




Here we demonstrate a feedback mechanism that down regulate EPAC1 gene transcription in 
response to cAMP elevating stimuli. We demonstrate that levels of pre-spliced EPAC1 mRNA, 
(Elferink and Reiners 1996), are rapidly down regulated by cAMP-elevating stimuli. Furthermore, 
the activity of the proximal EPAC1 promoter region is also suppressed by these cAMP stimuli, 
which further proves the transcriptional suppression of EPAC1. By analysing the EPAC1 proximal 
promoter region, we found a conserved binding element for the TEAD transcription factors. 
Crucially, the activity of TEAD depends on actin-cytoskeleton organisation and integrity (Dupont, 
Morsut et al. 2011). Consistent with our findings showing that the gene expression of EPAC1 is 
also dependent on actin-cytoskeleton. Here, we demonstrate that cAMP elevating stimuli down 
regulate TEAD activity in cardiac fibroblasts, which is associated with increased phosphorylation 
of YAP and a reduced levels of total YAP protein in the nucleus and cytoplasm.  
Also, we demonstrate that, YAP/TAZ-TEAD activities are needed for EPAC1 gene expression. For 
example, inhibition of TEAD activity using silencing of the TEAD co-factors YAP and TAZ, 
overexpression of a dominant-negative TEAD mutant or pharmacological inhibition of TEAD 
activity, all significantly down regulate the transcription of EPAC1. To our knowledge, this is the 
first time that EPAC1 expression has been linked to cytoskeleton integrity and YAP/TAZ-TEAD 
activity. 
Even though we reported a clear need for YAP/TAZ-TEAD activity for EPAC1 expression, our 
data show that activation of this mechanism on its own, via YAP/TAZ over expression, is not 
enough to rescue cAMP-induced suppression of EPAC1 gene expression. This emphasis the need 
for the presence of other mechanisms. Although, a complete rescue of cAMP-induced inhibition of 
EPAC1 promoter activity was observed following the over expression of constitutively active 
YAP/TAZ, but their over expression did not rescue the down regulation of EPAC mRNA levels. 
Since plasmid-based reporter gene vectors are not packaged with histone proteins into chromatin, 
we postulated that cAMP-induced down regulation of EPAC1 expression could also be mediated 
by epigenetic regulations and modifications on the histones. Hand in hand with this, a significant 
decrease was observed in H3K27 acetylation, an epigenetic modification associated with active 
transcription (Heintzman, Stuart et al. 2007), at the proximal EPAC1 promoter region in cardiac 
fibroblasts stimulated with forskolin. Our findings suggest that this loss of H3K27 acetylation was 
mediated by either HDAC1 or HDCA3, since loss of H3K27 acetylation at the EPAC1 promoter 
following forskolin stimulation was reversed by the HDAC1/3 selective inhibitor (MS-275). 




inhibition of YAP/TAZ-TEAD binding to regulate EPAC1 expression following cAMP stimulation. 
For instance, inhibition of HDACs1/3 or YAP/TAZ over expression alone, only partially reversed 
the inhibitory effects of forskolin on the mRNA levels of EPAC1 in cardiac fibroblasts. On the other 
hand, HDACs1/3 inhibition together with constitutively active YAP/TAZ completely reversed the 
inhibitory effects of forskolin.  
In summary, our data demonstrate that inhibition of YAP/TAZ-TEAD activity and HDACs1/3 -
mediated H3K27 deacetylation are functionally important in the suppression of EPAC1 expression 
in cardiac fibroblasts following cAMP stimulation. We suggest that these two mechanisms represent 
a novel mechanism of cross talk that controls EPAC1 signalling. These feedback cycles are found 
in almost all signalling pathways, functioning to maintain normal physiological signalling 
homeostasis and allowing for adaptive cellular responses to a continuous signal. Suppression of 
EPAC1 expression via the cycle shown here is likely to be important in the temporal regulation of 
EPAC1 signalling in cardiac fibroblasts, which produce temporary signal responses in prolonged 
cAMP elevation. Specific down regulation of EPAC1 but not PKA catalytic subunits indicate that 







Figure 5.29: Proposed mechanism underlying cAMP-dependent repression of EPAC1 
expression. 
In cardiac fibroblast with low levels of cAMP, PKA and EPAC activity are low and RhoA/ROCK 
activity is high. This results in actin polymerisation and nuclear translocation of YAP/TAZ. 
YAP/TAZ increase activity of TEAD transcription factors, which act via a conserved TEAD 
binding element in the proximal EPAC1 promoter to induce EPAC1 gene expression. Elevated 
cAMP levels activate PKA and EPAC1, which cooperate to inhibit RhoA/ROCK-mediated actin 
polymerisation, resulting in reduced actin polymerisation and acquisition of a stellate cell 
morphology. This induces nuclear export of YAP/TAZ, which in turn reduces TEAD activity. 
Elevated cAMP also induces a HDAC1/3-mediated reduction in histone H3K27 acetylation at the 
proximal EPAC1 promoter. The reduction in TEAD activity together with the reduction in histone 




















Aberrant proliferation and migration of cardiac fibroblasts is a major factor that contributes toward 
the development of cardiac fibrosis and ultimately heart failure, which is collectively the leading 
causes of global death in developed countries (Travers, Kamal et al. 2016, Humeres and 
Frangogiannis 2019, Yuan, Pan et al. 2019). To date, there are only limited anti-cardiac fibrosis 
therapies available to patients. Although several anti-fibrotic therapies have been studied in animal 
models of cardiac fibrosis, with some providing encouraging results, translating these promising 
findings into effective therapies for human patients has been challenging. Clinical trials of some 
therapies, such as the use of the phosphodiesterase inhibitor Milrinone, produced disappointing 
results, with long-term therapy actually being associated with increased morbidity and mortality in 
patients suffering from several chronic heart failure (Packer, Carver et al. 1991). Therefore, it is 
clear that new therapeutic strategies are needed to effectively limit the development of cardiac 
fibrosis and its progression to heart failure. To achieve this, it is essential to have a detail 
understanding of the underlying mechanisms the regulate the development of cardiac fibrosis. 
Several processes contribute towards the development of cardiac fibrosis, including, chronic 
inflammation (Nicoletti and Michel 1999, Suthahar, Meijers et al. 2017), ECM deposition (Kong, 
Christia et al. 2014, Suthahar, Meijers et al. 2017), pressure overload (Rodriguez-Pascual and Diez 
2017, Goh, He et al. 2019) and increased cardiac fibroblasts proliferation (Travers, Kamal et al. 
2016, Humeres and Frangogiannis 2019). Although many studies have highlighted and 
demonstrated the importance of up regulation in ECM gene expression, increases in the number of 
ECM producing cardiac fibroblasts through proliferation is also an important factor. Therefore, a 
better understanding of the mechanisms that normally regulate cardiac fibroblasts proliferation may 
help identify novel therapeutic targets which could be exploited to limit the progression of cardiac 
fibrosis.  
An important characteristic of cardiac failure is irregular second messenger signalling due to 
abnormal synthesis and metabolism of cAMP (Efendiev and Dessauer 2011, Boularan and Gales 
2015, Kim and Kass 2017). In this sense, the cAMP signalling pathway may therefore represent a 
promising therapeutic target. For example, cAMP inhibited the action and formation TGF-β and 
angiotensin II in rat hepatic fibroblasts (Windmeier and Gressner 1997), rat kidney fibroblasts 
(Kothapalli, Hayashi et al. 1998), human renal fibroblasts (Heusinger-Ribeiro, Eberlein et al. 2001) 
and human gingival fibroblasts (Black, Palamakumbura et al. 2007). Likewise, elevated levels of 
cAMP have been shown to have anti-cardiac fibrotic effects in experimental animal models of 




proliferation (Dubey, Gillespie et al. 2001, Liu, Ostrom et al. 2004, Ryzhov, Sung et al. 2014). For 
example, experiments in rats demonstrated that stimulation of A2BRs reduced tissue scar formation 
(Ryzhov, Sung et al. 2014). Consistent with this, silencing of the A2BRs up regulated collagen 
synthesis and the proliferation of cardiac fibroblast, whereas their overexpression demonstrated 
opposing results (Dubey, Gillespie et al. 2001). Some of these protective properties of cAMP may 
be mediated, at least in part via suppression of cardiac fibroblast proliferation. For example, cAMP 
elevating stimuli are known to inhibit proliferation in several different cell types, such as, 
keratinocytes (Takahashi, Honma et al. 2004), thyroid carcinoma cell line (Rocha, Paternot et al. 
2008), hepatoma cells (Van Meeteren, Loesberg et al. 1982) and vascular smooth muscle cells 
(Smith, Hudson et al. 2017). Moreover, several investigations have reported anti-cardiac fibrotic 
properties of PKA and EPAC signalling (Liu, Ostrom et al. 2004, Aroonsakool, Yokoyama et al. 
2008, Yokoyama, Patel et al. 2008, Insel, Murray et al. 2012, Liu, Xu et al. 2017, Sivertsen Asrud, 
Pedersen et al. 2019). Interestingly, it was also demonstrated that EPAC expression is down 
regulated during cardiac fibrosis (Insel, Murray et al. 2012). Therefore, it is important to 
characterise the mechanism responsible for EPAC down regulation in cardiac fibroblasts. 
Translating the anti-cardiac fibrotic of cAMP into clinical practise has been challenging. Direct 
delivery of cAMP analogues can be problematic due to poor cell permeability and stability. 
Moreover, elevating the levels of cAMP by inhibiting PDEs is associated with increased mortality 
in long term treatment (DiBianco 1989, Amsallem, Kasparian et al. 2005). Therefore, there is a need 
to characterise specific downstream cAMP signalling pathways to target therapeutically, rather than 
global disruption of the cAMP signalling system. 
One of the aims if this thesis was to characterise the regulation cardiac fibroblast proliferation by 
cAMP and the role played by the MKL1-SRF and YAP/TAZ-TEAD transcripfactor:co-factor 
complexes. We showed that cAMP-induced actin-depolymerisation inhibits mitogen-induced 
nuclear localisation of MKL1 and YAP in cardiac fibroblasts and this mechanism underlies, at least 
in part, the anti-proliferative (but not anti-migratory) effects of cAMP in these cells. In detail, 
elevation of cAMP levels in cardiac fibroblasts using either A2BR agonist, forskolin or Db-cAMP 
analogue rapidly down regulated Rho/ROCK signalling, suppressed actin-polymerisation (F-actin) 
levels, increased actin-depolymerisation (G-actin) levels and completely inhibited mitogen-induced 
nuclear localisation of MKL1 and reduced YAP nuclear localisation and levels. These anti-
mitogenic effects of cAMP were mediated by both PKA and EPAC, that acted in a cooperative 
manner and were associated with a change in cell morphology and reduction in actin polymerisation. 




ROCK signalling since it was associated with reduced ROCK phosphorylation and pharmacological 
inhibition of ROCK reduced similarly inhibited actin polymerisation and cardiac fibroblast 
proliferation. 
The anti-proliferative effects of cAMP signalling demonstrated here are in consistent with those 
reported previously in vascular smooth muscle cells and other cells types (Hayashi, Morishita et al. 
2000, Growcott, Spink et al. 2006, Rocha, Paternot et al. 2008, Smith, Hudson et al. 2017, Smith, 
Sessions et al. 2019). Previous studies in our lab showed that, cAMP elevation inhibits the 
proliferation of vascular smooth muscle cells by inhibiting entry into S-phase of the cell cycle via a 
mechanism that requires the activation of PKA and EPAC (Smith, Hudson et al. 2017). Using PKA 
and EPAC selective agonists, data presented here, show the necessity of PKA and EPAC activation. 
However, there are some key differences between the anti-mitogenic effects of PKA and EPAC 
signalling in cardiac fibroblasts and those previously reported in vascular smooth muscle cells. 
Selective activation of either PKA or EPAC alone did not inhibit serum-induced proliferation 
vascular smooth muscle cells (Hewer, Sala-Newby et al. 2011). This contrasts with the data 
presented here, which shows a significant but submaximal down regulation of proliferation in 
cardiac fibroblasts. In addition, PKA and EPAC activation acted synergistically to down regulate 
the proliferation of vascular smooth muscle cells, whereas the inhibitory effects of PKA and EPAC 
on the proliferation of cardiac fibroblasts were only additive. Interestingly, our data is also 
consistent with work published by Yokoyama et al showing that selective EPAC activation had 
anti-proliferative effects in rat smooth muscle cells (Yokoyama, Minamisawa et al. 2008). To add 
to the complexity, the effects of cAMP/PKA/EPAC signalling pathways on proliferation are 
variable depending on the cell types. For example, abundant published evidence reports the anti-
mitogenic properties of cAMP in vascular smooth muscle cells (Hewer, Sala-Newby et al. 2011, 
Kimura, Duggirala et al. 2014, Smith, Hudson et al. 2017). However, there are studies 
demonstrating that cAMP signalling can promote the prolfieration of endothelial cells (Smith, 
Hudson et al. 2017) epithelial cells (Yamaguchi, Nagao et al. 2003), embryonic stem cells (Lee, 
Kim et al. 2012) and even VSMC under some conditions (Hogarth, Sandbo et al. 2004). The reasons 
for different effects of cAMP on proliferation are not fully understood but may reflect differences 
in the relative expression levels of PKA and/or EPAC in these cell types or a variation in how these 
two cAMP effectors mediate downstream signalling pathways, including the actin remodelling 
mechanisms that have been implicated in mediating cAMP-dependent anti-mitogenesis (Bond, Wu 




The data here also shows that, pharmacological inhibition of ROCK with Y27632, depolymerises 
the actin filaments, induces morphological changes and down regulates the proliferation of cardiac 
fibroblasts. Our findings are again consistent with the effects of ROCK inhibition on vascular 
smooth muscle cells, where Y27632 induced similar effects. However, this is in contrast with other 
investigations where Y27632 promoted the proliferation of embryonic stem cells (Croze, Thi et al. 
2016), spinal cord astrocytes (Yu, Liu et al. 2012), keratin producing epidermal cells (Chapman, 
McDermott et al. 2014) and mouse embryonic fibroblasts (Kumper, Mardakheh et al. 2016). It has 
been suggested that, Y27632 promotes astrocytes proliferation via up regulating the protein levels 
of CDKs, therefore promoting the progression of cell cycle (Yu, Liu et al. 2012). Also it has been 
demonstrated that, Y27632 upregulated the genes involved with cell division and biosynthesis, such 
as, Crct1, Flg and Ivl, again promoting cell mitosis (Chapman, McDermott et al. 2014). Although, 
we did not check the effect of Y27632 on the protein and mRNA levels of CDKs or genes involved 
in cell division, but our results suggest that Y27632 down regulated the SRF and TEAD target 
genes, regulating proliferation, such as, Ccn1 and Ctgf. 
While cAMP-induced actin-depolymerisation down regulated the proliferation of cardiac 
fibroblasts, the migration of these cells was not affected. In some cases, elevated levels of cAMP 
(via Db-cAMP stimulation) and pharmacological ROCK inhibition even stimulated the migration 
of cardiac fibroblasts in the experiments presented here. Even though these stimulatory effects were 
modest, they contrasted with the large inhibitory effects of cAMP previously reported in vascular 
smooth muscle cells by our group (Smith, Hudson et al. 2017) and others (Yokoyama, Minamisawa 
et al. 2008, Hayashi, Murai et al. 2015, McKean, Murray et al. 2015, Parnell, McElroy et al. 2017, 
Smith, Hudson et al. 2017). This difference suggests the existence of a distinct signalling 
mechanisms involved in the regulation of proliferation and migration in these cells. In vascular 
smooth muscle cells, similar mechanisms have been implicated in the cAMP-dependent regulation 
of both proliferation and migration. For example, elevated levels of cAMP in vascular smooth 
muscle cells inhibits the activity of the actin-sensitive transcription factor:co-transcription factor 
complexes MKL-SRF and YAP/TAZ-TEAD, both of which have been shown to play a role in the 
regulation of vascular smooth muscle cells proliferation and migration (Johnson and Walker 1999, 
Smith, Hudson et al. 2017, Smith, Sessions et al. 2019). The regulation of MKL-SRF and 
YAP/TAZ-TEAD by cAMP stimulation in cardiac fibroblasts is presented in chapters 4 and 5 of 
this thesis where it is shown how they are negatively regulated by cAMP, consistent with previous 
work in vascular smooth muscle cells (Kimura, Duggirala et al. 2016, Parnell, McElroy et al. 2017). 




experiments presented here, the migration of these cells was not inhibited. This clearly implies that 
cardiac fibroblasts are able to migrate independently of MKL-SRF and YAP/TAZ-TEAD activity.  
The requirement of actin remodelling for cells to migrate is widely accepted. Cell migration requires 
continuous dynamic reorganisation of the actin, including increased actin polymerisation to promote 
lamellipodia formation and strengthen new focal adhesions at the leading edge but at the same time 
requires actin depolymerisation and focal adhesion disassembly at the rear, allowing for retraction 
of the trailing edge driven by actomyosin contractility, as explained in chapter 1 of this thesis 
(Pollard and Cooper 2009). Rho GTPase activity plays a key role in promoting actin polymerisation 
at the leading edge and is essential for migration of cardiac fibroblasts in two-dimensional migration 
assays (Jatho, Hartmann et al. 2015). Silencing of RhoA in cardiac fibroblasts inhibits their 
migration in 2D scratch wound assay (Jatho, Hartmann et al. 2015), consistent with a requirement 
for RhoA-mediated actin polymerisation. On the other hand, genetic silencing of RhoA increases 
the migration of cardiac fibroblast through a three-dimensional collagen gel by allowing and 
promoting an amoeboid mode of migration (Jatho, Hartmann et al. 2015). This indicates that cardiac 
fibroblasts use two mechanistically different modes to migrate, a RhoA and actin-dependent 
mesenchymal mode of migration and a RhoA and actin independent amoeboid mode of migration. 
The data presented here demonstrates that cAMP elevation with forskolin, Db-cAMP analogue or 
Y27632 does not inhibit cardiac fibroblast migration despite clear inhibitory effects on actin 
polymerisation. This suggests that cardiac fibroblasts adopt an amoeboid mode of migration under 
conditions of elevated cAMP and impaired actin polymerisation. Yokoyama et al also reported 
enhanced cardiac fibroblast migration in response to elevated cAMP. However, this enhancement 
was only evident with low but not high levels of cAMP (Yokoyama, Patel et al. 2008). The 
inhibitory effects of higher concentrations of forskolin reported by Yokoyama et al may be due to 
migrations assays being performed under serum free conditions, whereas, our migration assays were 
all performed in the presence of serum. Serum stimulates the activity of RhoGTPase suggesting that 
these differences may reflect the magnitude of inhibition of RhoGTPase activity and actin 
polymerisation. Here the data demonstrate forskolin stimulation reduces the percentage of F-actin 
from 40% to 30%. Notably, similar analyses in vascular smooth muscle cells demonstrate a much 
larger reduction in F-actin content in response to forskolin stimulation (from 57% to 9%). This 
larger inhibition of actin polymerisation by cAMP in vascular smooth muscle cells may explain the 
divergent effects of cAMP in the two different cell types. Although the physiological significance 
of the divergent effects of cAMP on cardiac fibroblast migration is currently unknown, the ability 




polymerisation, possibly by adopting an amoeboid mode of migration, may highlight the critical 
importance of rapid cardiac repair after acute myocardial injury, such as following MI. 
Various studies have demonstrated the controversial role of ROCK on cellular migration. Some 
investigations demonstrated the inhibitory roles of ROCK inhibition on migration (Yarrow, 
Totsukawa et al. 2005, Mikami, Yoshida et al. 2015, Sadok, McCarthy et al. 2015, Wang, Yang et 
al. 2016, Guerra, Oliveira et al. 2017, Smith, Hudson et al. 2017), whereas other showed that ROCK 
inhibition increases cellular mobility (Totsukawa, Wu et al. 2004, Yang and Kim 2014, Piltti, 
Varjosalo et al. 2015, Chang, Zhang et al. 2018). Here we showed that, even though Y27632 
induced significant morphological changes, depolymerised the actin filament, downregulated the 
proliferation of cardiac fibroblasts and decreased the mRNA levels of SRF and TEAD target genes, 
but it enhanced the migration of these cells, which is in contrast to the investigations mentioned 
above. This may reflect cell type specific differences. It could also imply that cardiac fibroblasts 
implement an amoeboid mode of migration under conditions when ROCK is inhibited or their actin 
filaments are depolymerised, once more, reflecting the significance of rapid cardiac repair after MI, 
to prevent myocardium rupture.  
Consistent with previous investigations in vascular smooth muscle cells, where it was reported that 
MKL1 localisation is regulated by cAMP (Smith, Hudson et al. 2017), here we also showed that 
cAMP elevating stimuli enhance the cytoplasmic localisation of MKL1 in cardiac fibroblasts 
(mediated by PKA and EPAC specific activation), down regulated the activities of SRF and TEAD 
reporter genes and suppressed the transcription of SRF and TEAD-target gene. Our data are also 
consistent with those reported in skin fibrosis where nuclear MKL1 expression was higher in 
fibrotic model compared to the healthy model (Shiwen, Stratton et al. 2015) and skin fibrosis was 
reduced in MKL1 knockout mice. Moreover, we demonstrated that pharmacological inhibition or 
genetic silencing of MKL, both exerted anti-proliferative effects in cardiac fibroblasts which is 
again consistent with those reported in vascular smooth muscle cells (Smith, Hudson et al. 2017) 
and prostate cancer cells (Evelyn, Wade et al. 2007). 
Numerous studies have characterised the ability of cAMP to stimulate EPAC activity and 
established important physiological and pathological functions of EPAC activity and signalling (de 
Rooij, Zwartkruis et al. 1998, de Rooij, Rehmann et al. 2000, Bos 2006, Hewer, Sala-Newby et al. 
2011). In chapters 3 and 4 of thesis, these functions were extended to characterise the role of EPAC 
signalling activity in regulating cardiac fibroblast proliferation and the regulation of the SRF co-




expression of the EPAC1 gene. In chapter 5, data is presented that characterises a novel regulatory 
mechanism that controls the expression of the EPAC1 gene in cardiac fibroblasts in response to 
changes in the levels of cAMP. The data presented demonstrates that EPAC1 mRNA and protein 
expression are repressed by elevated cAMP levels. At the transcriptional levels, data is presented 
that demonstrates that EPAC1 transcription is dependent on the activity of the YAP/TAZ-TEAD 
transcriptional complex. In addition to the regulation by YAP/TAZ-TEAD, data is also presented 
that demonstrates that EPAC1 expression is also controlled by Histone H3-K27-acetylation at the 
proximal promoter region.  Taken together, the data presented demonstrates that elevated 
intracellular cAMP rapidly represses the expression of EPAC1 mRNA and protein levels by 
antagonising both of these regulatory processes.  In this way, we show that EPAC1 expression is 
sensitive to changes in the organisation of the actin cytoskeleton, via YAP/TAZ-TEAD. The second 
epigenetic mechanisms involve cAMP-mediated deacetylation of H3K27 at the EPAC1 proximal 
promoter region, which presumable controls chromatin accessibility and access of the YAP/TAZ-
TEAD complex to the TEAD element located within the EPAC1 proximal promoter. Together, 
these mechanisms constitute a novel negative feedback mechanism that represses EPAC1 
expression in response to cAMP elevating stimuli. 
In more detail, cAMP elevation in cardiac fibroblasts using either forskolin, cAMP-analogues or 
physiological agonists of the A2BR rapidly represses EPAC1 expression in cardiac fibroblasts, 
suggesting that EPAC1 is sensitive to physiological changes in cAMP levels. This repression was 
mediated via signalling via both PKA and EPAC since selective activation or either EPAC or PKA 
alone inhibited EPAC1 mRNA expression, with simultaneous activation of PKA and EPAC acting 
additively. It is interesting to note that PKA activation was more effective than EPAC activation at 
down regulating EPAC1 expression. Firstly, this suggests the existence of a negative crosstalk 
between PKA and EPAC1. Similar negative-cross talk between PKA and EPAC1 signalling has 
been reported previously in other cell types. For example, PKA activity antagonises EPAC induced 
phosphorylation of AKT (Mei, Qiao et al. 2002). PKA can reduce the ability of the EPAC effector 
protein Rap1 to regulate angiogenesis (Menon, Doebele et al. 2012). PKA can also regulate cAMP-
dependent activation of EPAC by controlling the availability of cAMP via phosphodiesterases 
(Baillie, Scott et al. 2005). Secondly, the greater effectiveness of PKA compare to EPAC1 activation 
in repressing EPAC1 expression mirrors the effects of these cAMP sensors on actin remodelling 
and cell morphological change. This likely reflects the dependence of EPAC1 expression on 
integrity of the actin cytoskeleton. Repression of EPAC1 expression in cardiac fibroblasts in 




morphology characterised by a condensed cytoplasm, extended membrane protrusion and loss of F-
actin stress fibres. These cAMP-dependent morphological changes and inhibition of actin-
polymerisation have been described in several other cell types, including smooth muscle cells 
(Hewer, Sala-Newby et al. 2011, Smith, Hudson et al. 2017), astrocytes (Hatten 1985) and 
mesenchymal stem cells (Zhang, Seitz et al. 2011). Consistent with a role of actin remodelling in 
the regulation of EPAC1, the data presented demonstrates that the magnitude of stellate morphology 
and reduction in actin-cytoskeleton polymerisation induced by activation of PKA and EPAC in 
cardiac fibroblasts is mirrored by the repression of EPAC1 gene expression. However, it is 
intriguing to consider how EPAC1 activation alone represses EPAC1 expression, since we are 
unable to detect any morphological change, and by implication little actin remodelling, in response 
to EPAC1 activation alone. A similar lack of actin remodelling was reported in VSMC in response 
to selective EPAC1 activation (Smith, Hudson et al. 2017). This may suggest the involvement on 
an actin-independent mechanism controlled by EPAC1 signalling. This mechanism may be the 
same as that involved in controlling MKL1 nuclear localisation, a protein that is widely reported to 
be actin-sensitive, that in our experiments was also sensitive to EPAC1 activation, in the absence 
of any detectable morphological change. Cyclic-AMP-induced stellate morphological changes and 
inhibition of actin polymerisation are cell-type specific. Although elevated cAMP induces rapid and 
pronounced actin-cytoskeleton disruption in cardiac fibroblasts and smooth muscle cells, this does 
not occur in ECs (Smith, Teixeira et al. 2013) or as we show here, the H9C2 cardiac myocyte cell 
line. Correspondingly, we show that EPAC1 expression is not repressed by cAMP-elevating stimuli 
in the cardiomyocyte H9C2 cell line, further supporting the conclusion that that repression of 
EPAC1 expression in response to cAMP is, at least in part, mediated by changes in the actin-
cytoskeleton polymerisation status. Consistent with this, we also demonstrated that disruption of 
actin-polymerisation, using the ROCK inhibitor Y26732, or directly with the actin-binding drugs 
cytochalasin-D or latrunculin-B, also repress EPAC1 expression. To our knowledge this is the first 
time that EPAC1 expression has been linked to actin-cytoskeleton remodelling, although previous 
reports have linked EPAC1 localisation and function to actin organisation. For example, EPAC1 
interaction with the actin binding ERM (Ezrin, Radixin and Moesin) proteins has been implicated 
in localisation of EPAC1 to the plasma membrane cortical actin, where it participates in cAMP-
dependent regulation of cell proliferation and cell spreading (Gloerich and Bos 2010, Hochbaum, 
Barila et al. 2011). Our new data now establishes the existence of a novel negative crosstalk 
mechanism where PKA cooperates with EPAC activity to induce actin-cytoskeleton remodelling, 




This novel regulatory mechanism likely forms part of an important homeostatic physiological 
mechanisms that regulates the level of actin polymerisation within cardiac fibroblasts and other 
cells that display cAMP-induced actin depolymerisation. Based on the data presented it is likely 
that EPAC1 expression will gradually increase in response to increases in RhoA activity and actin 
polymerisation increases within a cell. Increased levels of EPAC1, in cooperation with PKA, will 
then enhance the repression of RhoA signalling and actin remodelling. Likewise, if RhoA activity 
and actin-polymerisation is low within a cell, EPAC1 expression will be repressed, thus relieving 
cAMP-dependent inhibition of the RhoA pathway and allowing actin polymerisation to be increase. 
Since actin dynamics play a central role in the regulation of so many diverse cellular functions, not 
least cell proliferation, this physiological homeostatic mechanism is likely to be very important in 







Figure 6.1: Schematic representation of positive and negative feedback loops regulating fibrosis 
and EPAC1 expression in cardiac fibroblasts 
Rho-ROCK signalling promotes actin polymerisation, which enhances YAP-TEAD-dependent 
gene expression. Increased YAP-TEAD activity promotes EPAC1 transcription. EPAC1, in 
cooperation with PKA, inhibits Rho-ROCK activity, thus reducing actin polymerisation. This 
forms a negative feedback loop that helps maintain actin cytoskeleton homeostasis.  HDACs are 
dysregulated in cardiac fibrosis. HDAC1/3 activity represses YAP-dependent EPAC1 expression, 
thus inactivating this negative feedback loop and allowing enhanced signalling through Rho-
ROCK, actin polymerisation and YAP-TEAD activity. YAP-TEAD activity also promotes cardiac 
fibrosis and cardiac fibroblast proliferation. Tissue fibrosis increases the stiffness of the local 






Data is presented demonstrating that EPAC1 transcription is controlled by TEAD family 
transcription factors. Analysis of the EPAC1 promoter identified a conserved consensus TEAD 
binding element in the proximal promoter. Binding of recombinant TEAD protein to this site was 
confirmed by EMSA analysis and mutation of this element in the context of a luciferase reporter 
gene assay significantly reduced EPAC1 promoter activity.  Importantly, TEAD transcription factor 
activity is known to be dependent on actin-cytoskeleton organisation and integrity (Dupont, Morsut 
et al. 2011), consistent with data presented showing that maximal EPAC1 expression is also 
dependent on actin-cytoskeleton integrity. Further confirming the importance of TEAD, data is 
presented demonstrating that maximal expression of the endogenous EPAC1 gene is dependent on 
YAP/TAZ-mediated TEAD activity. For example, inhibition of TEAD activity using silencing of 
the TEAD co-factors YAP and TAZ, overexpression of a dominant-negative TEAD mutant or 
inhibition of TEAD activity using two chemically distinct pharmacological inhibitors all 
significantly inhibited EPAC1 transcription. These data suggest that YAP/TAZ-TEAD is 
mechanistically responsible for coupling EPAC1 expression to the status of the actin cytoskeleton. 
In this way, enhanced YAP/TAZ-TEAD activity will promote EPAC1 expression that then acts in 
cooperation with PKA to promote actin de-polymerisation and in turn reduced YAP/TAZ-TEAD 
activity.  To our knowledge, this is the first time that EPAC1 expression has been linked to 
cytoskeleton integrity and YAP/TAZ-TEAD activity. A large body of evidence reported the role 
played by YAP/TAZ-TEAD in sensing bio-mechanical signals (Kim, Kim et al. 2013, Das, Fischer 
et al. 2016, Dupont 2016, Meng, Moroishi et al. 2016, Elosegui-Artola, Andreu et al. 2017, 
Dobrokhotov, Samsonov et al. 2018, Boopathy and Hong 2019). This also implies that under 
condition of tissue fibrosis, which is typically associated with increased ECM stiffness and 
enhanced YAP/TAZ-TEAD activation (Dupont, Morsut et al. 2011, Nukuda, Sasaki et al. 2015, 
Noguchi, Saito et al. 2017, Noguchi, Saito et al. 2018), EPAC1 expression will be enhanced. 
Increases in EPAC1 expression have been reported in several pathological conditions. For example, 
EPAC1 levels are elevated during cardiac hypertrophy. EPAC1 levels are also increased after 
experiment angioplasty injury to the rat carotid artery. It will be important to determine in the future 
if activation of YAP/TAZ-TEAD during these pathological processes is involved in mediating the 
reported increases in EPAC1. 
Although we demonstrate a clear requirement for YAP/TAZ-TEAD activity for EPAC1 expression, 
our data also demonstrates that activation of this mechanism in isolation, via expression of 
constitutively-active YAP or TAZ mutants, is insufficient for expression of EPAC1 mRNA, 




YAP or TAZ were able to completely reverse cAMP-dependent repression of the EPAC1 promoter 
driven reporter gene activity, they were not able to reverse the inhibition of EPAC1 mRNA levels. 
Since plasmid-based reporter gene vectors are not typically packaged with histone proteins into 
chromatin, we reasoned that histone-associated epigenetic regulation was also involved in cAMP-
mediated repression of EPAC1 expression. Consistent with this, we detected a significant decrease 
in histone-3 lysine-27 acetylation (H3K27Ac), an epigenetic modification associated with active 
transcription (Heintzman, Stuart et al. 2007), at the proximal EPAC1 promoter region in cardiac 
fibroblasts stimulated with forskolin. Our data suggests that this loss of H3K27Ac was mediated by 
HDAC1 or HDCA3, since loss of H3K27Ac at the EPAC1 promoter in response to forskolin 
stimulation was reversed by the HDAC1/3 selective inhibitor MS-275. Importantly, our data 
demonstrates that this epigenetic modification acts cooperatively with inhibition of YAP/TAZ-
TEAD to mediated cAMP-dependent repression of EPAC1 expression. For example, HDAC 
inhibition or expression of constitutively active YAP/TAZ alone only partially rescued EPAC1 
mRNA expression in forskolin-stimulated cells, whereas HDAC inhibition together with 
constitutively-active YAP/TAZ fully reverse the inhibitory effects of forskolin. 
Taken together, our data demonstrates that inhibition of YAP/TAZ-TEAD and HDAC1/3 -mediated 
H3K27-deacetylation underlies the repression of EPAC1 expression in cardiac fibroblasts in 
response to cAMP-elevating stimuli. We suggest that this mechanism represents a novel mechanism 
of cross talk that controls EPAC1 signalling. Such loops that feed an inverted output signal back to 
the input are found in nearly all known signalling pathways, serving to maintain normal 
physiological signalling homeostasis and allowing for adaptive cellular responses to a persistent 
signal. Down regulation of EPAC1 expression via the control loop we describe here is likely to be 
important in the temporal regulation of EPAC1 signalling, generating transient signals responses in 
prolonged cAMP-elevation. Selective down regulation of EPAC1 but not PKA catalytic subunits 
suggests that subsequent cAMP signalling may also be adapted towards PKA-specific response. 
6.2 LIMITATIONS OF THIS RESEARCH 
This study has potential limitations. Most of our experiments were carried out in rodents’ cardiac 
fibroblasts, therefore we need more replications in human cardiac fibroblasts. Moreover, a lot of 
our experiments were performed with forskolin, which can induce supra-physiological levels of 
cAMP. Although some data is presented demonstrating similar effects of GPCR agonists that 
induce more physiological levels of cAMP, more research is needed to fully characterise the 




Additionally, our investigations did not test the regulation or function of MKL2 compared to 
MKL1. Therefore, future investigations need to be carried out in order to address this. 
Also, our work did not test the role of specific TEAD isoforms or the role of different TEAD 
transcriptional coactivator. Considering the existence of different TEAD isoforms and 
transcriptional coactivators, it would be important to investigate the currently unidentified roles of 
each TEAD isoforms and each TEAD transcriptional coactivator in cardiac fibrosis. Elucidation 
of these different pathways promises the identification of new targets for specific inhibition of not 
only cardiac fibroblast proliferation and migration but also can be translated to the development of 
other diseases driven by EPAC1 expression, such as diabetics, cancer and fibrosis of other tissues. 
Furthermore, all of our experiments were carried out in vitro. Therefore, Future works need to be 
carried out in order to test the importance of the mechanisms described here in more complex 
models, for example in myocardial tissue slice models or in vivo.  
6.3 TRANSLATIONAL IMPLICATIONS 
One of the major findings presented in this is novel mechanism regulating EPAC1 expression levels 
in response to cAMP levels in cardiac fibroblasts. The translational potential of these findings 
should be considered, since changes in EPAC1 expression as well as activity have been implicated 
in tissue fibrosis. Studies in mice demonstrated that EPAC stimulation not only decreased tissue 
fibrosis, but also suppressed cardiac remodelling and infarct size after MI (Surinkaew, Aflaki et al. 
2019). Consistent with this, a number of published investigations demonstrated that EPAC1 
expression in cardiac fibroblasts is down regulated in response to profibrotic agents (Basoni, Nobles 
et al. 2005, Yokoyama, Patel et al. 2008, Insel, Murray et al. 2012), implying the protective roles of 
EPAC1 during cardiac fibrosis. The recent development of novel non-cyclic EPAC agonists may 
therefore have therapeutic potential as a treatment to limit cardiac fibrosis (Parnell, McElroy et al. 
2017). However, it should be noted that EPAC1 signalling in cardiomyocytes has been implicated 
in promoting cardiac hypertrophy (Laurent, Bisserier et al. 2015, Lezoualc'h, Fazal et al. 2016, 
Laudette, Zuo et al. 2018). Therefore, more research is now needed to test the potential of EPAC1 
targeting therapies for the treatment of cardiac fibrosis 
We demonstrated an important role for HDAC activity in the cAMP-mediated repression of EPAC1 
expression. This suggests that HDAC activity may be involved in the down regulation of EPAC1 
levels that are often observed in response to pro-fibrotic stimuli. Importantly, during the past decade, 
it was demonstrated that HDACs play a role in the progression of cardiac fibrosis (Ellmers, Scott et 




activity has been observed in cardiac fibrosis (Korfei, Skwarna et al. 2015). Several lines of 
evidence demonstrate that HDAC inhibition can alleviate cardiac fibrosis (Gallo, Latronico et al. 
2008, Eom, Cho et al. 2011) and HDAC inhibitor therapy has been reported to be an effective 
therapy for patients with cardiac fibrosis (Schiattarella and Hill 2015). Consistent with these 
findings, we showed that HDAC inhibition, in combination with YAP over expression, was able to 
rescue the inhibitory effects of cAMP signalling on EPAC1 expression. The implication is that the 
therapeutic effects of HDAC inhibitors during cardiac fibrosis may be due, in part, to the restoration 
of EPAC1 expression and, hence its signalling capacity. However, the effects of therapeutic 
elevation of EPAC1 levels in the heart need to be considered carefully and thoroughly researched 
before trials in patients. Several studies have reported elevated levels of EPAC1 expression in 
animal models of cardiomyopathy and patients with failing hearts (Ulucan, Wang et al. 2007, 
Metrich, Lucas et al. 2008). Likewise, EPAC1 knockout mice studies show that loss of EPAC1 is 
protective against pressure overload-induced cardiac dysfunction (Okumura, Fujita et al. 2014), 
while EPAC activation can promote cardiac hypertrophy (Laurent, Bisserier et al. 2015, Lezoualc'h, 
Fazal et al. 2016, Laudette, Zuo et al. 2018).  
The work presented in this thesis also highlights the important role of MKL-SRF and YAP/TAZ-
TEAD in the regulation of cardiac fibroblast proliferation. As such, these transcription factor 
complexes may represent attractive therapeutic targets to limit cardiac fibroblast proliferation. 
Consistent with an important role for MKL in promoting tissue fibrosis pharmacological MKL 
activation promotes myofibroblast differentiation that is often associated with tissue fibrosis 
(Velasquez, Sutherland et al. 2013). Furthermore, deletion of the MKL1 gene in mice reduces 
fibrosis and scar formation following MI or Angiotensin II treatment (Small, Thatcher et al. 2010). 
There is also evidence that the YAP/TAZ-TEAD complex plays an important role in promoting 
fibrosis. For example, YAP activation has been shown to promote the trans-differentiation of 
cardiac fibroblasts to myofibroblasts and in matrix remodelling of dilated cardiomyopathy (Jin, Zhu 
et al. 2018). Recently, investigations in rodents demonstrated that conditional deletion of 
LATS1 and LATS2 in cardiac fibroblasts, which normally repress YAP and TAZ activity, induced 
cardiac fibrosis in mice (Xiao, Hill et al. 2019). In Zebrafish models of cardiac injury, hearts with 
YAP mutants demonstrated lower collagen synthesis at seven days post-cryoinjury, implying 
important roles of YAP in scar formation during heart regeneration (Flinn, Jeffery et al. 2019). YAP 
knockout in primary rat cardiac cells revealed a fibroblast-specific role for YAP in regulating pro-




also have crucial roles in promoting inflammation, which is also an important factor prompting the 
fibrotic response (Flinn, Jeffery et al. 2019). 
Although transcription factors are traditionally thought to be challenging drug targets, 
pharmacological inhibitors of MKL-SRF (Evelyn, Wade et al. 2007, Sandbo, Kregel et al. 2009, 
Evelyn, Bell et al. 2010, Bell, Haak et al. 2013, Johnson, Rodansky et al. 2014) and YAP/TAZ-
TEAD (Liu-Chittenden, Huang et al. 2012, Zhang, Lin et al. 2014, Wang, Zhu et al. 2016, Kaan, 
Sim et al. 2017, Smith, Sessions et al. 2019) have been described. Pharmacological inhibition of 
MKL may have beneficial effects since local delivery of novel MKL inhibitors has been shown to 
prevent scar tissue formation in a preclinical model of fibrosis (Yu-Wai-Man, Spencer-Dene et al. 
2017). Pharmacological MKL inhibition has also been shown to reduce liver fibrosis via inhibition 
of type I collagen expression in hepatic stellate cells (Shi and Rockey 2017) and can prevent fibrosis 
in a murine model of skin injury (Haak, Tsou et al. 2014). However, more research is required to 
fully characterise the potential of MKL targeting therapies as some research point to important 
physiological and developmental role of the MKL-SRF complex in the heart. For example, deletion 
of MKL1 in the heart results in cardiac abnormalities, such as: extreme ventricular dilation and 
decreased cardiac output (Mokalled, Carroll et al. 2015). In recent years several pharmacological 
inhibitors have also been described that target the YAP/TAZ-TEAD complex. However, these have 
not yet been evaluated in the context of cardiac fibrosis. The data presented here demonstrates that 
YAP-TEAD inhibition reduces cardiac fibroblast proliferation and hence suggests potential 
therapeutic benefits. It is therefore important that the efficacy of YAP-TEAD inhibition in animal 
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